Nitric-oxide-donating	O
NSAIDs	O
as	O
agents	O
for	O
cancer	O
prevention	O
.	O
Nitric-oxide-donating	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NO-NSAIDs	O
)	O
,	O
which	O
consist	O
of	O
an	O
NSAID	O
with	O
an	O
NO-donating	O
moiety	O
covalently	O
attached	O
to	O
it	O
,	O
promise	O
to	O
contribute	O
significantly	O
towards	O
the	O
development	O
of	O
effective	O
chemoprevention	O
strategies	INDICATIONS
against	O
cancer	O
.	O
NO-NSAIDs	O
inhibit	O
the	O
growth	O
of	O
cultured	O
cancer	O
cells	O
10-6000-fold	O
more	O
potently	O
than	O
their	O
parent	O
NSAIDs	O
and	O
prevent	O
colon	INDICATIONS
cancer	INDICATIONS
in	O
animal	O
tumor	O
models	O
.	O
Clinical	O
data	O
indicate	O
that	O
they	O
are	O
extremely	O
safe	O
.	O
Mechanistically	O
,	O
NO-aspirin	O
,	O
the	O
best-studied	O
NO-NSAID	O
,	O
has	O
pleiotropic	O
effects	O
on	O
cell	O
signaling	O
(	O
it	O
inhibits	O
Wnt	O
signaling	O
,	O
induces	O
nitric	O
oxide	O
synthase	O
and	O
NF-kappaB	O
activation	O
and	O
induces	O
cyclooxygenase-2	O
expression	O
)	O
,	O
and	O
this	O
mechanistic	O
redundancy	O
might	O
be	O
central	O
to	O
its	O
mode	O
of	O
action	O
against	O
cancer	O
.	O
The	O
apparent	O
safety	O
and	O
superior	O
efficacy	O
of	O
NO-NSAIDs	O
makes	O
them	O
promising	O
chemopreventive	O
agents	O
against	O
cancer	O
.	O

Topiramate	O
in	O
the	O
prophylactic	O
treatment	O
of	O
migraine	INDICATIONS
in	INDICATIONS
children	INDICATIONS
.	O
We	O
present	O
a	O
prospective	O
case	O
series	O
of	O
24	O
children	O
diagnosed	O
with	O
migraine	INDICATIONS
refractory	O
to	O
prophylactics	O
and	O
treated	O
for	O
4	O
months	O
with	O
topiramate	O
as	O
the	O
only	O
prophylactic	O
drug	O
.	O
At	O
the	O
final	O
visit	O
,	O
the	O
mean	O
topiramate	O
dose	O
was	O
3.5	O
+/-	O
1.7	O
mg/kg/day	O
.	O
Nearly	O
all	O
patients	O
(	O
87.5	O
%	O
)	O
reported	O
a	O
shorter	O
duration	O
of	O
attacks	O
,	O
and	O
the	O
average	O
pain	O
intensity	O
was	O
rated	O
as	O
mild	O
by	O
14	O
patients	O
(	O
58.3	O
%	O
)	O
.	O
Eight	O
(	O
33.3	O
%	O
)	O
patients	O
had	O
adverse	O
events	O
,	O
none	O
of	O
which	O
were	O
serious	O
.	O
In	O
our	O
sample	O
of	O
pediatric	O
patients	O
,	O
topiramate	O
was	O
effective	O
for	O
the	O
prophylactic	O
treatment	O
of	O
migraine	INDICATIONS
in	INDICATIONS
children	INDICATIONS
.	O
It	O
was	O
well	O
tolerated	O
at	O
the	O
doses	O
used	O
for	O
titration	O
and	O
maintenance	O
.	O
Controlled	O
trials	O
are	O
needed	O
to	O
verify	O
the	O
efficacy	O
of	O
topiramate	O
for	O
migraine	INDICATIONS
in	INDICATIONS
children	INDICATIONS
.	O

Thyroid	O
function	O
in	O
a	O
formerly	O
goitrous	O
community	O
on	O
Karkar	O
Island	O
,	O
Papua	O
New	O
Guinea	O
.	O
During	O
a	O
survey	O
of	O
noncommunicable	INDICATIONS
disease	INDICATIONS
conducted	O
on	O
Karkar	O
Island	O
,	O
Madang	O
Province	O
in	O
1986	O
,	O
measures	O
of	O
thyroid	O
function	O
were	O
examined	O
in	O
adult	O
residents	O
of	O
a	O
formerly	O
goitrous	O
village	O
(	O
Gamog	O
)	O
and	O
a	O
neighbouring	O
community	O
(	O
Marup	O
)	O
with	O
no	O
history	O
of	O
iodine	INDICATIONS
deficiency	INDICATIONS
or	O
endemic	O
goitre	O
.	O
In	O
Gamog	O
,	O
almost	O
20	O
%	O
of	O
males	O
and	O
almost	O
30	O
%	O
of	O
females	O
had	O
palpable	O
goitre	O
(	O
maximum	O
prevalence	O
at	O
ages	O
35-54	O
years	O
)	O
but	O
visible	O
goitres	INDICATIONS
were	O
not	O
encountered	O
.	O
However	O
,	O
thyroid	O
function	O
tests	O
were	O
generally	O
similar	O
in	O
the	O
two	O
groups	O
,	O
suggesting	O
that	O
iodine	INDICATIONS
deficiency	INDICATIONS
is	O
no	O
longer	O
an	O
appreciable	O
problem	O
for	O
adults	O
in	O
Gamog	O
.	O
The	O
persistence	O
of	O
palpable	O
goitre	O
in	O
this	O
village	O
is	O
therefore	O
likely	O
to	O
be	O
a	O
residual	O
effect	O
of	O
previous	O
iodine	INDICATIONS
deficiency	INDICATIONS
.	O
Correction	O
of	O
the	O
iodine	INDICATIONS
deficiency	INDICATIONS
in	O
the	O
Gamog	O
community	O
began	O
with	O
the	O
program	O
of	O
iodized	O
oil	O
injections	O
,	O
which	O
was	O
undertaken	O
in	O
the	O
1970s	O
.	O
The	O
current	O
lack	O
of	O
iodine	INDICATIONS
deficiency	INDICATIONS
is	O
probably	O
due	O
in	O
the	O
main	O
to	O
dietary	O
change	O
associated	O
with	O
the	O
introduction	O
of	O
the	O
cash	O
economy	O
.	O
This	O
effect	O
may	O
have	O
occurred	O
in	O
many	O
formerly	O
goitrous	O
communities	O
in	O
Papua	O
New	O
Guinea	O
in	O
recent	O
years	O
,	O
although	O
persistence	O
of	O
iodine	INDICATIONS
deficiency	INDICATIONS
in	O
some	O
parts	O
of	O
the	O
country	O
should	O
not	O
be	O
discounted	O
.	O

Sickle	INDICATIONS
cell	INDICATIONS
anemia	INDICATIONS
.	O

Preterm	O
birth	O
and	O
risk	O
of	O
epilepsy	O
in	O
Swedish	O
adults	O
.	O
To	O
determine	O
whether	O
preterm	O
birth	O
is	O
associated	O
with	O
epilepsy	O
in	O
a	O
national	O
cohort	O
of	O
adults	O
aged	O
25-37	O
years	O
.	O
We	O
conducted	O
a	O
national	O
cohort	O
study	O
of	O
630,090	O
infants	O
born	O
in	O
Sweden	O
from	O
1973	O
through	O
1979	O
,	O
including	O
27,953	O
born	O
preterm	O
(	O
<	O
37	O
weeks	O
)	O
,	O
followed	O
from	O
2005	O
to	O
2009	O
for	O
1	O
)	O
hospitalization	O
for	O
epilepsy	O
and	O
2	O
)	O
outpatient	O
and	O
inpatient	O
prescription	O
of	O
antiepileptic	O
drugs	O
.	O
Epilepsy	O
diagnoses	O
and	O
medication	O
data	O
were	O
obtained	O
from	O
all	O
hospitals	O
and	O
pharmacies	O
throughout	O
Sweden	O
.	O
We	O
found	O
a	O
strong	O
association	O
between	O
preterm	O
birth	O
and	O
epilepsy	O
that	O
increased	O
by	O
earlier	O
gestational	O
age	O
.	O
After	O
adjusting	O
for	O
fetal	O
growth	O
and	O
potential	O
confounders	O
,	O
odds	O
ratios	O
for	O
hospitalization	O
for	O
epilepsy	O
were	O
4.98	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
2.87-8.62	O
)	O
for	O
those	O
born	O
at	O
23-31	O
weeks	O
,	O
1.98	O
(	O
95	O
%	O
CI	O
1.26-3.13	O
)	O
for	O
those	O
born	O
at	O
32-34	O
weeks	O
,	O
and	O
1.76	O
(	O
95	O
%	O
CI	O
1.30-2.38	O
)	O
for	O
those	O
born	O
at	O
35-36	O
weeks	O
,	O
relative	O
to	O
those	O
born	O
full-term	O
(	O
37-42	O
weeks	O
)	O
.	O
A	O
similar	O
but	O
slightly	O
weaker	O
trend	O
was	O
observed	O
for	O
the	O
association	O
between	O
preterm	O
birth	O
and	O
antiepileptic	O
drug	O
prescription	O
.	O
These	O
associations	O
persisted	O
after	O
excluding	O
individuals	O
with	O
cerebral	INDICATIONS
palsy	INDICATIONS
,	O
inflammatory	O
diseases	O
of	O
the	O
CNS	O
,	O
cerebrovascular	INDICATIONS
disease	INDICATIONS
,	O
and	O
brain	INDICATIONS
tumors	INDICATIONS
.	O
These	O
findings	O
suggest	O
that	O
preterm	O
birth	O
,	O
including	O
late	O
preterm	O
birth	O
,	O
is	O
strongly	O
associated	O
with	O
epilepsy	O
in	O
Swedish	O
adults	O
aged	O
25-37	O
years	O
.	O
This	O
association	O
was	O
independent	O
of	O
fetal	O
growth	O
and	O
was	O
not	O
mediated	O
by	O
cerebral	INDICATIONS
palsy	INDICATIONS
or	O
other	O
comorbidities	O
.	O

Honokiol	O
induces	O
apoptosis	O
and	O
autophagy	O
via	O
the	O
ROS/ERK1/2	O
signaling	O
pathway	O
in	O
human	O
osteosarcoma	INDICATIONS
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Osteosarcoma	INDICATIONS
is	O
the	O
most	O
common	O
primary	O
malignant	INDICATIONS
tumor	INDICATIONS
of	INDICATIONS
bone	INDICATIONS
,	O
the	O
long-term	O
survival	O
of	O
which	O
has	O
stagnated	O
in	O
the	O
past	O
several	O
decades	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
anticancer	O
effect	O
of	O
honokiol	O
(	O
HNK	O
)	O
,	O
an	O
active	O
component	O
isolated	O
and	O
purified	O
from	O
the	O
magnolia	O
officinalis	O
on	O
human	O
osteosarcoma	INDICATIONS
cells	O
.	O
Our	O
results	O
showed	O
that	O
honokiol	O
caused	O
dose-dependent	O
and	O
time-dependent	O
cell	O
death	O
in	O
human	O
osteosarcoma	INDICATIONS
cells	O
.	O
The	O
types	O
of	O
cell	O
death	O
induced	O
by	O
honokiol	O
were	O
primarily	O
autophagy	O
and	O
apoptosis	O
.	O
Furthermore	O
,	O
honokiol	O
induced	O
G0/G1	O
phase	O
arrest	O
,	O
elevated	O
the	O
levels	O
of	O
glucose-regulated	O
protein	O
(	O
GRP	O
)	O
-78	O
,	O
an	O
endoplasmic	O
reticular	O
stress	O
(	O
ERS	O
)	O
-associated	O
protein	O
,	O
and	O
increased	O
the	O
production	O
of	O
intracellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O
In	O
contrast	O
,	O
reducing	O
production	O
of	O
intracellular	O
ROS	O
using	O
N-acetylcysteine	O
,	O
a	O
scavenger	O
of	O
ROS	O
,	O
concurrently	O
suppressed	O
honokiol-induced	O
cellular	O
apoptosis	O
,	O
autophagy	O
,	O
and	O
cell	O
cycle	O
arrest	O
.	O
Consequently	O
,	O
honokiol	O
stimulated	O
phosphorylation	O
of	O
extracellular	O
signal-regulated	O
kinase	O
(	O
ERK	O
)	O
1/2	O
.	O
Furthermore	O
,	O
pretreatment	O
of	O
osteosarcoma	INDICATIONS
cells	O
with	O
PD98059	O
,	O
an	O
inhibitor	O
of	O
ERK1/2	O
,	O
inhibited	O
honokiol-induced	O
apoptosis	O
and	O
autophagy	O
.	O
Finally	O
,	O
honokiol	O
suppressed	O
tumor	INDICATIONS
growth	INDICATIONS
in	O
the	O
mouse	O
xenograft	O
model	O
.	O
Taken	O
together	O
,	O
our	O
results	O
revealed	O
that	O
honokiol	O
caused	O
G0/G1	O
phase	O
arrest	O
,	O
induced	O
apoptosis	O
,	O
and	O
autophagy	O
via	O
the	O
ROS/ERK1/2	O
signaling	O
pathway	O
in	O
human	O
osteosarcoma	INDICATIONS
cells	O
.	O
Honokiol	O
is	O
therefore	O
a	O
promising	O
candidate	O
for	O
development	O
of	O
antitumor	O
drugs	O
targeting	O
osteosarcoma	INDICATIONS
.	O

[	O
Case	O
of	O
ventricular	INDICATIONS
septal	INDICATIONS
defect	INDICATIONS
and	O
patent	O
ductus	INDICATIONS
arteriosus	INDICATIONS
associated	O
with	O
pulmonary	INDICATIONS
hypertension	INDICATIONS
:	O
a	O
pathological	O
contra-indication	O
to	O
surgical	O
therapy	O
]	O
.	O

Kaposi	O
's	O
sarcoma-associated	O
herpesvirus	O
latency	O
in	O
endothelial	O
and	O
B	O
cells	O
activates	O
gamma	O
interferon-inducible	O
protein	O
16-mediated	O
inflammasomes	O
.	O
Kaposi	INDICATIONS
's	INDICATIONS
sarcoma-associated	INDICATIONS
herpesvirus	INDICATIONS
(	INDICATIONS
KSHV	INDICATIONS
)	O
infections	O
of	O
endothelial	O
and	O
B	O
cells	O
are	O
etiologically	O
linked	O
with	O
Kaposi	INDICATIONS
's	INDICATIONS
sarcoma	INDICATIONS
(	O
KS	O
)	O
and	O
primary	INDICATIONS
effusion	INDICATIONS
B-cell	INDICATIONS
lymphoma	INDICATIONS
(	O
PEL	O
)	O
,	O
respectively	O
.	O
KS	O
endothelial	O
and	O
PEL	O
B	O
cells	O
carry	O
multiple	O
copies	O
of	O
the	O
nuclear	O
episomal	O
latent	O
KSHV	INDICATIONS
genome	O
and	O
secrete	O
a	O
variety	O
of	O
inflammatory	O
cytokines	O
,	O
including	O
interleukin-1β	O
(	O
IL-1β	O
)	O
and	O
IL-18	O
.	O
The	O
maturation	O
of	O
IL-1β	O
and	O
IL-18	O
depends	O
upon	O
active	O
caspase-1	O
,	O
which	O
is	O
regulated	O
by	O
a	O
multiprotein	O
inflammasome	O
complex	O
induced	O
by	O
sensing	O
of	O
danger	O
signals	O
.	O
During	O
primary	O
KSHV	INDICATIONS
infection	O
of	O
endothelial	O
cells	O
,	O
acting	O
as	O
a	O
nuclear	O
pattern	INDICATIONS
recognition	INDICATIONS
receptor	O
,	O
gamma	O
interferon-inducible	O
protein	O
16	O
(	O
IFI16	O
)	O
colocalized	O
with	O
the	O
KSHV	INDICATIONS
genome	O
in	O
the	O
nuclei	O
and	O
interacted	O
with	O
ASC	O
and	O
procaspase-1	O
to	O
form	O
a	O
functional	O
inflammasome	O
(	O
Kerur	O
N	O
et	O
al.	O
,	O
Cell	O
Host	O
Microbe	O
9:363-375	O
,	O
2011	O
)	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
endothelial	O
telomerase-immortalized	O
human	O
umbilical	O
cells	O
(	O
TIVE	O
)	O
supporting	O
KSHV	INDICATIONS
stable	O
latency	O
(	O
TIVE-LTC	O
cells	O
)	O
and	O
PEL	O
(	O
cavity-based	O
B-cell	INDICATIONS
lymphoma	INDICATIONS
1	O
[	O
BCBL-1	O
]	O
)	O
cells	O
show	O
evidence	O
of	O
inflammasome	O
activation	O
,	O
such	O
as	O
the	O
activation	O
of	O
caspase-1	O
and	O
cleavage	O
of	O
pro-IL-1β	O
and	O
pro-IL-18	O
.	O
Interaction	O
of	O
ASC	O
with	O
IFI16	O
but	O
not	O
with	O
AIM2	O
or	O
NOD-like	O
receptor	O
P3	O
(	O
NLRP3	O
)	O
was	O
detected	O
.	O
The	O
KSHV	INDICATIONS
latency-associated	O
viral	O
FLIP	O
(	O
vFLIP	O
)	O
gene	O
induced	O
the	O
expression	O
of	O
IL-1β	O
,	O
IL-18	O
,	O
and	O
caspase-1	O
mRNAs	O
in	O
an	O
NF-κB-dependent	O
manner	O
.	O
IFI16	O
and	O
cleaved	O
IL-1β	O
were	O
detected	O
in	O
the	O
exosomes	O
released	O
from	O
BCBL-1	O
cells	O
.	O
Exosomal	O
release	O
could	O
be	O
a	O
KSHV-mediated	INDICATIONS
strategy	O
to	O
subvert	O
IL-1β	O
functions	O
.	O
In	O
fluorescent	O
in	O
situ	O
hybridization	O
analyses	O
,	O
IFI16	O
colocalized	O
with	O
multiple	O
copies	O
of	O
the	O
KSHV	INDICATIONS
genome	O
in	O
BCBL-1	O
cells	O
.	O
IFI16	O
colocalization	O
with	O
ASC	O
was	O
also	O
detected	O
in	O
lung	O
PEL	O
sections	O
from	O
patients	O
.	O
Taken	O
together	O
,	O
these	O
findings	O
demonstrated	O
the	O
constant	O
sensing	O
of	O
the	O
latent	O
KSHV	INDICATIONS
genome	O
by	O
IFI16-mediated	O
innate	O
defense	O
and	O
unraveled	O
a	O
potential	O
mechanism	O
of	O
inflammation	O
induction	O
associated	O
with	O
KS	O
and	O
PEL	O
lesions	O
.	O

Avoidant	INDICATIONS
personality	INDICATIONS
disorder	INDICATIONS
and	O
social	O
phobia	O
:	O
distinct	O
enough	O
to	O
be	O
separate	O
disorders	O
?	O
Existing	O
evidence	O
from	O
anxiety	INDICATIONS
disorder	INDICATIONS
research	O
indicates	O
that	O
social	O
phobics	O
(	O
SP	O
)	O
with	O
avoidant	INDICATIONS
personality	INDICATIONS
disorder	INDICATIONS
(	O
AVPD	O
)	O
experience	O
more	O
anxiety	O
and	O
show	O
more	O
impairment	O
than	O
patients	O
with	O
SP	O
alone	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
in	O
patients	O
diagnosed	O
with	O
AVPD	O
,	O
the	O
co-occurrence	O
of	O
SP	O
adds	O
to	O
its	O
severity	O
.	O
We	O
hypothesized	O
that	O
the	O
addition	O
of	O
SP	O
will	O
not	O
add	O
to	O
the	O
severity	O
of	O
AVPD	O
alone	O
.	O
Two	O
groups	O
of	O
patients	O
(	O
AVPD=224	O
;	O
AVPD/SP=101	O
)	O
were	O
compared	O
at	O
baseline	O
and	O
2	O
years	O
later	O
on	O
multiple	O
demographic	O
and	O
clinical	O
variables	O
.	O
Patients	O
with	O
AVPD	O
and	O
an	O
additional	O
diagnosis	O
of	O
SP	O
differed	O
little	O
from	O
patients	O
with	O
AVPD	O
alone	O
.	O
These	O
findings	O
suggest	O
that	O
AVPD	O
and	O
SP	O
may	O
be	O
alternative	O
conceptualizations	O
of	O
the	O
same	O
disorder	O
.	O

Inflammation	O
induces	O
mitochondrial	O
dysfunction	O
and	O
dopaminergic	O
neurodegeneration	O
in	O
the	O
nigrostriatal	O
system	O
.	O
Evidence	O
suggests	O
that	O
chronic	INDICATIONS
inflammation	INDICATIONS
,	O
mitochondrial	O
dysfunction	O
,	O
and	O
oxidative	O
stress	O
play	O
significant	O
and	O
perhaps	O
synergistic	O
roles	O
in	O
Parkinson	INDICATIONS
's	INDICATIONS
disease	INDICATIONS
(	O
PD	O
)	O
,	O
where	O
the	O
primary	O
pathology	O
is	O
significant	O
loss	O
of	O
the	O
dopaminergic	O
neurons	O
in	O
the	O
substantia	O
nigra	O
.	O
The	O
use	O
of	O
anti-inflammatory	O
drugs	O
for	O
PD	O
treatment	O
has	O
been	O
proposed	O
,	O
and	O
inhibition	O
of	O
cyclo-oxygenase-2	O
(	O
COX-2	O
)	O
or	O
activation	O
of	O
peroxisome	O
proliferator-activated	O
receptor	O
gamma	O
(	O
PPAR-gamma	O
)	O
yields	O
neuroprotection	O
in	O
MPTP-induced	O
PD	O
.	O
Lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
inflammation-driven	O
dopaminergic	O
neurodegeneration	O
.	O
We	O
tested	O
the	O
hypothesis	O
that	O
celecoxib	O
(	O
Celebrex	O
,	O
COX-2	O
inhibitor	O
)	O
or	O
pioglitazone	O
(	O
Actos	O
,	O
PPAR-gamma	O
agonist	O
)	O
will	O
reduce	O
the	O
LPS-induced	O
inflammatory	O
response	O
,	O
spare	O
mitochondrial	O
bioenergetics	O
,	O
and	O
improve	O
nigral	O
dopaminergic	O
neuronal	O
survival	O
.	O
Rats	O
were	O
treated	O
with	O
vehicle	O
,	O
celecoxib	O
,	O
or	O
pioglitazone	O
and	O
were	O
intrastriatally	O
injected	O
with	O
LPS	O
.	O
Inflammation	O
,	O
mitochondrial	O
dysfunction	O
,	O
oxidative	O
stress	O
,	O
decreased	O
dopamine	O
,	O
and	O
nigral	O
dopaminergic	O
neuronal	O
loss	O
were	O
observed	O
post-LPS	O
.	O
Celecoxib	O
and	O
pioglitazone	O
provided	O
neuroprotective	O
properties	O
by	O
decreasing	O
inflammation	O
and	O
restoring	O
mitochondrial	O
function	O
.	O
Pioglitazone	O
also	O
attenuated	O
oxidative	O
stress	O
and	O
partially	O
restored	O
striatal	O
dopamine	O
as	O
well	O
as	O
demonstrated	O
dopaminergic	O
neuroprotection	O
and	O
reduced	O
nigral	O
microglial	O
activation	O
.	O
In	O
summary	O
,	O
intrastriatal	O
LPS	O
served	O
as	O
a	O
model	O
for	O
inflammation-induced	O
dopaminergic	O
neurodegeneration	O
,	O
anti-inflammatory	O
drugs	O
provided	O
protective	O
properties	O
,	O
and	O
pioglitazone	O
or	O
celecoxib	O
may	O
have	O
therapeutic	O
potential	O
for	O
the	O
treatment	O
of	O
neuro-inflammation	O
and	O
PD	O
.	O

The	O
use	O
of	O
taxanes	O
in	O
choriocarcinoma	INDICATIONS
;	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O
Both	O
preclinical	O
data	O
and	O
case	O
reports	O
support	O
the	O
use	O
of	O
taxanes	O
for	O
high-risk	O
metastatic	INDICATIONS
choriocarcinoma	INDICATIONS
.	O
We	O
report	O
the	O
case	O
of	O
a	O
31-year-old	O
with	O
metastatic	INDICATIONS
choriocarcinoma	INDICATIONS
who	O
required	O
3rd-line	O
treatment	O
with	O
a	O
paclitaxel-cisplatin-based	O
regimen	O
.	O
She	O
achieved	O
a	O
complete	O
response	O
and	O
remains	O
relapse-free	O
21	O
months	O
after	O
her	O
last	O
dose	O
of	O
chemotherapy	O
.	O
The	O
literature	O
suggests	O
that	O
paclitaxel	O
contributes	O
significantly	O
to	O
the	O
treatment	O
of	O
choriocarcinoma	INDICATIONS
and	O
its	O
use	O
should	O
be	O
explored	O
further	O
.	O
This	O
is	O
the	O
first	O
case	O
report	O
formally	O
reporting	O
its	O
combination	O
with	O
cisplatin	O
.	O

Acute	O
aortic	INDICATIONS
occlusion	INDICATIONS
as	O
a	O
late	O
complication	O
of	O
coarctation	INDICATIONS
repair	O
.	O
Late	O
morbidity	O
and	O
mortality	O
following	O
surgical	O
correction	O
of	O
coarctation	INDICATIONS
of	O
the	O
aorta	O
in	O
adults	O
are	O
primarily	O
related	O
to	O
associated	O
cardiovascular	INDICATIONS
disease	INDICATIONS
,	O
especially	O
persistent	O
systemic	INDICATIONS
hypertension	INDICATIONS
and	O
its	O
sequelae	O
.	O
complications	O
related	O
to	O
the	O
site	O
of	O
coarctation	INDICATIONS
repair	O
are	O
relatively	O
uncommon	O
in	O
this	O
age	O
group	O
and	O
include	O
residual	O
and	O
recurrent	O
coarctation	INDICATIONS
and	O
aneurysm	INDICATIONS
formation	O
.	O
An	O
unusual	O
case	O
is	O
presented	O
in	O
which	O
dehiscence	INDICATIONS
of	O
the	O
proximal	O
suture	O
line	O
of	O
a	O
Dacron	O
tube	O
graft	O
resulted	O
in	O
a	O
flap-valve	O
effect	O
,	O
pseudoaneurysm	INDICATIONS
formation	O
,	O
and	O
acute	O
functional	O
occlusion	O
of	O
the	O
aorta	O
.	O
The	O
angiographic	O
findings	O
are	O
described	O
and	O
the	O
relevant	O
literature	O
reviewed	O
.	O

Urokinase	O
in	O
thrombotic	INDICATIONS
coronary	INDICATIONS
occlusion	INDICATIONS
.	O

Quantitative	O
Assessment	O
of	O
In-Stent	INDICATIONS
Stenosis	INDICATIONS
After	O
Pipeline	O
Embolization	O
Device	O
Treatment	O
of	O
Intracranial	INDICATIONS
Aneurysms	INDICATIONS
:	O
A	O
Single-Institution	O
Series	O
and	O
Systematic	O
Review	O
.	O
Very	O
little	O
is	O
known	O
about	O
the	O
incidence	O
of	O
in-stent	INDICATIONS
stenosis	INDICATIONS
after	O
flow	O
diverter	O
treatment	O
of	O
intracranial	INDICATIONS
aneurysms	INDICATIONS
.	O
We	O
sought	O
to	O
evaluate	O
the	O
incidence	O
and	O
clinical	O
significance	O
of	O
in-stent	INDICATIONS
stenosis	INDICATIONS
at	O
angiographic	O
follow-up	O
after	O
Pipeline	O
embolization	O
device	O
(	O
PED	O
)	O
placement	O
using	O
quantitative	O
measures	O
.	O
The	O
clinical	O
and	O
radiological	O
records	O
from	O
all	O
patients	O
undergoing	O
PED	O
treatment	O
of	O
intracranial	INDICATIONS
aneurysms	INDICATIONS
at	O
a	O
major	O
U.S.	O
academic	O
center	O
from	O
March	O
2013	O
to	O
July	O
2017	O
were	O
retrospectively	O
reviewed	O
.	O
A	O
modified	O
version	O
of	O
the	O
North	O
American	O
Symptomatic	O
Carotid	O
Endarterectomy	O
criteria	O
was	O
used	O
to	O
quantify	O
the	O
degree	O
of	O
stenosis	INDICATIONS
on	O
the	O
most	O
recent	O
postprocedural	O
angiogram	O
.	O
The	O
percentage	O
of	O
stenosis	INDICATIONS
was	O
calculated	O
as	O
1	O
-	O
(	O
narrowest	O
vessel	O
diameter/maximal	O
midstent	O
diameter	O
within	O
the	O
artery	O
)	O
at	O
the	O
first	O
follow-up	O
angiogram	O
.	O
The	O
PubMed	O
,	O
Web	O
of	O
Science	O
,	O
and	O
EMBASE	O
databases	O
were	O
additionally	O
searched	O
from	O
inception	O
until	O
April	O
2018	O
for	O
the	O
rates	O
of	O
in-stent	INDICATIONS
stenosis	INDICATIONS
after	O
flow	O
diversion	O
.	O
A	O
total	O
of	O
155	O
patients	O
(	O
mean	O
age	O
,	O
58.3	O
years	O
;	O
30	O
males	O
)	O
with	O
162	O
aneurysms	INDICATIONS
underwent	O
treatment	O
with	O
the	O
PED	O
at	O
our	O
institution	O
.	O
In-stent	INDICATIONS
stenosis	INDICATIONS
was	O
detected	O
in	O
12	O
patients	O
(	O
7.1	O
%	O
)	O
at	O
6	O
months	O
.	O
The	O
mean	O
percentage	O
of	O
stenosis	INDICATIONS
was	O
39.7	O
%	O
.	O
All	O
12	O
patients	O
remained	O
asymptomatic	O
,	O
except	O
for	O
1	O
who	O
developed	O
hemiplegia	INDICATIONS
secondary	O
to	O
an	O
unrelated	O
ischemic	INDICATIONS
stroke	INDICATIONS
.	O
The	O
aneurysm	INDICATIONS
occlusion	O
rates	O
at	O
6	O
months	O
were	O
comparable	O
between	O
the	O
stenosis	INDICATIONS
and	O
nonstenosis	O
cohorts	O
(	O
76.9	O
%	O
and	O
71.6	O
%	O
,	O
respectively	O
)	O
.	O
Within	O
the	O
stenosis	INDICATIONS
cohort	O
,	O
further	O
follow-up	O
angiograms	O
after	O
6	O
months	O
were	O
available	O
for	O
6	O
patients	O
,	O
of	O
whom	O
3	O
(	O
50	O
%	O
)	O
had	O
either	O
complete	O
resolution	O
or	O
improvement	O
.	O
Of	O
the	O
43	O
included	O
studies	O
,	O
28	O
reported	O
on	O
the	O
use	O
of	O
the	O
PED	O
,	O
with	O
2448	O
patients	O
.	O
The	O
mean	O
reported	O
rate	O
of	O
in-stent	INDICATIONS
stenosis	INDICATIONS
after	O
PED	O
placement	O
was	O
8.8	O
%	O
(	O
range	O
,	O
0	O
%	O
-39	O
%	O
)	O
.	O
In-stent	INDICATIONS
stenosis	INDICATIONS
remains	O
a	O
rare	O
complication	O
of	O
PED	O
placement	O
for	O
intracranial	INDICATIONS
aneurysms	INDICATIONS
.	O
When	O
occurring	O
,	O
it	O
appears	O
to	O
largely	O
be	O
self-limiting	O
,	O
with	O
a	O
benign	O
clinical	O
course	O
.	O

The	O
evaluation	O
of	O
percutaneous	O
central	O
venous	O
catheters	O
--	O
a	O
convenient	O
technique	O
in	O
pediatric	O
patients	O
.	O
To	O
evaluate	O
the	O
feasibility	O
and	O
effectiveness	O
of	O
3	O
different	O
types	O
of	O
silastic	O
catheters	O
that	O
were	O
used	O
for	O
percutaneous	O
central	O
venous	O
catheterization	O
(	O
PCVC	O
)	O
through	O
peripheral	O
veins	O
.	O
The	O
study	O
was	O
prospective	O
and	O
consecutive	O
for	O
6	O
years	O
at	O
a	O
pediatric/neonatal	O
intensive	O
care	O
unit	O
and	O
pediatric	O
ward	O
in	O
Veterans	O
General	O
Hospital-Taipei	O
,	O
a	O
university-affiliated	O
medical	O
center	O
,	O
in	O
Taiwan	O
,	O
ROC	O
.	O
The	O
patients	O
who	O
had	O
PCVC	O
were	O
consecutively	O
enrolled	O
from	O
January	O
1988	O
to	O
December	O
1993	O
.	O
Three	O
types	O
of	O
silastic	O
catheters	O
were	O
used	O
.	O
The	O
classification	O
was	O
according	O
to	O
the	O
caliber	O
as	O
small	O
catheter	O
(	O
SC	O
,	O
0.30	O
mm	O
ID	O
)	O
,	O
mid-size	O
catheter	O
(	O
MC	O
,	O
0.51	O
mm	O
ID	O
)	O
and	O
large	O
catheter	O
(	O
LC	O
,	O
0.64	O
mm	O
ID	O
)	O
.	O
The	O
same	O
insertion	O
technique	O
,	O
catheter-through-needle	O
,	O
was	O
used	O
for	O
all	O
PCVC	O
placements	O
through	O
the	O
peripheral	O
vein	O
.	O
After	O
insertion	O
,	O
each	O
catheter	O
was	O
connected	O
to	O
a	O
conventional	O
short	O
cannula	O
(	O
24-	O
,	O
22-	O
,	O
or	O
20-gauge	O
)	O
of	O
compatible	O
caliber	O
,	O
and	O
then	O
linked	O
to	O
the	O
infusion	O
system	O
.	O
1318	O
PCVCs	O
were	O
used	O
in	O
1126	O
consecutive	O
patients	O
,	O
that	O
included	O
754	O
SCs	O
in	O
649	O
infants	O
(	O
among	O
them	O
60.9	O
%	O
were	O
less	O
than	O
1500	O
g	O
)	O
,	O
383	O
MCs	O
in	O
319	O
toddlers	O
,	O
and	O
181	O
LCs	O
in	O
158	O
children	O
.	O
Mean	O
(	O
SD	O
)	O
body	O
weight	O
at	O
the	O
time	O
of	O
catheter	O
insertion	O
was	O
SC	O
1.7	O
(	O
0.9	O
)	O
kg	O
,	O
MC	O
12.1	O
(	O
6.5	O
)	O
kg	O
and	O
LC	O
19.3	O
(	O
7.6	O
)	O
kg	O
.	O
Overall	O
,	O
mean	O
(	O
SD	O
)	O
duration	O
of	O
these	O
PCVC	O
was	O
16.4	O
(	O
8.4	O
)	O
days	O
.	O
A	O
significantly	O
longer	O
duration	O
was	O
noted	O
in	O
:	O
(	O
a	O
)	O
SC	O
group	O
with	O
19.7	O
(	O
10.4	O
)	O
days	O
than	O
the	O
other	O
two	O
groups	O
[	O
MC	O
12.4	O
(	O
6.5	O
)	O
days	O
,	O
LC	O
11.2	O
(	O
5.0	O
)	O
days	O
]	O
;	O
(	O
b	O
)	O
patients	O
with	O
body	O
weight	O
equal	O
to	O
or	O
less	O
than	O
3.0	O
kg	O
[	O
18.7	O
(	O
8.6	O
)	O
versus	O
14.1	O
(	O
6.1	O
)	O
;	O
and	O
(	O
c	O
)	O
insertion	O
sites	O
other	O
than	O
external	O
jugular	O
vein	O
(	O
EJV	O
)	O
[	O
18.8	O
(	O
9.7	O
)	O
versus	O
11.7	O
(	O
6.0	O
)	O
]	O
.	O
These	O
PCVCs	O
provided	O
reliable	O
venous	O
access	O
for	O
multiple	O
purposes	O
such	O
as	O
hyperalimentation	O
,	O
venous	O
access	O
or	O
sampling	O
of	O
blood	O
,	O
antibiotic	O
therapy	O
and	O
chemotherapy	O
.	O
MC	O
and	O
LC	O
were	O
also	O
used	O
for	O
monitoring	O
the	O
central	O
venous	O
pressure	O
.	O
Most	O
of	O
the	O
time	O
,	O
SC	O
and	O
MC	O
were	O
inserted	O
through	O
the	O
superficial	O
peripheral	O
vein	O
of	O
the	O
scalp	O
,	O
neck	O
and	O
extremities	O
,	O
while	O
LC	O
was	O
almost	O
approached	O
via	O
the	O
EJV	O
.	O
The	O
overall	O
success	O
rate	O
of	O
insertion	O
was	O
92.4	O
%	O
(	O
1318/1427	O
)	O
.	O
No	O
significant	O
difference	O
was	O
observed	O
among	O
the	O
different	O
catheter	O
groups	O
[	O
93.4	O
%	O
(	O
754/807	O
)	O
in	O
SC	O
,	O
90.5	O
%	O
(	O
383/423	O
)	O
in	O
MC	O
and	O
91.9	O
%	O
(	O
181/197	O
)	O
in	O
LC	O
]	O
and	O
the	O
different	O
insertion	O
sites	O
.	O
Within	O
each	O
group	O
of	O
PCVC	O
,	O
more	O
than	O
eighty	O
percent	O
of	O
catheters	O
were	O
removed	O
electively	O
:	O
83.3	O
%	O
in	O
SC	O
,	O
89.6	O
%	O
in	O
MC	O
and	O
84.5	O
%	O
in	O
LC	O
.	O
Probable	O
catheter-related	O
sepsis	INDICATIONS
accounted	O
for	O
2.7	O
%	O
(	O
36/1	O
,	O
318	O
)	O
of	O
all	O
PCVCs	O
.	O
With	O
this	O
study	O
,	O
the	O
cost	O
of	O
each	O
PCVC	O
set	O
is	O
3.0	O
US	O
dollar	O
.	O
This	O
study	O
indicates	O
that	O
the	O
use	O
of	O
three	O
different	O
calibers	O
of	O
silastic	O
catheter	O
is	O
feasible	O
and	O
effective	O
for	O
PCVC	O
in	O
pediatric	O
practice	O
.	O

Community	O
contact	O
persons	O
promote	O
utilization	O
of	O
obstetric	O
services	O
,	O
Anambra	O
State	O
,	O
Nigeria	O
.	O
The	O
Enugu	O
PMM	O
Team	O
.	O
Focus	O
group	O
discussions	O
revealed	O
delay	O
in	O
seeking	O
and	O
reaching	O
emergency	O
care	O
as	O
a	O
factor	O
contributing	O
to	O
maternal	O
mortality	O
in	O
Njikoka	O
Local	O
Government	O
Area	O
.	O
After	O
obstetric	O
services	O
at	O
local	O
hospitals	O
had	O
been	O
upgraded	O
,	O
48	O
community	O
contact	O
persons	O
were	O
recruited	O
.	O
They	O
were	O
trained	O
to	O
improve	O
community	O
awareness	O
of	O
obstetric	INDICATIONS
complications	INDICATIONS
and	O
to	O
facilitate	O
referral	O
of	O
women	O
with	O
complications	O
.	O
They	O
were	O
responsible	O
for	O
establishing	O
links	O
with	O
pregnant	O
women	O
,	O
improving	O
access	O
to	O
transport	O
,	O
and	O
mobilizing	O
the	O
community	O
to	O
donate	O
blood	O
.	O
Over	O
18	O
months	O
,	O
community	O
contact	O
persons	O
referred	O
18	O
women	O
with	O
major	O
obstetric	INDICATIONS
complications	INDICATIONS
for	O
treatment	O
at	O
health	O
facilities	O
.	O
Fifty-two	O
pregnant	O
women	O
were	O
referred	O
for	O
other	O
reasons	O
.	O
A	O
total	O
of	O
129	O
women	O
were	O
assisted	O
by	O
the	O
community	O
contact	O
persons	O
.	O
This	O
number	O
declined	O
sharply	O
over	O
time	O
,	O
from	O
60	O
in	O
the	O
first	O
half	O
of	O
1994	O
to	O
16	O
in	O
the	O
first	O
half	O
of	O
1995	O
.	O
The	O
community	O
contact	O
persons	O
intervention	O
cost	O
approximately	O
US	O
$	O
635	O
,	O
with	O
64	O
%	O
coming	O
from	O
project	O
funds	O
,	O
25	O
%	O
from	O
government	O
and	O
11	O
%	O
from	O
the	O
community	O
.	O
Community	O
contact	O
persons	O
can	O
perform	O
a	O
valuable	O
role	O
in	O
facilitating	O
referral	O
of	O
women	O
with	O
obstetric	INDICATIONS
complications	INDICATIONS
and	O
supporting	O
health	O
education	O
activities	O
.	O

The	O
prevention	O
of	O
sleep	O
problems	O
.	O
The	O
author	O
offers	O
guidelines	O
that	O
will	O
help	O
parents	O
with	O
the	O
prevention	O
of	O
colic	O
,	O
trained	O
night	O
feeding	O
,	O
trained	O
night	O
crying	O
,	O
fearful	O
night	O
crying	O
,	O
bedtime	O
temper	INDICATIONS
tantrums	INDICATIONS
,	O
and	O
bed-sharing	INDICATIONS
.	O
The	O
information	O
is	O
presented	O
chronologically	O
by	O
the	O
visit	O
at	O
which	O
it	O
should	O
be	O
addressed	O
.	O

Use	O
of	O
an	O
experimental	O
model	O
of	O
chlamydial	INDICATIONS
salpingitis	INDICATIONS
in	O
mice	O
for	O
the	O
evaluation	O
of	O
activity	O
of	O
antibiotics	O
and	O
anti-inflammatory	O
drugs	O
on	O
fertility	O
.	O
An	O
experimental	O
animal	O
model	O
has	O
been	O
used	O
to	O
study	O
the	O
separate	O
and	O
combined	O
use	O
of	O
antibiotics	O
and	O
anti-inflammatories	O
in	O
the	O
treatment	O
of	O
salpingitis	INDICATIONS
.	O
The	O
addition	O
of	O
an	O
anti-inflammatory	O
did	O
not	O
seem	O
to	O
help	O
preserve	O
fertility	O
.	O

Evaluation	O
of	O
the	O
patient	O
with	O
rheumatoid	INDICATIONS
arthritis	INDICATIONS
for	O
corrective	O
surgery	O
.	O

Pycnodysostosis	INDICATIONS
.	O

Pediatrics-epitomes	O
of	O
progress	O
:	O
antimicrobial	O
therapy	O
for	O
acute	INDICATIONS
otitis	INDICATIONS
media	INDICATIONS
in	O
children	O
.	O

[	O
The	O
ultrasound	O
semiotics	O
of	O
uncomplicated	O
wound	O
healing	O
after	O
inguinal	O
mesh	O
plastics	O
]	O
.	O
Dynamic	O
ultrasound	O
(	O
US	O
)	O
investigation	O
was	O
performed	O
in	O
89	O
patients	O
operated	O
on	O
inguinal	INDICATIONS
hernia	INDICATIONS
with	O
the	O
use	O
of	O
meshes	O
of	O
various	O
type	O
.	O
The	O
US	O
scanning	O
proved	O
to	O
be	O
a	O
highly	O
informative	O
means	O
of	O
visualization	O
,	O
allowing	O
the	O
objective	O
postoperative	O
assessment	O
of	O
muscular	O
and	O
aponeurotic	O
structures	O
as	O
well	O
as	O
the	O
implant	O
form	O
and	O
position	O
.	O
The	O
study	O
showed	O
,	O
that	O
the	O
mesh	O
implantation	O
was	O
always	O
accompanied	O
by	O
the	O
exudative	O
tissue	O
reaction	O
,	O
which	O
was	O
determined	O
by	O
the	O
physico-chemical	O
characteristics	O
of	O
the	O
implant	O
.	O

Influences	O
of	O
chlorpromazine	O
on	O
aqueous	INDICATIONS
humor	INDICATIONS
dynamics	O
.	O

Heterogeneity	O
of	O
lymphocyte	O
subpopulations	O
in	O
severe	INDICATIONS
combined	INDICATIONS
immunodeficiency	INDICATIONS
.	O
Evidence	O
against	O
a	O
stem	O
cell	O
defect	O
.	O
Surface	O
markers	O
typical	O
of	O
T	O
and	O
B	O
lymphocytes	O
were	O
present	O
on	O
varying	O
proportions	O
of	O
peripheral	O
blood	O
lymphocytes	O
from	O
three	O
infants	O
with	O
severe	INDICATIONS
combined	INDICATIONS
immunodeficiency	INDICATIONS
disease	INDICATIONS
.	O
Despite	O
this	O
,	O
functions	O
mediated	O
by	O
T	O
and	O
B	O
cells	O
were	O
either	O
absent	O
or	O
very	O
minimal	O
in	O
all	O
three	O
,	O
including	O
cell-mediated	INDICATIONS
responses	INDICATIONS
in	O
vivo	O
;	O
the	O
in	O
vitro	O
proliferative	O
response	O
to	O
mitogens	O
,	O
allogeneic	O
cells	O
,	O
or	O
antigens	O
;	O
effector	O
cell	O
function	O
in	O
lymphocyte-antibody	O
lymphocytolytic	O
interaction	O
assays	O
;	O
and	O
in	O
vitro	O
synthesis	O
of	O
IgG	O
,	O
IgA	O
,	O
and	O
IgM	O
.	O
In	O
contrast	O
,	O
mononuclear	O
cells	O
from	O
one	O
of	O
the	O
infants	O
were	O
tested	O
and	O
found	O
capable	O
of	O
lysing	INDICATIONS
both	O
human	O
and	O
chicken	O
antibody-coated	O
erythrocyte	O
targets	O
normally	O
.	O
Co-cultivation	O
experiments	O
with	O
unrelated	O
normal	O
control	O
lymphocytes	O
failed	O
to	O
demonstrate	O
suppressor	O
cell	O
activity	O
for	O
immunoglobulin	O
synthesis	O
in	O
these	O
infants	O
.	O
Augmentations	O
of	O
immunoglobulin	O
production	O
from	O
310	O
to	O
560	O
%	O
over	O
that	O
expected	O
on	O
the	O
basis	O
of	O
individual	O
culture	O
data	O
were	O
noted	O
in	O
co-cultures	O
of	O
one	O
of	O
the	O
infants	O
'	O
cells	O
with	O
two	O
different	O
unrelated	O
normal	O
control	O
cells	O
.	O
These	O
findings	O
suggest	O
that	O
that	O
infant	O
may	O
have	O
had	O
a	O
T	O
helper	O
cell	O
defect	O
or	O
that	O
his	O
T	O
cells	O
were	O
unable	O
to	O
produce	O
soluble	O
factors	O
necessary	O
for	O
B	O
cell	O
differentiation	O
.	O
The	O
finding	O
of	O
cells	O
with	O
differentiation	O
markers	O
characteristic	O
of	O
T	O
and	O
B	O
lymphocytes	O
in	O
each	O
of	O
these	O
patients	O
,	O
though	O
in	O
variable	O
quantities	O
,	O
is	O
further	O
evidence	O
for	O
heterogeneity	O
among	O
patients	O
with	O
the	O
clinical	INDICATIONS
syndrome	INDICATIONS
of	O
severe	INDICATIONS
combined	INDICATIONS
immunodeficiency	INDICATIONS
and	O
argues	O
against	O
the	O
concept	O
that	O
their	O
immunodeficiency	INDICATIONS
was	O
due	O
to	O
a	O
stem	O
cell	O
defect	O
.	O

Focal	INDICATIONS
Infections	INDICATIONS
:	O
Ileal	O
and	O
Colonic	O
Stasis	O
.	O

Consequences	O
of	O
prolonged	O
inhalation	INDICATIONS
of	INDICATIONS
ozone	INDICATIONS
on	O
F344/N	O
rats	O
:	O
collaborative	INDICATIONS
studies	O
.	O
Part	O
V	O
:	O
Effects	O
on	O
pulmonary	O
function	O
.	O
The	O
impact	O
of	O
a	O
20-month	O
exposure	O
to	O
ozone	O
on	O
the	O
pulmonary	O
function	O
of	O
rats	O
was	O
assessed	O
from	O
a	O
single	O
series	O
of	O
measurements	O
made	O
after	O
exposures	O
were	O
completed	O
.	O
Four	O
to	O
ten	O
male	O
and	O
female	O
F344/N	O
rats	O
per	O
group	O
were	O
exposed	O
six	O
hours	O
per	O
day	O
,	O
five	O
days	O
per	O
week	O
,	O
for	O
20	O
months	O
to	O
ozone	O
at	O
0.12	O
,	O
0.5	O
,	O
or	O
1.0	O
parts	O
per	O
million	O
(	O
ppm	O
)	O
,	O
or	O
to	O
clean	O
air	O
as	O
controls	O
.	O
One	O
to	O
three	O
days	O
after	O
the	O
last	O
exposure	O
,	O
the	O
rats	O
were	O
anesthetized	O
using	O
halothane	O
,	O
fitted	O
with	O
oral	O
endotracheal	O
and	O
esophageal	O
catheters	O
,	O
and	O
measured	O
using	O
plethysmographic	O
techniques	O
.	O
The	O
differences	O
between	O
mean	O
values	O
for	O
control	O
and	O
treated	O
rats	O
were	O
tested	O
for	O
significance	O
by	O
multiple	O
comparisons	O
.	O
The	O
values	O
and	O
intersubject	O
variability	O
for	O
more	O
than	O
30	O
measured	O
and	O
calculated	O
parameters	O
were	O
similar	O
to	O
those	O
reported	O
previously	O
for	O
rats	O
of	O
similar	O
age	O
.	O
The	O
only	O
consistent	O
exposure-related	O
effect	O
was	O
a	O
small	O
reduction	O
of	O
residual	O
volume	O
measured	O
during	O
slow	O
lung	O
deflation	O
.	O
This	O
trend	O
was	O
observed	O
in	O
most	O
exposure	O
groups	O
,	O
but	O
was	O
most	O
significant	O
in	O
females	O
exposed	O
to	O
ozone	O
at	O
the	O
0.5	O
ppm	O
level	O
.	O
Fibrosis	O
and	O
epithelial	O
changes	O
were	O
observed	O
in	O
the	O
terminal	O
bronchiole-alveolar	O
duct	O
region	O
in	O
parallel	O
studies	O
of	O
different	O
rats	O
from	O
the	O
same	O
exposure	O
groups	O
.	O
We	O
hypothesized	O
that	O
these	O
changes	O
stiffened	O
airspace	O
walls	O
and	O
acted	O
to	O
maintain	O
the	O
patency	O
of	O
the	O
air	O
pathway	O
at	O
a	O
lower	O
than	O
normal	O
lung	O
volume	O
during	O
deflation	O
.	O
Overall	O
,	O
the	O
exposures	O
had	O
little	O
impact	O
on	O
the	O
integrated	O
pulmonary	O
function	O
of	O
the	O
lung	O
as	O
measured	O
in	O
anesthetized	O
rats	O
.	O

Measles	O
virus	O
nucleotide	O
sequences	O
:	O
detection	O
by	O
hybridization	O
in	O
situ	O
.	O
A	O
tritium-labeled	O
probe	O
that	O
detects	O
measles	O
virus	O
nucleotide	O
sequences	O
was	O
hybridized	O
in	O
situ	O
to	O
cells	O
infected	O
with	O
measles	O
virus	O
and	O
to	O
sections	O
of	O
brain	O
tissue	O
from	O
patients	O
with	O
subacute	INDICATIONS
sclerosing	INDICATIONS
panencephalitis	INDICATIONS
and	O
from	O
patients	O
with	O
multiple	INDICATIONS
sclerosis	INDICATIONS
.	O
The	O
measles	O
virus	O
genome	O
was	O
detected	O
in	O
many	O
cells	O
in	O
subacute	INDICATIONS
sclerosing	INDICATIONS
panencephalitis	INDICATIONS
where	O
this	O
virus	O
would	O
have	O
been	O
missed	O
by	O
methods	O
such	O
as	O
immunofluorescence	O
.	O
Measles	O
virus	O
sequences	O
were	O
also	O
found	O
in	O
two	O
foci	O
in	O
one	O
of	O
four	O
cases	O
of	O
multiple	INDICATIONS
sclerosis	INDICATIONS
.	O
This	O
refined	O
method	O
of	O
hybridization	O
in	O
situ	O
,	O
which	O
can	O
be	O
useful	O
in	O
the	O
search	O
for	O
covert	O
virus	INDICATIONS
infections	INDICATIONS
of	O
man	O
,	O
provides	O
evidence	O
that	O
viruses	O
may	O
be	O
involved	O
in	O
multiple	INDICATIONS
sclerosis	INDICATIONS
.	O

[	O
The	O
health	O
status	O
of	O
the	O
rural	O
population	O
living	O
in	O
the	O
areas	O
contiguous	O
with	O
industrial	O
towns	O
]	O
.	O
Exposed	O
to	O
environmental	O
pollution	O
with	O
emissions	O
from	O
industrial	O
enterprises	O
,	O
the	O
population	O
of	O
their	O
contiguous	O
rural	O
areas	O
faces	O
a	O
high	O
risk	O
of	O
their	O
health	O
.	O
The	O
studies	O
of	O
the	O
health	O
status	O
of	O
the	O
population	O
from	O
the	O
contiguous	O
rural	O
areas	O
versus	O
that	O
from	O
the	O
non-contiguous	O
ones	O
have	O
established	O
that	O
measurements	O
of	O
a	O
risk	O
to	O
the	O
children	O
's	O
health	O
revealed	O
the	O
highest	O
risk	O
among	O
the	O
contiguous	O
areas	O
in	O
the	O
Sterlitamaksky	O
district	O
and	O
the	O
least	O
risk	O
among	O
the	O
non-contiguous	O
ones	O
in	O
the	O
Askinsky	O
district	O
.	O
The	O
markers	O
of	O
carcinogenic	O
ill-being	O
in	O
the	O
contiguous	O
rural	O
areas	O
were	O
the	O
incidence	O
of	O
cancer	INDICATIONS
of	INDICATIONS
the	INDICATIONS
lip	INDICATIONS
,	O
esophagus	O
,	O
stomach	O
,	O
larynx	INDICATIONS
,	O
cervix	INDICATIONS
uteri	INDICATIONS
,	O
uterine	O
appendages	O
,	O
and	O
prostate	O
and	O
leukemia	INDICATIONS
.	O
The	O
high	O
risk	O
of	O
cancer	INDICATIONS
of	INDICATIONS
the	INDICATIONS
lip	INDICATIONS
and	O
esophagus	O
in	O
the	O
control	O
area	O
and	O
in	O
other	O
non-contiguous	O
rural	O
areas	O
may	O
be	O
accounted	O
for	O
by	O
the	O
bad	O
life-style	O
in	O
villagers	O
,	O
alcohol	O
abuse	O
,	O
and	O
smoking	O
.	O

A	O
Phase	O
Ib	O
,	O
Open-Label	O
Study	O
of	O
Dalantercept	O
,	O
an	O
Activin	O
Receptor-Like	O
Kinase	O
1	O
Ligand	O
Trap	O
,	O
plus	O
Sorafenib	O
in	O
Advanced	O
Hepatocellular	INDICATIONS
Carcinoma	INDICATIONS
.	O
Patients	O
with	O
hepatocellular	INDICATIONS
carcinoma	INDICATIONS
(	O
HCC	O
)	O
often	O
have	O
limited	O
therapeutic	O
responses	O
to	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
tyrosine	O
kinase	O
inhibitor	O
sorafenib	O
,	O
which	O
is	O
standard	O
of	O
care	O
in	O
advanced	O
HCC	O
.	O
Targeting	O
the	O
activin	O
receptor-like	O
kinase	O
1	O
(	O
ALK1	O
)	O
and	O
VEGF	O
pathways	O
simultaneously	O
by	O
combining	O
the	O
ALK1	O
ligand	O
trap	O
dalantercept	O
with	O
sorafenib	O
may	O
result	O
in	O
more	O
effective	O
angiogenic	INDICATIONS
blockade	O
and	O
delay	O
tumor	INDICATIONS
progression	INDICATIONS
in	O
patients	O
with	O
advanced	O
HCC.Although	O
the	O
combination	O
was	O
generally	O
well	O
tolerated	O
,	O
there	O
was	O
no	O
additive	O
antitumor	O
activity	O
with	O
the	O
combination	O
of	O
dalantercept	O
plus	O
sorafenib	O
in	O
patients	O
with	O
advanced	O
HCC	O
.	O
No	O
complete	O
or	O
partial	O
responses	O
were	O
observed	O
,	O
and	O
overall	O
survival	O
ranged	O
from	O
1.9	O
to	O
23.3	O
months.These	O
results	O
suggest	O
that	O
,	O
in	O
this	O
patient	O
population	O
,	O
further	O
development	O
of	O
the	O
possible	O
limited	O
benefits	O
of	O
combination	O
therapy	O
with	O
dalantercept	O
plus	O
sorafenib	O
is	O
not	O
warranted	O
.	O
Targeting	O
the	O
activin	O
receptor-like	O
kinase	O
1	O
(	O
ALK1	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
pathways	O
may	O
result	O
in	O
more	O
effective	O
angiogenic	INDICATIONS
blockade	O
in	O
patients	O
with	O
hepatocellular	INDICATIONS
carcinoma	INDICATIONS
(	O
HCC	O
)	O
.	O
In	O
this	O
phase	O
Ib	O
study	O
,	O
patients	O
with	O
advanced	O
HCC	O
were	O
enrolled	O
to	O
dose-escalation	O
cohorts	O
,	O
starting	O
at	O
0.6	O
mg/kg	O
dalantercept	O
subcutaneously	O
every	O
3	O
weeks	O
plus	O
400	O
mg	O
sorafenib	O
orally	O
once	O
daily	O
,	O
or	O
to	O
a	O
dose	O
expansion	O
cohort	O
.	O
The	O
primary	O
objective	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
and	O
the	O
dalantercept	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
level	O
.	O
Secondary	O
objectives	O
were	O
to	O
assess	O
the	O
preliminary	O
activity	O
and	O
the	O
association	O
of	O
pharmacodynamic	O
biomarkers	O
with	O
tumor	O
response	O
.	O
A	O
total	O
of	O
21	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
.	O
Five	O
patients	O
received	O
0.6	O
mg/kg	O
dalantercept	O
in	O
the	O
first	O
dose	O
escalation	O
cohort	O
.	O
Based	O
on	O
the	O
initial	O
safety	O
results	O
,	O
the	O
dose	O
level	O
was	O
de-escalated	O
to	O
0.4	O
mg/kg	O
in	O
the	O
second	O
cohort	O
(	O
=	O
6	O
)	O
.	O
The	O
MTD	O
was	O
identified	O
as	O
0.4	O
mg/kg	O
and	O
used	O
for	O
the	O
dose	O
expansion	O
cohort	O
(	O
=	O
10	O
)	O
.	O
At	O
this	O
dose	O
level	O
,	O
the	O
combination	O
was	O
generally	O
well	O
tolerated	O
.	O
Overall	O
survival	O
ranged	O
from	O
1.9	O
to	O
23.3	O
months	O
,	O
and	O
the	O
best	O
overall	O
response	O
was	O
stable	O
disease	O
.	O
The	O
addition	O
of	O
dalantercept	O
to	O
sorafenib	O
did	O
not	O
improve	O
antitumor	O
activity	O
in	O
patients	O
with	O
HCC	O
.	O
The	O
dalantercept	O
program	O
in	O
this	O
population	O
was	O
discontinued	O
.	O

Computed	O
tomographic	O
appearance	O
of	O
urachal	INDICATIONS
carcinoma	INDICATIONS
associated	O
with	O
urachal	INDICATIONS
diverticulum	INDICATIONS
misdiagnosed	O
by	O
cystoscopy	O
.	O
Urachal	INDICATIONS
carcinoma	INDICATIONS
associated	O
with	O
the	O
urachal	INDICATIONS
diverticulum	INDICATIONS
is	O
rare	O
.	O
We	O
present	O
a	O
surgical	O
case	O
of	O
this	O
condition	O
that	O
was	O
initially	O
diagnosed	O
as	O
bladder	INDICATIONS
urothelial	INDICATIONS
carcinoma	INDICATIONS
by	O
cystoscopy	O
,	O
but	O
was	O
then	O
correctly	O
diagnosed	O
by	O
computed	O
tomography	O
(	O
CT	O
)	O
.	O
Whereas	O
the	O
CT	O
appearance	O
mimicked	O
that	O
of	O
bladder	INDICATIONS
cancer	INDICATIONS
,	O
accurate	O
localization	O
of	O
the	O
lesion	O
and	O
identification	O
of	O
the	O
median	O
umbilical	O
ligament	O
clarified	O
diagnosis	O
.	O

Diagnosis	O
of	O
primary	INDICATIONS
ovarian	INDICATIONS
cancer	INDICATIONS
.	O

Translumbar	O
aortography	O
followed	O
by	O
fatal	O
renal	INDICATIONS
failure	INDICATIONS
and	O
severe	O
hemorrhagic	INDICATIONS
diathesis	INDICATIONS
.	O

Modulation	O
of	O
cardiac	O
physiology	O
by	O
an	O
anti-Trypanosoma	O
cruzi	O
monoclonal	O
antibody	O
after	O
interaction	O
with	O
myocardium	O
.	O
Circulating	O
antibodies	O
from	O
human	O
and	O
murine	O
chagasic	O
sera	O
are	O
able	O
to	O
interact	O
with	O
myocardium	O
,	O
activating	O
neurotransmitter	O
receptors	O
.	O
Here	O
,	O
we	O
studied	O
the	O
effects	O
of	O
a	O
monoclonal	O
antibody	O
(	O
MAb	O
CAK20.12	O
)	O
,	O
which	O
recognizes	O
a	O
150	O
kilodalton	O
antigen	O
of	O
Trypanosoma	O
cruzi	O
and	O
reacts	O
with	O
normal	O
human	O
and	O
murine	O
striated	O
muscles	O
and	O
with	O
cardiac	O
tissue	O
.	O
The	O
MAb	O
CAK20.12	O
binds	O
to	O
purified	O
cardiac	O
membranes	O
and	O
interferes	O
with	O
the	O
binding	O
of	O
beta-adrenergic	O
receptor	O
radioligand	O
(	O
[	O
125I	O
]	O
CYP	O
)	O
and	O
muscarinic	O
cholinergic	O
receptor	O
(	O
mAChR	O
)	O
radioligand	O
(	O
[	O
3H	O
]	O
QNB	O
)	O
in	O
a	O
noncompetitive	O
way	O
.	O
As	O
a	O
consequence	O
of	O
this	O
interaction	O
,	O
beta-adrenergic	O
receptor	O
and	O
mAChR	O
were	O
activated	O
,	O
leading	O
to	O
increased	O
intracellular	O
levels	O
of	O
cyclic	O
AMP	O
as	O
a	O
result	O
of	O
beta-adrenergic	O
receptor-coupled	O
adenylate	O
cyclase	O
triggering	O
.	O
When	O
its	O
sympathetic	O
action	O
was	O
abrogated	O
,	O
it	O
also	O
induced	O
an	O
mAChR-mediated	O
increase	O
in	O
cyclic	O
GMP	O
.	O
Furthermore	O
,	O
cardiac	O
physiology	O
was	O
modified	O
by	O
MAb	O
CAK20.12	O
,	O
as	O
it	O
was	O
able	O
to	O
increase	O
cardiac	O
contractility	O
through	O
beta-adrenoceptor	O
activation	O
and	O
to	O
decrease	O
atrial	O
frequency	O
as	O
a	O
result	O
of	O
mAChR	O
activation	O
.	O
The	O
fact	O
that	O
this	O
MAb	O
modulates	O
and	O
modifies	O
the	O
mechanical	O
and	O
biochemical	O
activity	O
of	O
normal	O
murine	O
heart	O
established	O
an	O
important	O
basis	O
for	O
future	O
research	O
and	O
understanding	O
of	O
how	O
the	O
host	O
's	O
humoral	O
immune	O
response	O
acts	O
on	O
the	O
course	O
and	O
development	O
of	O
the	O
chronic	O
chagasic	O
myocardiopathy	INDICATIONS
.	O

[	O
Cloning	O
,	O
expression	O
and	O
functional	O
identification	O
of	O
a	O
type	O
III	O
polyketide	O
synthase	O
gene	O
from	O
Huperzia	O
serrata	O
]	O
.	O
A	O
cDNA	O
encoding	O
novel	O
type	O
III	O
polyketide	O
synthase	O
(	O
PKS	O
)	O
was	O
cloned	O
and	O
sequenced	O
from	O
young	O
leaves	O
of	O
Chinese	O
club	O
moss	O
Huperzia	O
serrata	O
(	O
Thunb	O
.	O
)	O
Trev	O
.	O
by	O
RT-PCR	O
using	O
degenerated	O
primers	O
based	O
on	O
the	O
conserved	O
sequences	O
of	O
known	O
CHSs	O
,	O
and	O
named	O
as	O
H.	O
serrata	O
PKS2	O
.	O
The	O
terminal	O
sequences	O
of	O
cDNA	O
were	O
obtained	O
by	O
the	O
3'-	O
and	O
5'-RACE	O
method	O
.	O
The	O
full-length	O
cDNA	O
of	O
H.	O
serrata	O
PKS2	O
contained	O
a	O
1212	O
bp	O
open	O
reading	O
frame	O
encoding	O
a	O
46.4	O
kDa	O
protein	O
with	O
404	O
amino	O
acids	O
.	O
The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
H.	O
serrata	O
PKS2	O
showed	O
50	O
%	O
-66	O
%	O
identities	O
to	O
those	O
of	O
other	O
chalcone	O
synthase	O
super	O
family	O
enzymes	O
of	O
plant	O
origin	O
.	O
The	O
recombinant	O
H.	O
serrata	O
PKS2	O
was	O
functionally	O
expressed	O
in	O
Escherichia	O
coli	O
with	O
an	O
additional	O
hexahistidine	O
tag	O
at	O
the	O
N-terminus	O
and	O
showed	O
unusually	O
versatile	O
catalytic	O
potency	O
to	O
produce	O
various	O
aromatic	O
tetraketides	O
,	O
including	O
chalcones	O
,	O
benzophenones	O
,	O
phloroglucinols	O
,	O
and	O
acridones	O
.	O
In	O
particular	O
,	O
the	O
enzyme	O
accepted	O
bulky	O
starter	O
substrates	O
N-methylanthraniloyl-CoA	O
,	O
and	O
carried	O
out	O
three	O
condensations	INDICATIONS
with	O
malonyl-CoA	O
to	O
produce	O
1	O
,	O
3-dihydroxy-N-methylacridone	O
.	O
Interestingly	O
,	O
H.	O
serrata	O
PKS2	O
lacks	O
most	O
of	O
the	O
consensus	O
active	O
site	O
sequences	O
with	O
acridone	O
synthase	O
from	O
Ruta	O
graveolens	O
(	O
Rutaceae	O
)	O
.	O

Serous	O
surface	O
carcinoma	INDICATIONS
of	INDICATIONS
the	INDICATIONS
ovary	INDICATIONS
and	O
peritoneum	INDICATIONS
.	O
A	O
flow	O
cytometric	O
study	O
.	O

Myositis	INDICATIONS
and	O
acute	INDICATIONS
respiratory	INDICATIONS
infection	INDICATIONS
.	O

Measurement	O
of	O
peripheral	O
muscle	O
resistance	O
in	O
rats	O
with	O
chronic	O
ischemia-induced	INDICATIONS
paraplegia	INDICATIONS
or	O
morphine-induced	O
rigidity	O
using	O
a	O
semi-automated	O
computer-controlled	O
muscle	O
resistance	O
meter	O
.	O
In	O
experimental	O
and	O
clinical	O
studies	O
,	O
an	O
objective	O
assessment	O
of	O
peripheral	O
muscle	O
resistance	O
represents	O
one	O
of	O
the	O
key	O
elements	O
in	O
determining	O
the	O
efficacy	O
of	O
therapeutic	O
manipulations	O
(	O
e.g	O
.	O
pharmacological	O
,	O
surgical	O
)	O
aimed	O
to	O
ameliorate	O
clinical	O
signs	O
of	O
spasticity	O
and/or	O
rigidity	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
characterize	O
a	O
newly	O
developed	O
limb	O
flexion	O
resistance	O
meter	O
which	O
permits	O
a	O
semi-automated	O
,	O
computer-controlled	O
measurement	O
of	O
peripheral	O
muscle	O
resistance	O
(	O
PMR	O
)	O
in	O
the	O
lower	O
extremities	O
during	O
a	O
forced	O
flexion	O
of	O
the	O
ankle	O
in	O
the	O
awake	O
rat	O
.	O
Ischemic	O
paraplegia	INDICATIONS
was	O
induced	O
in	O
Sprague-Dawley	O
rats	O
by	O
transient	O
aortic	INDICATIONS
occlusion	INDICATIONS
(	O
10	O
min	O
)	O
in	O
combination	O
with	O
systemic	O
hypotension	INDICATIONS
(	O
40	O
mm	O
Hg	O
)	O
.	O
After	O
ischemia	INDICATIONS
the	O
presence	O
of	O
spasticity	O
component	O
was	O
determined	O
by	O
the	O
presence	O
of	O
an	O
exaggerated	O
EMG	O
activity	O
recorded	O
from	O
gastrocnemius	O
muscle	O
after	O
nociceptive	O
or	O
proprioceptive	O
afferent	O
activation	O
and	O
by	O
velocity-dependent	O
increase	O
in	O
muscle	O
resistance	O
.	O
Rigidity	O
was	O
induced	O
by	O
high	O
dose	O
(	O
30	O
mg/kg	O
,	O
i.p	O
.	O
)	O
of	O
morphine	O
.	O
Animals	O
with	O
defined	O
ischemic	O
spasticity	O
or	O
morphine-induced	O
rigidity	O
were	O
then	O
placed	O
into	O
a	O
plastic	O
restrainer	O
and	O
a	O
hind	O
paw	O
attached	O
by	O
a	O
tape	O
to	O
a	O
metal	O
plate	O
driven	O
by	O
a	O
computer-controlled	O
stepping	O
motor	O
equipped	O
with	O
a	O
resistance	O
transducer	O
.	O
The	O
resistance	O
of	O
the	O
ankle	O
to	O
rotation	O
was	O
measured	O
under	O
several	O
testing	O
paradigms	O
:	O
(	O
i	O
)	O
variable	O
degree	O
of	O
ankle	O
flexion	O
(	O
40	O
degrees	O
,	O
50	O
degrees	O
,	O
and	O
60	O
degrees	O
)	O
,	O
(	O
ii	O
)	O
variable	O
speed/rate	O
of	O
ankle	O
flexion	O
(	O
2	O
,	O
3	O
,	O
and	O
4	O
sec	O
)	O
,	O
(	O
iii	O
)	O
the	O
effect	O
of	O
inhalation	O
anesthesia	O
,	O
(	O
iv	O
)	O
the	O
effect	O
of	O
intrathecal	O
baclofen	O
,	O
(	O
v	O
)	O
the	O
effect	O
of	O
dorsal	O
L2-L5	O
rhizotomy	O
,	O
or	O
(	O
vi	O
)	O
systemic	O
naloxone	O
treatment	O
.	O
In	O
animals	O
with	O
ischemic	O
paraplegia	INDICATIONS
an	O
increased	O
EMG	O
response	O
after	O
peripheral	O
nociceptive	O
or	O
proprioceptive	O
activation	O
was	O
measured	O
.	O
In	O
control	O
animals	O
average	O
muscle	O
resistance	O
was	O
78	O
mN	O
and	O
was	O
significantly	O
increased	O
in	O
animals	O
with	O
ischemic	O
spasticity	O
(	O
981-7900	O
mN	O
)	O
.	O
In	O
ischemic-spastic	O
animals	O
a	O
significant	O
increase	O
in	O
measured	O
muscle	O
resistance	O
was	O
seen	O
after	O
increased	O
velocity	O
(	O
4	O
>	O
3	O
>	O
2	O
sec	O
)	O
and	O
the	O
angle	O
(	O
40	O
degrees	O
>	O
50	O
degrees	O
>	O
60	O
degrees	O
)	O
of	O
the	O
ankle	O
rotation	O
.	O
In	O
spastic	O
animals	O
,	O
deep	O
halothane	O
anesthesia	O
,	O
intrathecal	O
baclofen	O
or	O
dorsal	O
rhizotomy	O
decreased	O
muscle	O
resistance	O
to	O
39-80	O
%	O
of	O
pretreatment	O
values	O
.	O
Systemic	O
treatment	O
with	O
morphine	O
induced	O
muscle	INDICATIONS
rigidity	INDICATIONS
and	O
corresponding	O
increase	O
in	O
muscle	O
resistance	O
.	O
Morphine-induced	O
increase	O
in	O
muscle	O
resistance	O
was	O
independent	O
on	O
the	O
velocity	O
of	O
the	O
ankle	O
rotation	O
and	O
was	O
reversed	O
by	O
naloxone	O
.	O
These	O
data	O
show	O
that	O
by	O
using	O
this	O
system	O
it	O
is	O
possible	O
to	O
objectively	O
measure	O
the	O
degree	O
of	O
peripheral	O
muscle	O
resistance	O
.	O
The	O
use	O
of	O
this	O
system	O
may	O
represent	O
a	O
simple	O
and	O
effective	O
experimental	O
tool	O
in	O
screening	O
new	O
pharmacological	O
compounds	O
and/or	O
surgical	O
manipulations	O
targeted	O
to	O
modulate	O
spasticity	O
and/or	O
rigidity	O
after	O
a	O
variety	O
of	O
neurological	INDICATIONS
disorders	INDICATIONS
such	O
as	O
spinal	INDICATIONS
cord	INDICATIONS
traumatic	O
or	O
ischemic	O
injury	INDICATIONS
,	INDICATIONS
multiple	INDICATIONS
sclerosis	INDICATIONS
,	INDICATIONS
cerebral	INDICATIONS
palsy	O
,	O
or	O
Parkinson	INDICATIONS
's	INDICATIONS
disease	INDICATIONS
.	O

Spatial	O
and	O
temporal	O
variations	O
of	O
mechanical	O
properties	O
and	O
mineral	O
content	O
of	O
the	O
external	O
callus	O
during	O
bone	O
healing	O
.	O
After	O
bone	INDICATIONS
fracture	INDICATIONS
,	O
various	O
cellular	O
activities	O
lead	O
to	O
the	O
formation	O
of	O
different	O
tissue	O
types	O
,	O
which	O
form	O
the	O
basis	O
for	O
the	O
process	O
of	O
secondary	O
bone	O
healing	O
.	O
Although	O
these	O
tissues	O
have	O
been	O
quantified	O
by	O
histology	O
,	O
their	O
material	O
properties	O
are	O
not	O
well	O
understood	O
.	O
Thus	O
,	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
correlate	O
the	O
spatial	O
and	O
temporal	O
variations	O
in	O
the	O
mineral	O
content	O
and	O
the	O
nanoindentation	O
modulus	O
of	O
the	O
callus	O
formed	O
via	O
intramembranous	O
ossification	O
over	O
the	O
course	O
of	O
bone	O
healing	O
.	O
Midshaft	O
tibial	O
samples	O
from	O
a	O
sheep	O
osteotomy	O
model	O
at	O
time	O
points	O
of	O
2	O
,	O
3	O
,	O
6	O
and	O
9	O
weeks	O
were	O
employed	O
.	O
PMMA	O
embedded	O
blocks	O
were	O
used	O
for	O
quantitative	O
back	O
scattered	O
electron	O
imaging	O
and	O
nanoindentation	O
of	O
the	O
newly	O
formed	O
periosteal	O
callus	O
near	O
the	O
cortex	O
.	O
The	O
resulting	O
indentation	O
modulus	O
maps	O
show	O
the	O
heterogeneity	O
in	O
the	O
modulus	O
in	O
the	O
selected	O
regions	O
of	O
the	O
callus	O
.	O
The	O
indentation	O
modulus	O
of	O
the	O
embedded	O
callus	O
is	O
about	O
6	O
GPa	O
at	O
the	O
early	O
stage	O
.	O
At	O
later	O
stages	O
of	O
mineralization	O
,	O
the	O
average	O
indentation	O
modulus	O
reaches	O
14	O
GPa	O
.	O
There	O
is	O
a	O
slight	O
decrease	O
in	O
average	O
indentation	O
modulus	O
in	O
regions	O
distant	O
to	O
the	O
cortex	O
,	O
probably	O
due	O
to	O
remodelling	O
of	O
the	O
peripheral	O
callus	O
.	O
The	O
spatial	O
and	O
temporal	O
distribution	O
of	O
mineral	O
content	O
in	O
the	O
callus	O
tissue	O
also	O
illustrates	O
the	O
ongoing	O
remodelling	O
process	O
observed	O
from	O
histological	O
analysis	O
.	O
Most	O
interestingly	O
the	O
average	O
indentation	O
modulus	O
,	O
even	O
at	O
9	O
weeks	O
,	O
remains	O
as	O
low	O
as	O
13	O
GPa	O
,	O
which	O
is	O
roughly	O
60	O
%	O
of	O
that	O
for	O
cortical	O
sheep	O
bone	O
.	O
The	O
decreased	O
indentation	O
modulus	O
in	O
the	O
callus	O
compared	O
to	O
cortex	O
is	O
due	O
to	O
the	O
lower	O
average	O
mineral	O
content	O
and	O
may	O
be	O
perhaps	O
also	O
due	O
to	O
the	O
properties	O
of	O
the	O
organic	O
matrix	O
which	O
might	O
be	O
different	O
from	O
normal	O
bone	O
.	O

[	O
A	O
case	O
of	O
drug-induced	O
interstitial	INDICATIONS
pneumonitis	INDICATIONS
after	O
adjuvant	O
chemotherapy	O
with	O
gemcitabine	O
for	O
bile	INDICATIONS
duct	INDICATIONS
cancer	INDICATIONS
]	O
.	O
A	O
70-year-old	O
man	O
received	O
pancreaticoduodenectomy	O
for	O
bile	INDICATIONS
duct	INDICATIONS
cancer	INDICATIONS
and	O
had	O
been	O
administered	O
gemcitabine	O
for	O
1	O
year	O
as	O
adjuvant	O
chemotherapy	O
.	O
He	O
complained	O
of	O
shortness	O
of	O
breath	O
on	O
effort	O
and	O
was	O
admitted	O
for	O
gemcitabine-induced	O
interstitial	INDICATIONS
pneumonitis	INDICATIONS
.	O
His	O
respiratory	O
status	O
was	O
worsening	O
after	O
admission	O
,	O
so	O
he	O
was	O
transferred	O
in	O
the	O
intensive-care	O
unit	O
and	O
required	O
mechanical	O
ventilator	O
and	O
steroid	O
pulse	O
therapy	O
with	O
1,000	O
mg/day	O
of	O
methylprednisolone	O
.	O
His	O
symptoms	O
and	O
radiological	O
findings	O
were	O
dramatically	O
improved	O
.	O
The	O
patient	O
could	O
be	O
discharged	O
on	O
the	O
24th	O
day	O
after	O
admission	O
.	O
Interstitial	INDICATIONS
pneumonitis	INDICATIONS
induced	O
by	O
gemcitabine	O
is	O
rare	O
,	O
but	O
could	O
lead	O
to	O
severe	O
complications	O
,	O
which	O
could	O
develop	O
after	O
long-term	O
administration	O
and	O
should	O
be	O
treated	O
by	O
corticosteroid	O
as	O
soon	O
as	O
possible	O
.	O

Resting	O
state	O
brain	O
function	O
analysis	O
using	O
concurrent	O
BOLD	O
in	O
ASL	O
perfusion	O
fMRI	O
.	O
The	O
past	O
decade	O
has	O
seen	O
astounding	O
discoveries	O
about	O
resting-state	O
brain	O
activity	O
patterns	O
in	O
normal	O
brain	O
as	O
well	O
as	O
their	O
alterations	O
in	O
brain	INDICATIONS
diseases	INDICATIONS
.	O
While	O
the	O
vast	O
majority	O
of	O
resting-state	O
studies	O
are	O
based	O
on	O
the	O
blood-oxygen-level-dependent	O
(	O
BOLD	O
)	O
functional	O
MRI	O
(	O
fMRI	O
)	O
,	O
arterial	O
spin	O
labeling	O
(	O
ASL	O
)	O
perfusion	O
fMRI	O
can	O
simultaneously	O
capture	O
BOLD	O
and	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
signals	O
,	O
providing	O
a	O
unique	O
opportunity	O
for	O
assessing	O
resting	O
brain	O
functions	O
with	O
concurrent	O
BOLD	O
(	O
ccBOLD	O
)	O
and	O
CBF	O
signals	O
.	O
Before	O
taking	O
that	O
benefit	O
,	O
it	O
is	O
necessary	O
to	O
validate	O
the	O
utility	O
of	O
ccBOLD	O
signal	O
for	O
resting-state	O
analysis	O
using	O
conventional	O
BOLD	O
(	O
cvBOLD	O
)	O
signal	O
acquired	O
without	O
ASL	O
modulations	O
.	O
To	O
address	O
this	O
technical	O
issue	O
,	O
resting	O
cvBOLD	O
and	O
ASL	O
perfusion	O
MRI	O
were	O
acquired	O
from	O
a	O
large	O
cohort	O
(	O
n	O
=	O
89	O
)	O
of	O
healthy	O
subjects	O
.	O
Four	O
widely	O
used	O
resting-state	O
brain	O
function	O
analyses	O
were	O
conducted	O
and	O
compared	O
between	O
the	O
two	O
types	O
of	O
BOLD	O
signal	O
,	O
including	O
the	O
posterior	O
cingulate	O
cortex	O
(	O
PCC	O
)	O
seed-based	O
functional	O
connectivity	O
(	O
FC	O
)	O
analysis	O
,	O
independent	O
component	O
analysis	O
(	O
ICA	O
)	O
,	O
analysis	O
of	O
amplitude	O
of	O
low	O
frequency	O
fluctuation	O
(	O
ALFF	O
)	O
,	O
and	O
analysis	O
of	O
regional	O
homogeneity	O
(	O
ReHo	O
)	O
.	O
Consistent	O
default	O
mode	O
network	O
(	O
DMN	O
)	O
as	O
well	O
as	O
other	O
resting-state	O
networks	O
(	O
RSNs	O
)	O
were	O
observed	O
from	O
cvBOLD	O
and	O
ccBOLD	O
using	O
PCC-FC	O
analysis	O
and	O
ICA	O
.	O
ALFF	O
from	O
both	O
modalities	O
were	O
the	O
same	O
for	O
most	O
of	O
brain	O
regions	O
but	O
were	O
different	O
in	O
peripheral	O
regions	O
suffering	O
from	O
the	O
susceptibility	O
gradients	O
induced	O
signal	O
drop	O
.	O
ReHo	O
showed	O
difference	O
in	O
many	O
brain	O
regions	O
,	O
likely	O
reflecting	O
the	O
SNR	O
and	O
resolution	O
differences	O
between	O
the	O
two	O
BOLD	O
modalities	O
.	O
The	O
DMN	O
and	O
auditory	O
networks	O
showed	O
highest	O
CBF	O
values	O
among	O
all	O
RSNs	O
.	O
These	O
results	O
demonstrated	O
the	O
feasibility	O
of	O
ASL	O
perfusion	O
MRI	O
for	O
assessing	O
resting	O
brain	O
functions	O
using	O
its	O
concurrent	O
BOLD	O
in	O
addition	O
to	O
CBF	O
signal	O
,	O
which	O
provides	O
a	O
potentially	O
useful	O
way	O
to	O
maximize	O
the	O
utility	O
of	O
ASL	O
perfusion	O
MRI	O
.	O

Excitotoxicity	O
.	O
Experimental	O
correlates	O
to	O
human	O
epilepsy	O
.	O
Neurochemical	O
observations	O
on	O
cortical	O
biopsies	O
form	O
48	O
patients	O
under	O
surgical	O
treatment	O
for	O
pharmacoresistant	O
partial	INDICATIONS
epilepsy	INDICATIONS
showed	O
a	O
70-80	O
%	O
increase	O
in	O
glutamate	O
concentration	O
when	O
expressed	O
in	O
relation	O
to	O
neuron	O
specific	O
enolase	O
.	O
Intraperitoneal	O
administration	O
of	O
one	O
of	O
its	O
receptor	O
agonists	O
,	O
kainic	O
acid	O
(	O
KA	O
)	O
,	O
to	O
the	O
rat	O
led	O
to	O
increased	O
epileptogenic	O
activity	O
of	O
the	O
limbic	O
type	O
in	O
a	O
dose-dependent	O
fashion	O
.	O
The	O
KA	O
injection	O
also	O
led	O
to	O
a	O
neuronal	O
cell	O
death	O
and	O
a	O
gliosis	INDICATIONS
,	O
closely	O
correlated	O
to	O
the	O
extent	O
of	O
seizure	O
activity	O
.	O
In	O
biopsies	O
from	O
human	O
epileptogenic	O
cortex	O
,	O
the	O
concentration	O
of	O
neuron	O
specific	O
enolase	O
correlated	O
inversely	O
to	O
that	O
of	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
a	O
marker	O
for	O
astrocytic	O
glial	O
cells	O
.	O
Stimulation	O
of	O
the	O
KA	O
receptor	O
decreased	O
the	O
extent	O
of	O
phosphorylation	O
of	O
the	O
largest	O
subunit	O
of	O
neurofilaments	O
(	O
NF-H	O
)	O
that	O
have	O
consequences	O
for	O
structural	O
stability	O
and	O
axonal	O
transport	O
.	O
Phosphorylated	O
NF-H	O
decreased	O
also	O
in	O
human	O
epileptic	O
cortex	O
,	O
indicating	O
either	O
an	O
overactivity	O
of	O
excitatory	O
neurotransmitters	O
or	O
a	O
loss	O
of	O
axonal	O
compartments	O
.	O

Continuous	O
video	O
EEG	O
for	O
patients	O
with	O
acute	INDICATIONS
encephalopathy	INDICATIONS
in	O
a	O
pediatric	O
intensive	O
care	O
unit	O
.	O
In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
incidence	O
of	O
electrographic	O
seizures	INDICATIONS
among	O
patients	O
in	O
a	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
presenting	O
with	O
acute	INDICATIONS
encephalopathy	INDICATIONS
.	O
Risk	O
factors	O
and	O
duration	O
of	O
continuous	O
EEG	O
monitoring	O
needed	O
to	O
capture	O
electrographic	O
seizures	INDICATIONS
were	O
also	O
assessed	O
.	O
Based	O
on	O
a	O
NeuroICU	O
clinical	O
care	O
pathway	O
,	O
all	O
patients	O
with	O
acute	INDICATIONS
encephalopathy	INDICATIONS
admitted	O
to	O
the	O
PICU	O
are	O
monitored	O
with	O
continuous	O
video	O
electroencephalogram	O
(	O
cVEEG	O
)	O
for	O
48	O
h	O
or	O
until	O
the	O
encephalopathy	INDICATIONS
improves	O
.	O
Ninety-four	O
consecutive	O
patients	O
included	O
on	O
the	O
pathway	O
over	O
a	O
year	O
were	O
identified	O
.	O
Mean	O
age	O
was	O
6.7	O
years	O
(	O
range	O
32	O
days-17.9	O
years	O
)	O
.	O
Data	O
pertaining	O
to	O
patient	O
clinical	O
information	O
and	O
electrographic	O
seizures	INDICATIONS
,	O
including	O
non-convulsive	O
seizures	INDICATIONS
(	O
NCS	O
)	O
and	O
non-convulsive	O
status	INDICATIONS
epilepticus	INDICATIONS
(	O
NCSE	O
)	O
,	O
were	O
extracted	O
from	O
a	O
prospective	O
database	O
.	O
Thirty	O
percent	O
(	O
28/94	O
)	O
had	O
seizures	INDICATIONS
captured	O
on	O
cVEEG	O
including	O
17	O
patients	O
(	O
18	O
%	O
)	O
with	O
NCSE	O
.	O
Variables	O
associated	O
with	O
electrographic	O
seizures	INDICATIONS
were	O
age	O
<	O
24	O
months	O
and	O
clinical	O
seizure	O
(	O
s	O
)	O
prior	O
to	O
EEG	O
placement	O
.	O
The	O
first	O
seizure	O
captured	O
on	O
cVEEG	O
occurred	O
in	O
the	O
first	O
24	O
h	O
for	O
the	O
majority	O
of	O
patients	O
(	O
97	O
%	O
)	O
.	O
Acute	INDICATIONS
brain	INDICATIONS
injury	INDICATIONS
and	O
electrographic	O
seizures	INDICATIONS
were	O
associated	O
with	O
worse	O
outcome	O
.	O
Electrographic	O
seizures	INDICATIONS
are	O
common	O
in	O
pediatric	O
patients	O
with	O
acute	INDICATIONS
encephalopathy	INDICATIONS
.	O
This	O
study	O
supports	O
the	O
practice	O
of	O
cVEEG	O
monitoring	O
for	O
at	O
least	O
24	O
h	O
in	O
pediatric	O
patients	O
with	O
acute	INDICATIONS
encephalopathy	INDICATIONS
,	O
particularly	O
if	O
they	O
are	O
less	O
then	O
24	O
months	O
of	O
age	O
and/or	O
if	O
a	O
clinical	O
event	O
suspicious	O
for	O
seizure	O
precedes	O
the	O
encephalopathy	INDICATIONS
.	O

Prevalence	O
and	O
risk	O
factors	O
of	O
musculoskeletal	INDICATIONS
disorders	INDICATIONS
among	O
farmers	O
involved	O
in	O
manual	O
farm	O
operations	O
.	O
The	O
aim	O
of	O
the	O
current	O
investigation	O
is	O
to	O
determine	O
the	O
risk	O
factors	O
affecting	O
the	O
musculoskeletal	O
system	O
of	O
100	O
manual	O
working	O
farmers	O
of	O
India	O
.	O
The	O
information	O
regarding	O
prevalence	O
and	O
risk	O
factors	O
of	O
musculoskeletal	INDICATIONS
disorders	INDICATIONS
(	O
MSDs	O
)	O
was	O
collected	O
using	O
a	O
semi-structured	O
questionnaire	O
.	O
For	O
evaluating	O
the	O
risk	O
in	O
operations	O
,	O
rapid	O
entire	O
body	O
assessment	O
(	O
REBA	O
)	O
and	O
rapid	O
upper	INDICATIONS
limb	INDICATIONS
assessment	O
(	O
RULA	O
)	O
techniques	O
were	O
used	O
.	O
The	O
existence	O
of	O
various	O
risk	O
factors	O
and	O
their	O
influence	O
on	O
the	O
MSDs	O
were	O
found	O
significant	O
during	O
crop	O
cutting/harvesting	O
and	O
weeding	O
operations	O
.	O
Manual	O
farm	O
working	O
postures	O
may	O
be	O
exposing	O
farmers	O
to	O
a	O
substantial	O
risk	O
of	O
developing	O
MSDs	O
in	O
one	O
or	O
more	O
body	O
parts	O
including	O
lower	O
back	O
,	O
fingers	O
,	O
hands/wrists	O
,	O
and	O
shoulders	O
.	O
Postural	O
analysis	O
by	O
RULA	O
and	O
REBA	O
shows	O
the	O
high	O
prevalence	O
of	O
MSDs	O
which	O
should	O
be	O
reduced	O
by	O
ergonomic	O
interventions	O
.	O

MMP-7	O
and	O
fcDNA	O
serum	O
levels	O
in	O
early	O
NSCLC	INDICATIONS
and	O
idiopathic	INDICATIONS
interstitial	INDICATIONS
pneumonia	INDICATIONS
:	O
preliminary	O
study	O
.	O
A	O
non-invasive	O
test	O
to	O
facilitate	O
the	O
diagnosis	O
of	O
non-small	INDICATIONS
cell	INDICATIONS
lung	INDICATIONS
cancer	INDICATIONS
(	O
NSCLC	INDICATIONS
)	O
and	O
idiopathic	INDICATIONS
pulmonary	INDICATIONS
fibrosis	INDICATIONS
(	O
IPF	O
)	O
is	O
still	O
not	O
available	O
and	O
represents	O
an	O
important	O
goal	O
.	O
Forty-eight	O
patients	O
with	O
stage	INDICATIONS
I	INDICATIONS
NSCLC	INDICATIONS
,	O
45	O
with	O
IPF	O
,	O
30	O
with	O
other	O
idiopathic	INDICATIONS
interstitial	INDICATIONS
pneumonias	INDICATIONS
(	O
IIPs	O
)	O
including	O
idiopathic	O
non-specific	INDICATIONS
interstitial	INDICATIONS
pneumonia	INDICATIONS
(	O
NSIP	INDICATIONS
)	O
and	O
chronic	O
hypersensitivity	INDICATIONS
pneumonitis	INDICATIONS
(	O
HP	O
)	O
,	O
35	O
with	O
diffuse	O
non-malignant	O
disease	O
and	O
30	O
healthy	O
donors	O
were	O
enrolled	O
onto	O
the	O
study	O
.	O
Free	O
circulating	O
(	O
fc	O
)	O
DNA	O
and	O
MMP-7	O
levels	O
were	O
evaluated	O
by	O
Real	O
Time	O
PCR	O
and	O
ELISA	O
,	O
respectively	O
.	O
Median	O
fcDNA	O
levels	O
were	O
similar	O
in	O
NSCLC	INDICATIONS
(	O
127	O
ng/mL	O
,	O
range	O
23.6-345	O
ng/mL	O
)	O
and	O
IPF	O
(	O
106	O
ng/mL	O
,	O
range	O
22-224	O
ng/mL	O
)	O
patients	O
,	O
and	O
significantly	O
lower	O
in	O
IIPs	O
patients	O
,	O
in	O
individuals	O
with	O
other	O
diseases	O
and	O
in	O
healthy	O
donors	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Conversely	O
,	O
median	O
MMP-7	O
values	O
were	O
significantly	O
higher	O
in	O
IPF	O
patients	O
(	O
9.10	O
ng/mL	O
,	O
range	O
3.88-19.72	O
ng/mL	O
)	O
than	O
in	O
those	O
with	O
NSCLC	INDICATIONS
(	O
6.31	O
ng/mL	O
,	O
range	O
3.38-16.36	O
ng/mL	O
;	O
p	O
<	O
0.0001	O
)	O
,	O
NSIP	INDICATIONS
(	O
6.50	O
ng/mL	O
,	O
range	O
1.50-22.47	O
ng/mL	O
;	O
p	O
=	O
0.007	O
)	O
,	O
other	O
diseases	O
(	O
5.41	O
ng/mL	O
,	O
range	O
1.78-15.91	O
,	O
p	O
<	O
0.0001	O
)	O
or	O
healthy	O
donors	O
(	O
4.35	O
ng/mL	O
,	O
range	O
2.45-7.23	O
;	O
p	O
<	O
0.0001	O
)	O
.	O
Serum	O
MMP-7	O
levels	O
seem	O
to	O
be	O
capable	O
of	O
distinguishing	O
IPF	O
patients	O
from	O
those	O
with	O
any	O
other	O
lung	INDICATIONS
disease	INDICATIONS
.	O
fcDNA	O
levels	O
were	O
similar	O
in	O
NSCLC	INDICATIONS
and	O
IPF	O
patients	O
,	O
confirming	O
its	O
potential	O
role	O
as	O
a	O
biomarker	O
,	O
albeit	O
non-specific	O
,	O
for	O
the	O
differential	O
diagnosis	O
of	O
NSCLC	INDICATIONS
.	O

On	O
the	O
way	O
to	O
the	O
Tokyo	O
Summer	O
Olympic	O
Games	O
(	O
2020	O
)	O
.	O
Prevention	O
of	O
severe	O
head	O
and	O
neck	INDICATIONS
injuries	INDICATIONS
in	O
judo	O
:	O
it	O
's	O
time	O
for	O
action	O
.	O
not	O
found	O

[	O
Contribution	O
to	O
the	O
study	O
of	O
cirrhosis	INDICATIONS
caused	O
by	O
thorotrast	O
.	O
Use	O
of	O
a	O
recent	O
method	O
of	O
nuclear	O
physics	O
for	O
the	O
verification	O
of	O
the	O
presence	O
of	O
thorium	O
in	O
bioptic	O
material	O
]	O
.	O

Counselees	O
'	O
Expressed	O
Level	O
of	O
Understanding	O
of	O
the	O
Risk	O
Estimate	O
and	O
Surveillance	O
Recommendation	O
are	O
Not	O
Associated	O
with	O
Breast	INDICATIONS
Cancer	INDICATIONS
Surveillance	O
Adherence	O
.	O
We	O
studied	O
counselees	O
'	O
expressed	O
understanding	O
of	O
the	O
risk	O
estimate	O
and	O
surveillance	O
recommendation	O
in	O
the	O
final	O
consultation	O
for	O
breast	INDICATIONS
cancer	INDICATIONS
genetic	O
counseling	O
in	O
relation	O
with	O
their	O
risk	O
perception	O
,	O
worry	O
and	O
cancer	O
surveillance	O
adherence	O
1	O
year	O
post-counseling	O
.	O
Consecutive	O
counselees	O
were	O
included	O
from	O
2008	O
to	O
2010	O
.	O
Counselees	O
with	O
an	O
indication	O
for	O
diagnostic	O
DNA-testing	O
for	O
themselves	O
or	O
a	O
breast	INDICATIONS
cancer	INDICATIONS
affected	O
relative	O
were	O
requested	O
to	O
complete	O
online	O
questionnaires	O
before	O
and	O
after	O
counseling	O
and	O
one	O
year	O
after	O
counseling	O
(	O
N	O
=	O
152-124	O
)	O
.	O
Self-reported	O
surveillance	O
was	O
compared	O
to	O
surveillance	O
recommendations	O
.	O
Consultations	O
were	O
videotaped	O
.	O
Counselees	O
'	O
reactions	O
to	O
the	O
risks	O
and	O
recommendations	O
were	O
coded	O
.	O
Statements	O
about	O
the	O
risk	O
perception	O
and	O
surveillance	O
intentions	O
of	O
breast	INDICATIONS
cancer	INDICATIONS
unaffected	O
counselees	O
were	O
transcribed	O
.	O
Associations	O
with	O
outcomes	O
were	O
explored	O
.	O
Almost	O
all	O
breast	INDICATIONS
cancer	INDICATIONS
unaffected	O
counselees	O
(	O
>	O
90	O
%	O
)	O
reacted	O
to	O
their	O
risk	O
estimate	O
with	O
an	O
utterance	O
indicating	O
understanding	O
and	O
this	O
reaction	O
was	O
not	O
significantly	O
associated	O
with	O
their	O
post-visit	O
risk	O
perception	O
alignment	O
.	O
Over	O
one-third	O
(	O
38.6	O
%	O
)	O
overestimated	O
their	O
risk	O
post-counseling	O
.	O
Few	O
counselees	O
(	O
5.8	O
%	O
)	O
expressed	O
surveillance	O
intentions	O
.	O
One	O
year	O
after	O
counseling	O
,	O
about	O
three-quarters	O
(	O
74.0	O
%	O
)	O
of	O
the	O
breast	INDICATIONS
cancer	INDICATIONS
unaffected	O
counselees	O
had	O
adhered	O
to	O
the	O
surveillance	O
recommendation	O
.	O
Almost	O
one-quarter	O
(	O
23.3	O
%	O
)	O
had	O
performed	O
more	O
mammograms/MRI	O
scans	O
than	O
recommended	O
,	O
which	O
was	O
associated	O
with	O
prior	O
mammography	O
uptake	O
(	O
n	O
=	O
47	O
;	O
X	O
(	O
2	O
)	O
=	O
5.2	O
;	O
p	O
=	O
.02	O
)	O
.	O
Counselees	O
'	O
post-counseling	O
overestimation	O
of	O
their	O
risk	O
,	O
high	O
levels	O
of	O
worry	O
and	O
high	O
surveillance	O
uptake	O
were	O
not	O
reflected	O
in	O
their	O
reactions	O
to	O
the	O
counselor	O
's	O
information	O
during	O
the	O
final	O
visit	O
.	O

[	O
A	O
case	O
of	O
malignant	INDICATIONS
mesothelioma	INDICATIONS
of	INDICATIONS
the	INDICATIONS
pleura	INDICATIONS
and	O
peritoneum	INDICATIONS
with	O
high	O
serum	O
levels	O
of	O
CA15-3	O
]	O
.	O

Elucidation	O
of	O
glutamine	O
lipid	O
biosynthesis	O
in	O
marine	O
bacteria	O
reveals	O
its	O
importance	O
under	O
phosphorus	O
deplete	O
growth	O
in	O
Rhodobacteraceae	O
.	O
Marine	O
microorganisms	O
employ	O
multiple	O
strategies	INDICATIONS
to	O
cope	O
with	O
transient	O
and	O
persistent	O
nutrient	O
limitation	O
,	O
one	O
of	O
which	O
,	O
for	O
alleviating	O
phosphorus	O
(	O
P	O
)	O
stress	O
,	O
is	O
to	O
substitute	O
membrane	O
glycerophospholipids	O
with	O
non-P	O
containing	O
surrogate	O
lipids	O
.	O
Such	O
a	O
membrane	O
lipid	O
remodelling	O
strategy	O
enables	O
the	O
most	O
abundant	O
marine	O
phytoplankton	O
and	O
heterotrophic	O
bacteria	O
to	O
adapt	O
successfully	O
to	O
nutrient	O
scarcity	O
in	O
marine	O
surface	O
waters	O
.	O
An	O
important	O
group	O
of	O
non-P	O
lipids	O
,	O
the	O
aminolipids	O
which	O
lack	O
a	O
diacylglycerol	O
backbone	O
,	O
are	O
poorly	O
studied	O
in	O
marine	O
microbes	O
.	O
Here	O
,	O
using	O
a	O
combination	O
of	O
genetic	O
,	O
lipidomics	O
and	O
metagenomics	O
approaches	O
,	O
we	O
reveal	O
for	O
the	O
first	O
time	O
the	O
genes	O
(	O
glsB	O
,	O
olsA	O
)	O
required	O
for	O
the	O
formation	O
of	O
the	O
glutamine-containing	O
aminolipid	O
.	O
Construction	O
of	O
a	O
knockout	O
mutant	O
in	O
either	O
glsB	O
or	O
olsA	O
in	O
the	O
model	O
marine	O
bacterium	O
Ruegeria	O
pomeroyi	O
DSS-3	O
completely	O
abolished	O
glutamine	O
lipid	O
production	O
.	O
Moreover	O
,	O
both	O
mutants	O
showed	O
a	O
considerable	O
growth	O
cost	O
under	O
P-deplete	O
conditions	O
and	O
the	O
olsA	O
mutant	O
,	O
that	O
is	O
unable	O
to	O
produce	O
the	O
glutamine	O
and	O
ornithine	O
aminolipids	O
,	O
ceased	O
to	O
grow	O
under	O
P-deplete	O
conditions	O
.	O
Analysis	O
of	O
sequenced	O
microbial	O
genomes	O
show	O
that	O
glsB	O
is	O
primarily	O
confined	O
to	O
the	O
Rhodobacteraceae	O
family	O
,	O
which	O
includes	O
the	O
ecologically	O
important	O
marine	O
Roseobacter	O
clade	O
that	O
are	O
key	O
players	O
in	O
the	O
marine	O
sulphur	O
and	O
nitrogen	O
cycles	O
.	O
Analysis	O
of	O
the	O
genes	O
involved	O
in	O
glutamine	O
lipid	O
biosynthesis	O
in	O
the	O
Tara	O
ocean	O
metagenome	O
dataset	O
revealed	O
the	O
global	O
occurrence	O
of	O
glsB	O
in	O
marine	O
surface	O
waters	O
and	O
a	O
positive	O
correlation	O
between	O
glsB	O
abundance	O
and	O
N*	O
(	O
a	O
measure	O
of	O
the	O
deviation	O
from	O
the	O
canonical	O
Redfield	O
ratio	O
)	O
,	O
suggesting	O
glutamine	O
lipid	O
plays	O
an	O
important	O
role	O
in	O
the	O
adaptation	O
of	O
marine	O
Rhodobacteraceae	O
to	O
P	O
limitation	O
.	O

Do	O
you	O
need	O
aspirin	O
therapy	O
?	O
Your	O
risks	O
of	O
heart	INDICATIONS
attack	INDICATIONS
and	O
stroke	O
based	O
upon	O
your	O
current	O
and	O
past	O
medical	O
history	O
must	O
be	O
weighed	O
against	O
the	O
chances	O
of	O
internal	INDICATIONS
bleeding	INDICATIONS
.	O

Epidemiology	O
of	O
lymphomas	INDICATIONS
.	O
Non-Hodgkin	INDICATIONS
lymphoma	INDICATIONS
(	O
NHL	O
)	O
is	O
the	O
fifth	O
most	O
common	O
cancer	O
in	O
the	O
US	O
,	O
with	O
about	O
55,000	O
new	O
cases	O
estimated	O
for	O
the	O
year	O
2000	O
.	O
According	O
to	O
the	O
new	O
Surveillance	O
,	O
Epidemiology	O
,	O
and	O
End	O
Results	O
(	O
SEER	O
)	O
data	O
from	O
1973	O
to	O
1997	O
,	O
the	O
age-adjusted	O
incidence	O
rates	O
rose	O
by	O
about	O
80	O
%	O
,	O
with	O
an	O
annual	O
percentage	O
increase	O
of	O
nearly	O
3	O
%	O
,	O
which	O
is	O
faster	O
than	O
for	O
the	O
majority	O
of	O
cancers	O
.	O
The	O
increasing	O
incidence	O
of	O
NHL	O
is	O
largely	O
unexplained	O
.	O
AIDS-related	INDICATIONS
NHL	INDICATIONS
accounts	O
for	O
some	O
but	O
not	O
all	O
of	O
the	O
increase	O
.	O
The	O
American	O
Cancer	O
Society	O
predicts	O
about	O
7,400	O
new	O
cases	O
of	O
Hodgkin	INDICATIONS
Disease	INDICATIONS
(	INDICATIONS
HD	INDICATIONS
)	O
in	O
the	O
year	O
2000	O
in	O
the	O
US	O
.	O
The	O
incidence	O
of	O
HD	O
is	O
consistently	O
lower	O
than	O
that	O
of	O
NHL	O
,	O
and	O
has	O
decreased	O
about	O
16	O
%	O
since	O
the	O
1970s	O
.	O
Only	O
a	O
small	O
portion	O
of	O
the	O
decrease	O
in	O
HD	O
incidence	O
can	O
be	O
explained	O
by	O
misdiagnosis	O
of	O
HD	O
as	O
NHL	O
.	O
Further	O
research	O
is	O
needed	O
on	O
the	O
cofactors	O
that	O
predispose	O
AIDS	O
cases	O
to	O
lymphoma	INDICATIONS
,	O
as	O
well	O
as	O
other	O
possible	O
causes	O
of	O
NHL	O
such	O
as	O
immunosuppression	O
,	O
genetics	O
,	O
viruses	O
,	O
medical	O
conditions	O
,	O
pesticides	O
,	O
solvents	O
,	O
hair	O
dyes	O
,	O
and	O
diet	O
.	O
Further	O
evaluation	O
of	O
the	O
role	O
of	O
viruses	O
,	O
occupational	O
exposures	O
,	O
and	O
genetics	O
in	O
the	O
etiology	O
of	O
HD	O
should	O
prove	O
valuable	O
.	O

Randomized	O
surgical	O
clinical	O
trials	O
for	O
treatment	O
of	O
coronary	INDICATIONS
artery	INDICATIONS
disease	INDICATIONS
.	O
The	O
impact	O
of	O
randomized	O
clinical	O
trials	O
of	O
surgical	O
therapy	O
for	O
treatment	O
of	O
coronary	INDICATIONS
artery	INDICATIONS
disease	INDICATIONS
is	O
evaluated	O
.	O
Trials	O
are	O
reviewed	O
leading	O
to	O
the	O
following	O
suggestions	O
:	O
1	O
.	O
Large	O
multicenter	O
trials	O
have	O
a	O
major	O
impact	O
on	O
clinical	O
practice	O
;	O
2	O
.	O
Small	O
trials	O
have	O
less	O
impact	O
;	O
3	O
.	O
Findings	O
in	O
agreement	O
with	O
current	O
practice	O
are	O
accepted	O
enthusiastically	O
;	O
4	O
.	O
Findings	O
disagreeing	O
with	O
current	O
practice	O
are	O
met	O
very	O
critically	O
;	O
and	O
5	O
.	O
Surgical	O
trials	O
have	O
special	O
problems	O
because	O
of	O
a	O
great	O
variability	O
between	O
clinics	O
,	O
the	O
potential	O
of	O
uneven	O
learning	O
curves	O
,	O
and	O
potential	O
``	O
cross-over	O
''	O
from	O
medical	O
to	O
surgical	O
therapy	O
.	O

Experimental	O
human	O
bacillary	INDICATIONS
dysentery	INDICATIONS
;	O
polyvalent	O
dysentery	O
vaccine	O
in	O
its	O
prevention	O
.	O

Subcutaneous	O
Injectable	O
Drugs	INDICATIONS
Hypersensitivity	INDICATIONS
and	O
Desensitization	O
:	O
Insulin	O
and	O
Monoclonal	O
Antibodies	O
.	O
Injectable	O
drugs	O
,	O
including	O
monoclonal	O
antibodies	O
,	O
are	O
becoming	O
crucial	O
components	O
in	O
the	O
management	O
of	O
chronic	INDICATIONS
diseases	INDICATIONS
.	O
The	O
most	O
common	O
side	O
effects	O
are	O
local	INDICATIONS
reactions	INDICATIONS
at	O
the	O
site	O
of	O
administration	O
.	O
With	O
the	O
increased	O
and	O
prolonged	O
use	O
of	O
these	O
medications	O
,	O
we	O
are	O
seeing	O
increased	O
reports	O
of	O
hypersensitivity	INDICATIONS
reactions	INDICATIONS
.	O
The	O
aim	O
of	O
this	O
article	O
is	O
to	O
discuss	O
the	O
signs	O
and	O
symptoms	O
of	O
these	O
reactions	O
as	O
well	O
as	O
management	O
,	O
which	O
may	O
involve	O
desensitization	O
for	O
3	O
commonly	O
encountered	O
injectable	O
drugs	O
:	O
tumor	O
necrosis	O
factor-α	O
inhibitors	O
(	O
etanercept	O
and	O
adalimumab	O
)	O
,	O
insulin	O
,	O
and	O
omalizumab	O
.	O

Genetic	O
diversity	O
reflects	O
geographical	O
origin	O
of	O
Ralstonia	O
solanacearum	O
strains	O
isolated	O
from	O
plant	O
and	O
water	O
sources	O
in	O
Spain	O
.	O
The	O
characterization	O
and	O
intraspecific	O
diversity	O
of	O
a	O
collection	O
of	O
45	O
Ralstonia	O
solanacearum	O
strains	O
isolated	O
in	O
Spain	O
from	O
different	O
sources	O
and	O
geographical	O
origins	O
is	O
reported	O
.	O
To	O
test	O
the	O
influence	O
of	O
the	O
site	O
and	O
the	O
host	O
on	O
strain	O
diversity	O
,	O
phenotypic	O
and	O
genotypic	O
analysis	O
were	O
performed	O
by	O
a	O
polyphasic	O
approach	O
.	O
Biochemical	O
and	O
metabolic	O
profiles	O
were	O
compared	O
.	O
Serological	O
relationship	O
was	O
evaluated	O
by	O
Indirect-ELISA	O
using	O
polyclonal	O
and	O
monoclonal	O
antibodies	O
.	O
For	O
genotypic	O
analysis	O
,	O
hrpB	O
and	O
egl	O
DNA	O
sequence	O
analysis	O
,	O
repetitive	O
sequences	O
(	O
rep-PCR	O
)	O
,	O
amplified	O
fragment	O
length	O
polymorphism	O
(	O
AFLP	INDICATIONS
)	O
profiles	O
and	O
macrorestriction	O
with	O
XbaI	O
followed	O
by	O
pulsed	O
field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
were	O
performed	O
.	O
The	O
biochemical	O
and	O
metabolic	O
characterization	O
,	O
serological	O
tests	O
,	O
rep-PCR	O
typing	O
and	O
phylogenetic	O
analysis	O
showed	O
that	O
all	O
analysed	O
strains	O
belonged	O
to	O
phylotype	O
II	O
sequevar	O
1	O
and	O
shared	O
homogeneous	O
profiles	O
.	O
However	O
,	O
interesting	O
differences	O
among	O
strains	O
were	O
found	O
by	O
AFLP	INDICATIONS
and	O
macrorestriction	O
with	O
XbaI	O
followed	O
by	O
PFGE	O
techniques	O
,	O
some	O
profiles	O
being	O
related	O
to	O
the	O
geographical	O
origin	O
of	O
the	O
strains	O
.	O
Diversity	O
results	O
obtained	O
offer	O
new	O
insights	O
into	O
the	O
biogeography	O
of	O
this	O
quarantine	O
organism	O
and	O
its	O
possible	O
sources	O
and	O
reservoirs	O
in	O
Spain	O
and	O
Mediterranean	O
countries	O
.	O

Asymmetrical	O
nostril	O
axis	O
angle	O
in	O
the	O
post	O
traumatic	O
nose	O
.	O
Nasal	O
tip	O
reconstruction	O
is	O
a	O
challenging	O
part	O
of	O
septorhinoplasty	O
in	O
post-traumatic	O
patients	O
.	O
Aesthetic	O
appearance	O
of	O
the	O
nose	O
is	O
dependent	O
on	O
adequate	O
tip	O
definition	O
,	O
projection	O
and	O
rotation	O
.	O
Our	O
aim	O
is	O
to	O
establish	O
if	O
caudal	O
septal	O
dislocation	O
(	O
secondary	O
to	O
fracture	O
or	O
subluxation	INDICATIONS
)	O
is	O
a	O
significant	O
factor	O
in	O
causing	O
asymmetry	O
in	O
nostril	O
axis	O
angle	O
(	O
NAA	O
)	O
to	O
effect	O
surgical	O
intervention	O
.	O
In	O
addition	O
,	O
to	O
assess	O
if	O
there	O
is	O
an	O
association	O
between	O
the	O
side	O
of	O
dislocation	O
and	O
the	O
magnitude	O
of	O
NAA	O
.	O
Photographic	O
assessment	O
of	O
NAA	O
was	O
measured	O
in	O
a	O
study	O
group	O
of	O
26	O
patients	O
with	O
caudal	O
dislocation	O
of	O
the	O
septum	O
and	O
a	O
control	O
group	O
of	O
26	O
patients	O
without	O
caudal	O
septal	O
dislocation	O
.	O
All	O
52	O
patients	O
were	O
awaiting	O
a	O
septorhinoplasty	O
procedure	O
due	O
to	O
nasal	O
trauma	O
.	O
Caudal	O
septal	O
dislocation	O
causes	O
a	O
mean	O
difference	O
in	O
NAA	O
of	O
7.95o	O
compared	O
to	O
1.38o	O
difference	O
in	O
the	O
control	O
group	O
.	O
We	O
also	O
found	O
there	O
is	O
a	O
greater	O
degree	O
of	O
upward	O
tip	O
rotation	O
on	O
the	O
side	O
of	O
the	O
dislocation	O
resulting	O
in	O
a	O
larger	O
NAA	O
.	O
Caudal	O
dislocation	O
of	O
the	O
septum	O
causes	O
a	O
significant	O
asymmetry	O
in	O
NAA	O
,	O
with	O
a	O
greater	O
degree	O
of	O
rotation	O
on	O
the	O
side	O
of	O
the	O
dislocation	O
.	O
We	O
should	O
be	O
aware	O
of	O
this	O
fallacy	O
prior	O
to	O
surgery	O
.	O

Topical	O
and	O
intralesional	O
therapies	O
for	O
alopecia	INDICATIONS
areata	INDICATIONS
.	O
Alopecia	INDICATIONS
areata	INDICATIONS
is	O
a	O
common	O
form	O
of	O
nonscarring	O
alopecia	O
.	O
It	O
affects	O
males	O
and	O
females	O
equally	O
and	O
has	O
no	O
racial	O
predilection	O
.	O
It	O
usually	O
affects	O
the	O
scalp	O
,	O
but	O
any	O
hair-bearing	O
area	O
can	O
be	O
involved	O
.	O
It	O
presents	O
as	O
patchy	INDICATIONS
hair	INDICATIONS
loss	INDICATIONS
,	O
loss	INDICATIONS
of	INDICATIONS
hair	INDICATIONS
on	O
the	O
entire	O
scalp	O
(	O
alopecia	INDICATIONS
totalis	INDICATIONS
)	O
,	O
or	O
the	O
whole	O
body	O
(	O
alopecia	INDICATIONS
universalis	INDICATIONS
)	O
.	O
The	O
histopathology	O
varies	O
according	O
to	O
the	O
disease	O
stage	O
,	O
but	O
usually	O
a	O
perifollicular	O
lymphocytic	INDICATIONS
infiltrate	INDICATIONS
is	O
seen	O
.	O
The	O
course	O
of	O
the	O
disease	O
and	O
response	O
to	O
treatment	O
are	O
unpredictable	O
.	O
Various	O
therapeutic	O
modalities	O
are	O
used	O
including	O
topical	O
,	O
intralesional	O
,	O
and	O
systemic	O
agents	O
,	O
although	O
none	O
are	O
curative	O
or	O
preventive	O
.	O
This	O
article	O
will	O
review	O
the	O
available	O
topical	O
and	O
intralesional	O
agents	O
that	O
are	O
used	O
in	O
the	O
treatment	O
of	O
alopecia	INDICATIONS
areata	INDICATIONS
and	O
suggest	O
a	O
management	O
approach	O
based	O
on	O
the	O
age	O
of	O
the	O
patient	O
and	O
extent	O
of	O
the	O
disease	O
.	O

Treatment	O
Outcomes	O
in	O
Infections	O
Caused	O
by	O
``	O
SPICE	O
''	O
(	O
Serratia	O
,	O
Pseudomonas	O
,	O
Indole-positive	O
Proteus	INDICATIONS
,	O
Citrobacter	O
,	O
and	O
Enterobacter	O
)	O
Organisms	O
:	O
Carbapenem	O
versus	O
Noncarbapenem	O
Regimens	O
.	O
Techniques	O
used	O
to	O
identify	O
AmpC	O
β-lactamases	O
in	O
SPICE	O
(	O
Serratia	O
,	O
Pseudomonas	O
,	O
indole-positive	O
Proteus	INDICATIONS
,	O
Citrobacter	O
,	O
and	O
Enterobacter	O
)	O
organisms	O
are	O
not	O
yet	O
optimized	O
for	O
the	O
clinical	O
laboratory	O
and	O
are	O
not	O
routinely	O
used	O
.	O
Clinicians	O
are	O
often	O
left	O
with	O
an	O
uncertainty	O
on	O
the	O
choice	O
of	O
antibiotic	O
when	O
a	O
SPICE	O
organism	O
is	O
isolated	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
outcomes	O
of	O
carbapenem	O
versus	O
noncarbapenem	O
regimens	O
in	O
treating	O
bacteremia	INDICATIONS
or	O
urinary	INDICATIONS
tract	INDICATIONS
infection	INDICATIONS
from	O
a	O
SPICE	O
organism	O
in	O
clinical	O
practice	O
.	O
This	O
single-center	O
,	O
retrospective	O
,	O
cohort	O
study	O
analyzed	O
data	O
from	O
adult	O
patients	O
who	O
had	O
clinical	INDICATIONS
infection	INDICATIONS
with	O
a	O
SPICE	O
organism	O
isolated	O
from	O
blood	O
or	O
urine	O
cultures	O
.	O
Patients	O
were	O
assigned	O
to	O
a	O
carbapenem-	O
or	O
noncarbapenem-treated	O
group	O
.	O
The	O
primary	O
end	O
point	O
was	O
clinical	O
response	O
,	O
defined	O
as	O
a	O
resolution	O
of	O
signs	O
and	O
symptoms	O
of	O
infection	O
at	O
the	O
end	O
of	O
therapy	O
.	O
A	O
total	O
of	O
332	O
patients	O
were	O
assessed	O
,	O
and	O
145	O
patients	O
met	O
the	O
inclusion	O
criteria	O
for	O
the	O
study	O
.	O
There	O
were	O
20	O
patients	O
who	O
received	O
a	O
carbapenem	O
,	O
while	O
125	O
received	O
a	O
noncarbapenem	O
regimen	O
.	O
The	O
percentage	O
of	O
patients	O
who	O
were	O
bacteremic	O
was	O
46.2	O
%	O
.	O
Clinical	O
response	O
overall	O
was	O
achieved	O
in	O
80	O
%	O
of	O
patients	O
on	O
a	O
carbapenem	O
versus	O
90.3	O
%	O
of	O
patients	O
on	O
a	O
noncarbapenem	O
regimen	O
(	O
P	O
=	O
0.24	O
)	O
.	O
The	O
rate	O
of	O
microbiologic	O
cure	O
was	O
90	O
%	O
in	O
patients	O
on	O
a	O
carbapenem	O
versus	O
91.2	O
%	O
in	O
patients	O
on	O
a	O
noncarbapenem	O
regimen	O
(	O
P	O
=	O
1	O
)	O
.	O
In	O
this	O
study	O
in	O
patients	O
treated	O
for	O
infection	O
with	O
a	O
SPICE	O
organism	O
in	O
clinical	O
practice	O
,	O
the	O
rates	O
of	O
clinical	O
response	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
carbapenem	O
and	O
noncarbapenem	O
groups	O
.	O
Current	O
CLSI	O
breakpoints	O
set	O
for	O
SPICE	O
organisms	O
may	O
still	O
be	O
reliable	O
and	O
may	O
not	O
require	O
additional	O
testing	O
for	O
AmpC	O
β-lactamases	O
.	O

Carbon	INDICATIONS
monoxide	INDICATIONS
poisoning	INDICATIONS
as	O
an	O
epigenetic	O
factor	O
for	O
Leber	INDICATIONS
's	INDICATIONS
hereditary	INDICATIONS
optic	INDICATIONS
neuropathy	INDICATIONS
.	O
A	O
45-year-old	O
Korean	O
woman	O
visited	O
our	O
hospital	O
complaining	O
of	O
poor	INDICATIONS
vision	INDICATIONS
after	O
carbon	O
monoxide	O
(	O
CO	O
)	O
poisoning	O
.	O
We	O
have	O
confirmed	O
the	O
presence	O
of	O
a	O
point	O
mutation	O
at	O
position	O
11778	O
in	O
the	O
ND4	O
gene	O
of	O
mitochondrial	O
DNA	O
.	O
This	O
case	O
suggests	O
that	O
CO	O
poisoning	O
may	O
precipitate	O
the	O
clinical	O
expression	O
of	O
Leber	INDICATIONS
's	INDICATIONS
hereditary	INDICATIONS
optic	INDICATIONS
neuropathy	INDICATIONS
(	INDICATIONS
LHON	INDICATIONS
)	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
would	O
be	O
the	O
first	O
case	O
report	O
of	O
clinical	O
expression	O
of	O
LHON	O
precipitated	O
by	O
CO	O
poisoning	O
.	O

[	O
Epidemiologic	O
aspects	O
of	O
multiple	INDICATIONS
sclerosis	INDICATIONS
]	O
.	O
Epidemiology	O
plays	O
a	O
prominent	O
role	O
in	O
the	O
search	O
for	O
environmental	O
risk	O
factors	O
in	O
multiple	INDICATIONS
sclerosis	INDICATIONS
(	INDICATIONS
MS	INDICATIONS
)	O
.	O
The	O
basic	O
pattern	O
with	O
the	O
predilection	O
for	O
temperate	O
zones	O
of	O
the	O
globe	O
,	O
whites	O
,	O
females	O
and	O
medium	O
age	O
groups	O
was	O
confirmed	O
throughout	O
.	O
Whether	O
or	O
not	O
MS	O
is	O
increasing	O
in	O
frequency	O
is	O
highly	O
debated	O
.	O
Although	O
no	O
clear	O
risk	O
factors	O
have	O
been	O
demonstrated	O
so	O
far	O
,	O
a	O
certain	O
association	O
of	O
the	O
MS	O
risk	O
with	O
the	O
factors	O
``	O
low	O
temperatures	O
and	O
precipitation	O
''	O
,	O
``	O
consumption	O
of	O
animal	O
proteins/fats	O
or	O
meat	O
''	O
,	O
``	O
familiar	O
occurrence	O
of	O
MS	O
''	O
and	O
with	O
a	O
late	O
occurrence	O
of	O
common	O
childhood	O
infections	O
became	O
obvious	O
.	O
Many	O
other	O
putative	O
risk	O
factors	O
were	O
not	O
confirmed	O
in	O
most	O
studies	O
.	O

[	O
Insulin	O
turnover	O
in	O
diabetic	O
patients	O
with	O
renal	INDICATIONS
disorders	INDICATIONS
based	O
on	O
the	O
data	O
of	O
double	O
radioindicator	O
studies	O
]	O
.	O

The	O
2012	O
European	O
guideline	O
on	O
the	O
diagnosis	O
and	O
treatment	O
of	O
gonorrhoea	INDICATIONS
in	O
adults	O
recommends	O
dual	O
antimicrobial	O
therapy	O
.	O

Separation	O
of	O
early	O
afterdepolarizations	O
from	O
arrhythmogenic	O
substrate	O
in	O
the	O
isolated	O
perfused	O
hypokalaemic	O
murine	O
heart	O
through	O
modifiers	O
of	O
calcium	O
homeostasis	O
.	O
We	O
resolved	O
roles	O
for	O
early	O
afterdepolarizations	O
(	O
EADs	O
)	O
and	O
transmural	O
gradients	O
of	O
repolarization	O
in	O
arrhythmogenesis	O
in	O
Langendorff-perfused	O
hypokalaemic	O
murine	O
hearts	O
paced	O
from	O
the	O
right	O
ventricular	O
epicardium	O
.	O
Left	O
ventricular	O
epicardial	O
and	O
endocardial	O
monophasic	O
action	O
potentials	O
(	O
MAPs	O
)	O
and	O
arrhythmogenic	O
tendency	O
were	O
compared	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
L-type	O
Ca	O
(	O
2+	O
)	O
channel	O
blocker	O
nifedipine	O
(	O
10	O
nm-1	O
microm	O
)	O
and	O
the	O
calmodulin	O
kinase	O
type	O
II	O
inhibitor	O
KN-93	O
(	O
2	O
microm	O
)	O
.	O
All	O
the	O
hypokalaemic	O
hearts	O
studied	O
showed	O
prolonged	O
epicardial	O
and	O
endocardial	O
MAPs	O
,	O
decreased	O
epicardial-endocardial	O
APD	O
(	O
90	O
)	O
difference	O
,	O
EADs	O
,	O
triggered	O
beats	O
and	O
ventricular	INDICATIONS
tachycardia	INDICATIONS
(	O
VT	O
)	O
(	O
n	O
=	O
6	O
)	O
.	O
In	O
all	O
spontaneously	O
beating	O
hearts	O
,	O
100	O
(	O
but	O
not	O
10	O
)	O
nm	O
nifedipine	O
reduced	O
both	O
the	O
incidence	O
of	O
EADs	O
and	O
triggered	O
beats	O
from	O
66.9	O
+/-	O
15.7	O
%	O
to	O
28.3	O
+/-	O
8.7	O
%	O
and	O
episodes	O
of	O
VT	O
from	O
10.8	O
+/-	O
6.3	O
%	O
to	O
1.2	O
+/-	O
0.7	O
%	O
of	O
MAPs	O
(	O
n	O
=	O
6	O
hearts	O
,	O
P	O
<	O
0.05	O
)	O
;	O
1	O
microm	O
nifedipine	O
abolished	O
all	O
these	O
phenomena	O
(	O
n	O
=	O
6	O
)	O
.	O
In	O
contrast	O
programmed	O
electrical	O
stimulation	O
(	O
PES	O
)	O
still	O
triggered	O
VT	O
in	O
six	O
of	O
six	O
hearts	O
with	O
0	O
,	O
10	O
and	O
100	O
nm	O
but	O
not	O
1	O
microm	O
nifedipine	O
.	O
1	O
microm	O
nifedipine	O
selectively	O
reduced	O
epicardial	O
(	O
from	O
66.1	O
+/-	O
3.4	O
to	O
46.2	O
+/-	O
2.5	O
ms	O
)	O
but	O
not	O
endocardial	O
APD	O
(	O
90	O
)	O
,	O
thereby	O
restoring	O
DeltaAPD	O
(	O
90	O
)	O
from	O
-5.9	O
+/-	O
2.5	O
to	O
15.5	O
+/-	O
3.2	O
ms	O
,	O
close	O
to	O
normokalaemic	O
values	O
.	O
KN-93	O
similarly	O
reduced	O
EADs	O
,	O
triggered	O
beats	O
and	O
VT	O
in	O
spontaneously	O
beating	O
hearts	O
to	O
29.6	O
+/-	O
8.9	O
%	O
and	O
1.7	O
+/-	O
1.1	O
%	O
respectively	O
(	O
n	O
=	O
6	O
)	O
yet	O
permitted	O
PES-induced	O
VT	O
(	O
n	O
=	O
6	O
)	O
,	O
in	O
the	O
presence	O
of	O
a	O
persistently	O
negative	O
DeltaAPD	O
(	O
90	O
)	O
.	O
These	O
findings	O
empirically	O
implicate	O
both	O
EADs	O
and	O
triggered	O
beats	O
alongside	O
arrhythmogenic	O
substrate	O
of	O
DeltaAPD	O
(	O
90	O
)	O
in	O
VT	O
pathogenesis	O
at	O
the	O
whole	O
heart	O
level	O
.	O

[	O
THE	O
ACTION	O
OF	O
A	O
CHELATING	O
AGENT	O
ON	O
THE	O
COURSE	O
OF	O
CERTAIN	O
EXPERIMENTAL	O
VIRAL	INDICATIONS
INFECTIONS	INDICATIONS
,	O
AS	O
WELL	O
AS	O
ON	O
THE	O
DEVELOPMENT	O
OF	O
CERTAIN	O
TUMORS	O
:	O
EHRLICH	O
CARCINOMA	INDICATIONS
AND	O
ROUS	INDICATIONS
SARCOMA	INDICATIONS
]	O
.	O

The	O
contribution	O
of	O
intraoperative	O
medial	O
compartment	O
stability	O
to	O
post-operative	O
knee	O
flexion	O
angle	O
in	O
unicompartmental	O
knee	O
arthroplasty	O
.	O
Given	O
the	O
knee	O
kinematics	O
and	O
soft	O
tissue	O
balance	O
in	O
unicompartmental	O
knee	O
arthroplasty	O
(	O
UKA	O
)	O
,	O
it	O
was	O
hypothesised	O
that	O
intraoperative	O
medial	O
compartment	O
stability	O
will	O
result	O
in	O
good	O
functional	O
outcome	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
influence	O
of	O
soft	O
tissue	O
balance	O
on	O
post-operative	O
knee	O
flexion	O
in	O
UKA	O
.	O
The	O
influence	O
of	O
soft	O
tissue	O
balance	O
on	O
post-operative	O
knee	O
flexion	O
in	O
UKA	O
was	O
first	O
examined	O
retrospectively	O
by	O
using	O
a	O
newly	O
developed	O
tensor	O
device	O
in	O
30	O
consecutive	O
patients	O
diagnosed	O
with	O
either	O
isolated	O
medial	O
compartmental	O
osteoarthritis	INDICATIONS
or	O
idiopathic	O
necrosis	O
.	O
The	O
intraoperative	O
component	O
gap	O
of	O
the	O
medial	O
compartment	O
was	O
measured	O
by	O
using	O
the	O
tensor	O
while	O
applying	O
a	O
20-lb	O
joint	O
distraction	O
force	O
at	O
0°	O
,	O
10°	O
,	O
30°	O
,	O
45°	O
,	O
60°	O
,	O
90°	O
,	O
120°	O
,	O
and	O
135°	O
of	O
knee	O
flexion	O
,	O
with	O
calculation	O
of	O
the	O
joint	O
looseness	O
.	O
Correlations	O
between	O
the	O
soft	O
tissue	O
parameters	O
and	O
post-operative	O
knee	O
flexion	O
angles	O
were	O
analysed	O
1	O
year	O
after	O
surgery	O
.	O
The	O
post-operative	O
knee	O
flexion	O
angle	O
was	O
negatively	O
correlated	O
with	O
the	O
component	O
gap	O
at	O
45°	O
,	O
60°	O
,	O
and	O
90°	O
of	O
flexion	O
(	O
R	O
=	O
-0.41	O
,	O
P	O
<	O
0.05	O
;	O
R	O
=	O
-0.44	O
,	O
P	O
<	O
0.05	O
;	O
and	O
R	O
=	O
-0.44	O
,	O
P	O
<	O
0.05	O
,	O
respectively	O
)	O
.	O
Furthermore	O
,	O
the	O
post-operative	O
knee	O
flexion	O
angle	O
was	O
negatively	O
correlated	O
with	O
joint	O
looseness	O
at	O
45°	O
,	O
60°	O
,	O
and	O
90°	O
of	O
flexion	O
(	O
R	O
=	O
-0.40	O
,	O
P	O
<	O
0.05	O
;	O
R	O
=	O
-0.41	O
,	O
P	O
<	O
0.05	O
;	O
and	O
R	O
=	O
-0.36	O
,	O
P	O
<	O
0.05	O
,	O
respectively	O
)	O
.	O
The	O
intraoperative	O
medial	O
compartment	O
stability	O
of	O
knee	O
flexion	O
in	O
midrange	O
resulted	O
in	O
increasing	O
post-operative	O
knee	O
flexion	O
angle	O
in	O
UKA	O
.	O
Medial	O
soft	O
tissue	O
release	O
should	O
be	O
minimised	O
,	O
and	O
assessment	O
of	O
soft	O
tissue	O
balance	O
using	O
a	O
tensor	O
can	O
be	O
performed	O
to	O
predict	O
the	O
post-operative	O
knee	O
flexion	O
angle	O
during	O
surgery	O
for	O
UKA	O
.	O
LEVEL	O
OF	O
EVIDENCE	O
:	O
III	O
.	O

Meta-analyses	O
of	O
antihypertensive	O
therapy	O
:	O
Are	O
some	O
of	O
them	O
misleading	O
?	O
Meta-analysis	O
has	O
become	O
a	O
very	O
popular	O
tool	O
to	O
compare	O
the	O
efficacy	O
of	O
different	O
antihypertensive	O
regimens	O
.	O
Combining	O
results	O
from	O
various	O
outcome	O
studies	O
may	O
provide	O
evidence	O
to	O
guide	O
the	O
therapeutic	O
approach	O
even	O
before	O
results	O
from	O
large	O
prospective	O
studies	O
are	O
available	O
.	O
However	O
,	O
meta-analysis	O
may	O
be	O
misleading	O
if	O
it	O
is	O
not	O
done	O
meticulously	O
.	O
Some	O
meta-analyses	O
that	O
received	O
broad	O
news	O
media	O
coverage	O
in	O
the	O
recent	O
years	O
were	O
misleading	O
.	O
One	O
analysis	O
suggested	O
that	O
the	O
use	O
of	O
short-acting	O
nifedipine	O
in	O
moderate	O
to	O
high	O
doses	O
in	O
patients	O
with	O
coronary	INDICATIONS
disease	INDICATIONS
increased	O
mortality	O
.	O
This	O
claim	O
was	O
refuted	O
later	O
by	O
observational	O
studies	O
.	O
Based	O
on	O
another	O
meta-analysis	O
,	O
it	O
was	O
claimed	O
that	O
diuretics	O
and	O
beta-blockers	O
are	O
equally	O
effective	O
in	O
reducing	O
cardiovascular	INDICATIONS
morbidity	INDICATIONS
and	O
mortality	O
.	O
Another	O
more	O
careful	O
meta-analysis	O
,	O
omitting	O
one	O
study	O
in	O
which	O
most	O
patients	O
were	O
on	O
combination	O
therapy	O
and	O
not	O
on	O
beta-blocker	O
monotherapy	O
,	O
showed	O
the	O
superiority	O
of	O
diuretic	O
versus	O
b-blocker	O
treatment	O
in	O
the	O
elderly	O
.	O
Calcium	O
antagonists	O
were	O
recently	O
blamed	O
for	O
increasing	O
the	O
rate	O
of	O
myocardial	INDICATIONS
infarction	INDICATIONS
and	O
congestive	INDICATIONS
heart	INDICATIONS
failure	INDICATIONS
in	O
hypertensive	O
patients	O
,	O
and	O
therefore	O
their	O
use	O
was	O
not	O
recommended	O
as	O
first-line	O
therapy	O
in	O
hypertension	INDICATIONS
.	O
This	O
recommendation	O
was	O
based	O
on	O
a	O
meta-analysis	O
subject	O
to	O
major	O
drawbacks	O
and	O
was	O
misleading	O
.	O
Another	O
notion	O
based	O
on	O
meta-analysis	O
was	O
that	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
reduce	O
left	O
ventricular	O
mass	O
more	O
than	O
diuretics	O
.	O
This	O
notion	O
was	O
refuted	O
by	O
three	O
large	O
randomized	O
studies	O
.	O
A	O
recent	O
meta-analysis	O
,	O
which	O
showed	O
a	O
similar	O
blood	O
pressure	O
lowering	O
effect	O
for	O
all	O
angiotensin	O
receptor	O
blockers	O
,	O
was	O
refuted	O
by	O
head-to-head	O
studies	O
.	O
Thus	O
,	O
when	O
performed	O
correctly	O
,	O
meta-analysis	O
can	O
be	O
an	O
important	O
tool	O
,	O
but	O
when	O
uncritically	O
employed	O
,	O
it	O
is	O
prone	O
to	O
be	O
misleading	O
.	O

The	O
clinical	O
value	O
of	O
dacryoscintigraphy	O
in	O
the	O
selection	O
of	O
surgical	O
approach	O
for	O
patients	O
with	O
functional	O
lacrimal	INDICATIONS
duct	INDICATIONS
obstruction	INDICATIONS
.	O
Dacryoscintigraphy	O
is	O
widely	O
known	O
to	O
be	O
an	O
effective	O
modality	O
in	O
diagnosing	O
abnormalities	O
of	O
the	O
lacrimal	O
system	O
that	O
cause	O
epiphora	O
(	O
pathological	O
overflow	O
of	O
tear	O
)	O
.	O
However	O
,	O
dacryoscintigraphy	O
rarely	O
serves	O
beyond	O
the	O
simple	O
diagnostic	O
use	O
for	O
lacrimal	INDICATIONS
duct	INDICATIONS
obstruction	INDICATIONS
.	O
In	O
our	O
study	O
,	O
dacryoscintigraphy	O
results	O
of	O
patients	O
with	O
functional	O
lacrimal	INDICATIONS
duct	INDICATIONS
obstruction	INDICATIONS
are	O
newly	O
classified	O
into	O
three	O
types	O
,	O
the	O
effects	O
and	O
prognoses	O
of	O
silicone	O
tube	O
intubation	O
are	O
noted	O
according	O
to	O
each	O
type	O
,	O
and	O
the	O
role	O
of	O
dacryoscintigraphy	O
in	O
determining	O
appropriate	O
surgical	O
approaches	O
is	O
evaluated	O
.	O
Subjects	O
were	O
36	O
eyes	O
of	O
29	O
patients	O
complaining	O
of	O
epiphora	O
who	O
had	O
increased	O
tear	O
meniscus	O
,	O
but	O
showed	O
no	O
sign	O
of	O
obstruction	O
on	O
duct	O
syringing	O
.	O
Impression	O
of	O
functional	O
lacrimal	INDICATIONS
duct	INDICATIONS
obstruction	INDICATIONS
was	O
made	O
through	O
dacryoscintigraphy	O
,	O
and	O
silicone	O
tubes	O
were	O
inserted	O
.	O
Patients	O
were	O
classified	O
according	O
to	O
the	O
results	O
of	O
dacryoscintigraphy	O
;	O
those	O
with	O
delayed	O
secretion	O
in	O
the	O
distal	O
nasolacrimal	O
duct	O
were	O
typed	O
as	O
class	O
I	O
;	O
those	O
with	O
delays	O
in	O
the	O
proximal	O
nasolacrimal	O
duct	O
class	O
II	O
;	O
and	O
delayed	O
secretion	O
from	O
the	O
pre-lacrimal	O
sac	O
to	O
the	O
lacrimal	O
sac	O
as	O
class	O
III	O
.	O
All	O
patients	O
had	O
silicone	O
tube	O
intubations	O
together	O
with	O
selective	O
punctoplasty	O
.	O
Symptomatic	O
improvement	O
was	O
observed	O
in	O
all	O
6	O
cases	O
of	O
distal	O
nasolacrimal	O
duct	O
obstruction	O
(	O
100	O
%	O
)	O
,	O
14	O
of	O
18	O
proximal	O
obstruction	O
cases	O
(	O
77.8	O
%	O
)	O
,	O
and	O
8	O
of	O
12	O
pre-lacrimal	O
obstructions	O
(	O
66.7	O
%	O
)	O
.	O
Functional	O
lacrimal	INDICATIONS
duct	INDICATIONS
obstruction	INDICATIONS
is	O
easily	O
diagnosed	O
with	O
dacryoscintigraphy	O
.	O
Furthermore	O
,	O
its	O
may	O
be	O
classified	O
by	O
types	O
of	O
obstruction	O
to	O
predict	O
post-operative	O
results	O
of	O
silicone	O
tube	O
insertion	O
.	O
Cases	O
suspicious	O
of	O
pre-lacrimal	O
sac	O
obstructions	O
in	O
particular	O
may	O
achieve	O
better	O
operative	O
results	O
with	O
adjuvant	O
treatments	O
in	O
addition	O
to	O
silicone	O
tube	O
insertion	O
.	O

A	O
comparative	O
study	O
of	O
the	O
induction	O
of	O
epidermal	INDICATIONS
hyperplasia	INDICATIONS
by	O
natural	O
and	O
synthetic	O
retinoids	O
.	O
Retinoids	O
are	O
potent	O
inducers	O
of	O
epidermal	INDICATIONS
hyperplasia	INDICATIONS
.	O
In	O
the	O
present	O
study	O
the	O
ability	O
to	O
induce	O
epidermal	INDICATIONS
hyperplasia	INDICATIONS
by	O
a	O
variety	O
of	O
retinoids	O
has	O
been	O
compared	O
.	O
Thirteen	O
retinoids	O
and	O
beta-carotene	O
were	O
applied	O
topically	O
in	O
an	O
acetone	O
vehicle	O
to	O
the	O
dorsal	O
skin	O
of	O
hairless	O
mice	O
and	O
the	O
dose-response	O
and	O
time	O
course	O
for	O
the	O
induction	O
of	O
hyperplasia	O
were	O
measured	O
.	O
Peak	O
hyperplasia	O
occurred	O
4	O
to	O
5	O
days	O
after	O
a	O
single	O
topical	O
dose	O
,	O
and	O
was	O
induced	O
by	O
doses	O
well	O
below	O
those	O
producing	O
gross	O
or	O
histological	O
signs	O
of	O
cutaneous	O
toxicity	O
.	O
The	O
induction	O
of	O
hyperplasia	O
was	O
dose-dependent	O
,	O
the	O
number	O
of	O
epidermal	O
cell	O
layers	O
increasing	O
initially	O
in	O
proportion	O
to	O
the	O
log	O
of	O
the	O
dose	O
and	O
then	O
tending	O
to	O
plateau	O
or	O
,	O
in	O
some	O
cases	O
decrease	O
,	O
after	O
which	O
further	O
increases	O
in	O
dose	O
were	O
associated	O
with	O
the	O
appearance	O
of	O
gross	O
and	O
histological	O
toxicity	O
.	O
The	O
slopes	O
of	O
the	O
initial	O
increasing	O
phase	O
were	O
determined	O
and	O
potencies	O
expressed	O
as	O
the	O
dose	O
producing	O
a	O
50	O
%	O
increase	O
in	O
the	O
number	O
of	O
epidermal	O
cell	O
layers	O
.	O
All-trans-retinoic	O
acid	O
and	O
its	O
analogs	O
,	O
etretinate	O
and	O
its	O
free	O
acid	O
,	O
(	O
E	O
)	O
-4	O
[	O
2-	O
(	O
5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-	O
2-naphthalenyl	O
)	O
-1-propenyl	O
]	O
-benzoic	O
acid	O
(	O
arotinoid	O
)	O
derivatives	O
,	O
retinol	O
and	O
retinal	O
produced	O
an	O
increase	O
in	O
the	O
number	O
of	O
cell	O
layers	O
proportionate	O
to	O
the	O
log	O
of	O
the	O
dose	O
.	O
Decarboxylated	O
(	O
E	O
)	O
-4	O
[	O
2-	O
(	O
5,6,7,8-tetrahydro-5,5,8,8-	O
-tetramethyl-2-naphthalenyl-1-propenyl	O
]	O
-benzoic	O
acid	O
,	O
a	O
cis-locked	O
aryl	O
triene	O
derivative	O
of	O
retinoic	O
acid	O
and	O
beta-carotene	O
were	O
inactive	O
.	O
Similar	O
time	O
courses	O
were	O
observed	O
when	O
retinoids	O
were	O
dosed	O
p.o	O
.	O
The	O
relative	O
potencies	O
of	O
the	O
retinoids	O
in	O
this	O
system	O
show	O
similar	O
trends	O
to	O
those	O
reported	O
for	O
biological	O
activities	O
measured	O
in	O
other	O
in	O
vivo	O
and	O
in	O
vitro	O
assays	O
.	O

Canagliflozin-Induced	O
Diabetic	INDICATIONS
Ketoacidosis	INDICATIONS
:	O
Case	O
Report	O
and	O
Review	O
of	O
the	O
Literature	O
.	O
Sodium-glucose	O
co-transporter	O
2	O
(	O
SGLT-2	O
)	O
inhibitors	O
are	O
relatively	O
new	O
antihyperglycemic	O
agents	O
that	O
lower	O
renal	O
glucose	O
reabsorption	O
.	O
They	O
are	O
used	O
as	O
adjunctive	O
therapy	O
to	O
standard	O
diabetes	O
treatment	O
.	O
We	O
present	O
the	O
case	O
of	O
a	O
62-year-old	O
woman	O
with	O
a	O
past	O
medical	O
history	O
of	O
type	INDICATIONS
2	INDICATIONS
diabetes	INDICATIONS
mellitus	INDICATIONS
and	O
sudden-onset	O
diabetic	INDICATIONS
ketoacidosis	INDICATIONS
(	O
DKA	O
)	O
.	O
Use	O
of	O
canagliflozin	O
,	O
a	O
SGLT-2	O
inhibitor	O
,	O
was	O
determined	O
to	O
be	O
the	O
cause	O
of	O
the	O
DKA	O
.	O
The	O
patient	O
ultimately	O
recovered	O
after	O
5	O
days	O
in	O
the	O
intensive	O
care	O
unit	O
.	O
She	O
was	O
changed	O
to	O
long-	O
and	O
short-acting	O
insulins	INDICATIONS
and	O
instructed	O
to	O
avoid	O
canagliflozin	O
.	O
Although	O
SGLT-2	O
inhibitors	O
are	O
effective	O
at	O
lowering	O
a	O
patient	O
's	INDICATIONS
hemoglobin	INDICATIONS
A1C	O
,	O
physicians	O
must	O
be	O
aware	O
of	O
the	O
rare	O
but	O
dangerous	O
potential	O
adverse	O
effect	O
of	O
inducing	O
DKA	O
.	O
This	O
article	O
reports	O
an	O
illustrative	O
case	O
and	O
presents	O
a	O
review	O
of	O
the	O
literature	O
.	O

Induction	O
of	O
axon	O
growth	O
in	O
the	O
adult	O
brain	O
:	O
A	O
new	O
approach	O
to	O
restoration	O
in	O
Parkinson	INDICATIONS
's	INDICATIONS
disease	INDICATIONS
.	O
not	O
found	O

The	O
histopathology	O
of	O
a	O
case	O
of	O
encephalitis	INDICATIONS
periaxialis	INDICATIONS
concentrica	INDICATIONS
.	O

Abnormal	O
haemoglobins	O
in	O
the	O
Sudan	O
savanna	O
of	O
Nigeria	O
.	O
II	O
.	O
Immunological	O
response	O
to	O
malaria	O
in	O
normals	O
and	O
subjects	O
with	O
sickle	INDICATIONS
cell	INDICATIONS
trait	INDICATIONS
.	O
Children	O
born	O
in	O
areas	O
hyperendemic	O
for	O
Plasmodium	INDICATIONS
falciparum	INDICATIONS
are	O
protected	O
by	O
maternal	O
antibodies	O
for	O
up	O
to	O
about	O
five	O
months	O
of	O
life	O
,	O
after	O
which	O
they	O
are	O
subject	O
to	O
intense	O
infection	O
until	O
they	O
acquire	O
sufficient	O
immunity	O
--	O
by	O
about	O
five	O
years	O
of	O
age	O
.	O
Children	O
with	O
sickle	INDICATIONS
cell	INDICATIONS
trait	INDICATIONS
(	O
Hb.AS	O
)	O
are	O
at	O
an	O
advantage	O
during	O
these	O
critical	O
years	O
,	O
probably	O
because	O
of	O
preferential	O
phagocytosis	O
of	O
parasitized	O
red	O
cells	O
.	O
This	O
could	O
lead	O
to	O
either	O
(	O
i	O
)	O
early	O
processing	O
of	O
antigen	O
by	O
macrophages	O
and	O
an	O
accelerated	O
immune	O
response	O
,	O
or	O
(	O
ii	O
)	O
less	O
antigenic	O
stimulus	O
and	O
hence	O
lower	O
antibody	O
production	O
.	O
Immunoglobulin	O
(	O
Ig	O
)	O
G	O
and	O
IgM	O
determinations	O
,	O
agar	O
gel	O
diffusion	O
(	O
Ouchterlony	O
)	O
against	O
soluble	O
P.	O
falciparum	O
antigen	O
,	O
the	O
indirect	O
fluorescent	O
antibody	O
(	O
IFA	O
)	O
test	O
using	O
P.	O
falciparum	O
and	O
P.	INDICATIONS
malariae	INDICATIONS
antigens	O
,	O
and	O
the	O
indirect	O
haemagglutination	O
(	O
IHA	O
)	O
test	O
with	O
P.	O
falciparum	O
antigen	O
were	O
performed	O
on	O
sera	O
from	O
a	O
population	O
with	O
different	O
Hb	O
electrophoretic	O
types	O
in	O
the	O
hyperendemic	O
malarial	O
area	O
of	O
Garki	O
,	O
Kano	O
State	O
,	O
Nigeria	O
.	O
Plasma	O
immunoglobulins	O
and	O
antimalarial	O
antibodies	O
rose	O
with	O
age	O
.	O
After	O
the	O
first	O
year	O
of	O
life	O
,	O
lower	O
mean	O
concentrations	O
of	O
immunoglobulins	O
(	O
especially	O
IgM	O
)	O
,	O
and	O
lower	O
mean	O
titres	O
of	O
antibodies	O
specific	O
against	O
P.	O
falciparum	O
(	O
Ouchterlony	O
,	O
IHA	O
and	O
less	O
significantly	O
IFA	O
)	O
were	O
present	O
in	O
Hb.AS	O
compared	O
to	O
Hb.AA	O
;	O
these	O
differences	O
increased	O
with	O
age	O
.	O
Antimalarial	O
intervention	O
was	O
followed	O
by	O
a	O
decline	O
of	O
all	O
values	O
and	O
final	O
levels	O
showed	O
little	O
difference	O
between	O
haemoglobin	O
types	O
.	O
It	O
was	O
unlikely	O
that	O
either	O
a	O
relative	O
inability	O
to	O
produce	O
antibody	O
or	O
a	O
more	O
rapid	O
catabolism	O
of	O
immunoglobulins	O
was	O
responsible	O
for	O
the	O
lower	O
levels	O
in	O
sickle	INDICATIONS
cell	INDICATIONS
trait	INDICATIONS
.	O
The	O
observations	O
are	O
more	O
easily	O
explained	O
by	O
the	O
hypothesis	O
that	O
Hb.AS	O
persons	O
have	O
less	O
antigenic	O
stimulus	O
due	O
to	O
the	O
early	O
removal	O
of	O
parasitized	O
sickled	O
cells	O
by	O
macrophages	O
,	O
which	O
then	O
degrade	O
the	O
antigens	O
.	O
The	O
antibody	O
difference	O
between	O
Hb.AA	O
and	O
Hb.AS	O
increased	O
throughout	O
life	O
,	O
suggesting	O
that	O
this	O
process	O
remained	O
a	O
feature	O
of	O
sickle	INDICATIONS
cell	INDICATIONS
trait	INDICATIONS
even	O
after	O
parasite	O
frequencies	O
and	O
densities	O
were	O
similar	O
in	O
the	O
two	O
Hb	O
groups	O
.	O
These	O
observations	O
have	O
implications	O
in	O
the	O
aetiology	O
of	O
tropical	INDICATIONS
splenomegaly	INDICATIONS
syndrome	INDICATIONS
,	O
which	O
is	O
rarely	O
seen	O
in	O
sickle	INDICATIONS
cell	INDICATIONS
trait	INDICATIONS
subjects	O
.	O
Mean	O
IgG	O
and	O
IgM	O
were	O
slightly	O
higher	O
in	O
Hb.AS	O
than	O
Hb.AA	O
infants	O
,	O
the	O
difference	O
for	O
IgG	O
achieving	O
significance	O
.	O
This	O
suggested	O
that	O
during	O
infancy	O
early	O
phagocytosis	O
of	O
parasitized	O
cells	O
had	O
led	O
to	O
enhanced	O
processing	O
of	O
antigen	O
and	O
hence	O
an	O
earlier	O
immune	O
response	O
in	O
Hb.AS	O
,	O
but	O
this	O
was	O
unlikely	O
to	O
be	O
a	O
major	O
factor	O
in	O
survival	O
.	O
IFA	O
titres	O
against	O
P.	INDICATIONS
malariae	INDICATIONS
were	O
slightly	O
but	O
not	O
significantly	O
lower	O
in	O
Hb.AS	O
,	O
possibly	O
as	O
a	O
result	O
of	O
cross-reaction	O
with	O
P.	O
falciparum	O
antibody	O
or	O
of	O
a	O
slight	O
degree	O
of	O
protection	O
against	O
P.	INDICATIONS
malariae	INDICATIONS
.	O

[	O
Immunoglobulins	O
in	O
pulmonary	INDICATIONS
tuberculosis	INDICATIONS
]	O
.	O

The	O
use	O
of	O
the	O
bladder-tumour	INDICATIONS
associated	O
analyte	O
test	O
to	O
determine	O
the	O
type	O
of	O
cystoscopy	O
in	O
the	O
follow-up	O
of	O
patients	O
with	O
bladder	INDICATIONS
cancer	INDICATIONS
.	O

Feasibility	O
of	O
testing	O
and	O
detection	O
of	O
HIV-1	INDICATIONS
drug	O
resistance	O
in	O
proviral	O
DNA	O

[	O
A	O
NEW	O
METHOD	O
FOR	O
THE	O
MEASUREMENT	O
OF	O
MUSCLE	INDICATIONS
RELAXATION	INDICATIONS
IN	O
WHITE	O
MICE	O
]	O
.	O

[	O
Angiographic	O
characteristics	O
of	O
metastatic	INDICATIONS
brain	INDICATIONS
tumor	INDICATIONS
]	O
.	O

Insulin	INDICATIONS
sensitivity	INDICATIONS
,	O
and	O
β-cell	O
function	O
in	O
relation	O
to	O
hemoglobin	O
A1C	O
.	O
The	O
A1C	O
diagnostic	O
criterion	O
for	O
identifying	O
individuals	O
at	O
increased	O
risk	O
for	O
diabetes	O
,	O
introduced	O
by	O
the	O
American	O
Diabetes	O
Association	O
in	O
2010	O
,	O
was	O
not	O
defined	O
on	O
the	O
basis	O
of	O
the	O
principal	O
pathophysiological	O
abnormalities	O
responsible	O
for	O
the	O
development	O
and	O
progression	O
of	O
type	INDICATIONS
2	INDICATIONS
diabetes	INDICATIONS
;	O
we	O
therefore	O
wished	O
to	O
gain	O
a	O
deeper	O
insight	O
into	O
the	O
metabolic	O
abnormalities	O
characterizing	O
the	O
group	O
of	O
at	O
risk	O
individuals	O
with	O
an	O
A1C	O
value	O
of	O
5.7-6.4	O
%	O
.	O
As	O
many	O
as	O
338	O
non-diabetic	O
offspring	O
of	O
type	O
2	O
diabetic	O
patients	O
were	O
consecutively	O
recruited	O
.	O
Insulin	O
secretion	O
was	O
assessed	O
using	O
both	O
indexes	O
derived	O
from	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
)	O
,	O
and	O
intravenous	O
glucose	O
tolerance	O
test	O
(	O
IVGTT	O
)	O
.	O
Insulin	INDICATIONS
sensitivity	INDICATIONS
was	O
measured	O
by	O
hyperinsulinemic	O
euglycemic	O
clamp	O
.	O
As	O
compared	O
with	O
subjects	O
with	O
A1C	O
<	O
5.7	O
%	O
,	O
individuals	O
with	O
A1C	O
of	O
5.7-6.4	O
%	O
exhibited	O
lower	O
insulin	INDICATIONS
sensitivity	INDICATIONS
after	O
adjusting	O
for	O
age	O
,	O
gender	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O
Insulin	O
secretion	O
estimated	O
from	O
the	O
OGTT	O
,	O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O
By	O
contrast	O
,	O
as	O
compared	O
with	O
subjects	O
with	O
A1C	O
<	O
5.7	O
%	O
,	O
the	O
acute	O
insulin	O
response	O
(	O
AIR	O
)	O
during	O
an	O
IVGTT	O
and	O
both	O
IVGTT-derived	O
and	O
OGTT-derived	O
disposition	O
indexes	O
were	O
reduced	O
in	O
individuals	O
with	O
A1C	O
of	O
5.7-6.4	O
%	O
after	O
adjusting	O
for	O
age	O
,	O
gender	O
and	O
BMI	O
.	O
As	O
A1C	O
increased	O
to	O
≥	O
5.7	O
%	O
,	O
a	O
sharp	O
decrease	O
in	O
insulin	INDICATIONS
sensitivity	INDICATIONS
and	O
β-cell	O
function	O
,	O
measured	O
as	O
disposition	O
index	O
,	O
was	O
observed	O
.	O
Caucasian	O
individuals	O
with	O
A1C	O
≥	O
5.7	O
%	O
exhibit	O
both	O
core	O
pathophysiological	O
defects	O
of	O
type	INDICATIONS
2	INDICATIONS
diabetes	INDICATIONS
i.e	O
.	O
insulin	INDICATIONS
resistance	INDICATIONS
and	O
β-cell	O
dysfunction	O
.	O

[	O
Pulmonary	INDICATIONS
aspergilloma	INDICATIONS
.	O
Pathology	O
and	O
pathogenesis	O
]	O
.	O

Ovalbumin	O
fused	O
with	O
diphtheria	O
toxin	O
protects	O
mice	O
from	O
ovalbumin	O
induced	O
anaphylactic	INDICATIONS
shock	INDICATIONS
.	O
For	O
those	O
with	O
allergy	O
,	O
vaccination	O
with	O
a	O
specific	O
allergen	O
has	O
often	O
been	O
used	O
as	O
a	O
major	O
therapeutic	O
measure	O
.	O
However	O
,	O
the	O
universal	O
application	O
of	O
this	O
technique	O
in	O
clinics	O
have	O
been	O
restricted	O
due	O
to	O
its	O
low	O
success	O
rates	O
and	O
the	O
risk	O
of	O
active	O
systemic	O
anaphylactic	INDICATIONS
shock	INDICATIONS
(	O
ASAS	O
)	O
.	O
In	O
this	O
regard	O
,	O
we	O
constructed	O
a	O
fusion	O
protein	O
(	O
OVA-DT	O
)	O
,	O
ovalbumin	O
(	O
OVA	O
)	O
fused	O
with	O
diphtheria	O
toxin	O
protein	O
(	O
DT	O
)	O
,	O
which	O
may	O
exert	O
a	O
specific	O
cytotoxicity	O
to	O
cells	O
bearing	O
OVA-specific	O
IgE	O
.	O
Its	O
therapeutic	O
effect	O
was	O
evaluated	O
in	O
mice	O
(	O
BALB/c	O
)	O
sensitized	O
with	O
OVA	O
(	O
Os-mice	O
)	O
.	O
OVA	O
challenges	O
to	O
the	O
OVA-sensitized	O
mice	O
(	O
Os-mice	O
)	O
caused	O
ASAS	O
to	O
death	O
within	O
30	O
min	O
,	O
but	O
OVA-DT	O
treatment	O
afforded	O
mice	O
complete	O
protection	O
.	O
When	O
OVA-DT	O
was	O
treated	O
to	O
the	O
Os-mice	O
,	O
none	O
showed	O
the	O
signs	O
of	O
ASAS	O
when	O
re-challenged	O
48	O
h	O
after	O
the	O
treatment	O
.	O
OVA-DT	O
itself	O
was	O
not	O
found	O
to	O
be	O
toxic	O
or	O
allergenic	O
in	O
normal	O
mice	O
.	O
The	O
effect	O
of	O
OVA-DT	O
on	O
the	O
biological	O
functions	O
of	O
mast	O
cells	O
was	O
also	O
studied	O
.	O
Binding	O
of	O
OVA-DT	O
to	O
OVA-specific	O
IgE	O
bearing	O
mast	O
cells	O
and	O
the	O
inhibition	O
of	O
histamine	O
release	O
from	O
these	O
cells	O
were	O
observed	O
.	O
In	O
addition	O
,	O
OVA-DT	O
treatment	O
inhibited	O
the	O
proliferation	O
of	O
OVA-specific	O
B	O
cells	O
in	O
mice	O
.	O
In	O
Os-mice	O
treated	O
with	O
OVA-DT	O
,	O
levels	O
of	O
anti-OVA	O
IgG2a	O
in	O
serum	O
and	O
the	O
production	O
of	O
IFN-gamma	O
by	O
splenic	O
lymphocytes	O
were	O
found	O
to	O
increase	O
,	O
but	O
the	O
production	O
of	O
IL-4	O
by	O
these	O
cells	O
decreased	O
.	O
Re-direction	O
of	O
cytokine	O
profiles	O
from	O
OVA-specific	O
Th2	O
to	O
OVA-specific	O
Thl	O
is	O
suggested	O
.	O
These	O
results	O
indicate	O
that	O
OVA-DT	O
can	O
protect	O
Os-mice	O
from	O
ASAS	O
due	O
to	O
OVA	O
challenge	O
,	O
because	O
it	O
inactivates	O
OVA-specific	O
IgE-expressing	O
cells	O
,	O
including	O
mast	O
cells	O
and	O
B	O
cells	O
.	O

Wireless	O
Patrol	O
Sign-In	O
System	O
with	O
Mental	INDICATIONS
Fatigue	INDICATIONS
Detection	O
.	O
Current	O
sign-in	O
methods	O
of	O
patrolling	O
security	O
guards	O
mainly	O
comprise	O
signature	O
,	O
image	O
identification	O
,	O
and	O
fingerprint	O
identification	O
;	O
notably	O
,	O
none	O
of	O
these	O
methods	O
indicate	O
the	O
physical	O
and	O
mental	O
conditions	O
of	O
such	O
guards	O
.	O
In	O
particular	O
,	O
when	O
patrolling	O
security	O
guards	O
perform	O
their	O
duties	O
consecutively	O
for	O
a	O
long	O
period	O
of	O
time	O
,	O
adequate	O
attention	O
should	O
be	O
directed	O
toward	O
their	O
levels	O
of	O
mental	INDICATIONS
fatigue	INDICATIONS
.	O
When	O
a	O
handwriting	O
sign-in	O
system	O
is	O
adopted	O
,	O
security	O
guards	O
may	O
not	O
record	O
their	O
sign-in	O
time	O
accurately	O
,	O
or	O
they	O
may	O
fake	O
signatures	O
during	O
long	O
shifts	O
.	O
In	O
addition	O
,	O
image	O
identification	O
systems	O
can	O
not	O
comprehensively	O
reflect	O
the	O
physical	O
and	O
mental	O
statuses	O
of	O
on-duty	O
security	O
guards	O
,	O
particularly	O
their	O
levels	O
of	O
fatigue	O
.	O
Monitor	O
fatigue	O
in	O
patrolling	O
security	O
guards	O
is	O
important	O
to	O
avoid	O
burnout	INDICATIONS
and	O
stress	O
in	O
the	O
workplace	O
.	O
Therefore	O
,	O
in	O
this	O
study	O
,	O
a	O
patrolling	O
sign-in	O
system	O
that	O
integrates	O
physiological	O
signals	O
and	O
images	O
was	O
designed	O
.	O
A	O
thermometer	O
,	O
hand	O
dynamometer	O
,	O
and	O
electromyography	O
sensor	O
were	O
combined	O
to	O
measure	O
physiological	O
signals	O
.	O
Results	O
showed	O
that	O
hand	O
grip	O
strength	O
and	O
the	O
median	O
frequency	O
of	O
electromyography	O
signals	O
gradually	O
reduced	O
when	O
muscle	O
fatigue	O
occurred	O
.	O
The	O
system	O
determined	O
whether	O
a	O
security	O
guard	O
had	O
signed	O
in	O
punctually	O
and	O
whether	O
this	O
person	O
should	O
stay	O
on	O
duty	O
.	O
Overall	O
,	O
this	O
system	O
was	O
verified	O
to	O
operate	O
effectively	O
,	O
and	O
it	O
is	O
therefore	O
applicable	O
for	O
monitoring	O
the	O
sign-in	O
of	O
patrolling	O
security	O
guards	O
who	O
work	O
long	O
shifts	O
.	O
This	O
case	O
series	O
study	O
proposed	O
a	O
conceptual	O
prototype	O
of	O
the	O
system	O
;	O
large-scale	O
testing	O
should	O
be	O
performed	O
in	O
subsequent	O
research	O
.	O

Natural	O
history	O
of	O
atrial	INDICATIONS
septal	INDICATIONS
defect	INDICATIONS
.	O

REGION-SPECIFIC	O
NEURON	O
AND	O
SYNAPSE	O
LOSS	O
IN	O
THE	O
HIPPOCAMPUS	O
OF	O
APP	O
(	O
SL	O
)	O
/PS1	O
KNOCK-IN	O
MICE	O
.	O
Transgenic	O
mouse	O
models	O
with	O
knock-in	O
(	O
KI	O
)	O
expression	O
of	O
human	O
mutant	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
and/or	O
human	O
presenilin	O
1	O
(	O
PS1	O
)	O
may	O
be	O
helpful	O
to	O
elucidate	O
the	O
cellular	O
consequences	O
of	O
APP	O
and	O
PS1	O
misprocessing	O
in	O
the	O
aging	O
brain	O
.	O
Age-related	O
alterations	O
in	O
total	O
numbers	O
of	O
neurons	O
and	O
in	O
numbers	O
of	O
synaptophysin-immunoreactive	O
presynaptic	O
boutons	O
(	O
SIPB	O
)	O
,	O
as	O
well	O
as	O
the	O
amyloid	INDICATIONS
plaque	INDICATIONS
load	O
were	O
analyzed	O
in	O
the	O
hippocampal	O
dentate	O
gyrus	O
(	O
DG	O
)	O
,	O
CA3	O
,	O
and	O
CA1-2	O
of	O
2-	O
and	O
10-month-old	O
APP	O
(	O
SL	O
)	O
/PS1	O
homozygous	O
KI	O
,	O
APP	O
(	O
SL	O
)	O
(	O
expressing	O
human	O
mutant	O
APP751	O
carrying	O
the	O
Swedish	O
[	O
K670N/M671L	O
]	O
and	O
London	O
[	O
V717I	O
]	O
mutations	O
under	O
Thy-1	O
promoter	O
)	O
,	O
and	O
PS1	O
homozygous	O
KI	O
mice	O
(	O
expressing	O
human	O
PS1	O
mutations	O
[	O
M233T	O
and	O
L235P	O
]	O
)	O
.	O
APP	O
(	O
SL	O
)	O
/PS1	O
homozygous	O
KI	O
mice	O
,	O
but	O
neither	O
APP	O
(	O
SL	O
)	O
mice	O
nor	O
PS1	O
homozygous	O
KI	O
mice	O
,	O
showed	O
substantial	O
age-related	O
loss	O
of	O
neurons	O
(	O
-47.2	O
%	O
)	O
and	O
SIPB	O
(	O
-22.6	O
%	O
)	O
,	O
specifically	O
in	O
CA1-2	O
.	O
PS1	O
homozygous	O
KI	O
mice	O
showed	O
an	O
age-related	O
increase	O
in	O
hippocampal	O
granule	O
cell	O
numbers	O
(	O
+37.9	O
%	O
)	O
.	O
Loss	O
of	O
neurons	O
and	O
SIPB	O
greatly	O
exceeded	O
the	O
amount	O
of	O
local	O
extracellular	O
Aβ	O
aggregation	O
and	O
astrocytes	O
,	O
whereas	O
region-specific	O
accumulation	O
of	O
intraneuronal	O
Aβ	O
preceded	O
neuron	O
and	O
synapse	O
loss	O
.	O
An	O
age-related	O
increase	O
in	O
the	O
ratio	O
of	O
SIPB	O
to	O
neuron	O
numbers	O
in	O
CA1-2	O
of	O
APP	O
(	O
SL	O
)	O
/PS1	O
homozygous	O
KI	O
mice	O
was	O
suggestive	O
of	O
compensatory	O
synaptic	O
plasticity	O
.	O
These	O
findings	O
indicate	O
a	O
region-selectivity	O
in	O
intra-	O
and	O
extraneuronal	O
Aβ	O
accumulation	O
in	O
connection	O
with	O
neuron	O
and	O
synapse	O
loss	O
in	O
the	O
hippocampus	O
of	O
APP	O
(	O
SL	O
)	O
/PS1	O
homozygous	O
KI	O
mice	O
.	O

Chemical	O
transmitter	O
substances	O
in	O
brain	INDICATIONS
stem	INDICATIONS
of	O
cat	O
.	O

Effect	O
of	O
nipradilol	O
on	O
silent	INDICATIONS
myocardial	INDICATIONS
ischemia	INDICATIONS
and	O
heart	O
rate	O
variability	O
in	O
chronic	INDICATIONS
stable	INDICATIONS
angina	INDICATIONS
.	O
Silent	O
myocardial	O
ischemic	O
episodes	O
as	O
well	O
as	O
decreased	INDICATIONS
heart	INDICATIONS
rate	INDICATIONS
variability	O
(	O
HRV	O
)	O
indices	O
are	O
associated	O
with	O
an	O
unfavorable	O
outcome	O
in	O
patients	O
with	O
coronary	INDICATIONS
artery	INDICATIONS
disease	INDICATIONS
.	O
Nipradilol	O
,	O
which	O
is	O
a	O
nonselective	O
beta-adrenergic	O
and	O
nitrate-like	O
vasodilator	O
anti-anginal	O
agent	O
developed	O
in	O
Japan	O
,	O
may	O
ameliorate	O
silent	INDICATIONS
myocardial	INDICATIONS
ischemia	INDICATIONS
,	O
while	O
it	O
also	O
improves	O
exercise	O
tolerance	O
and	O
HRV	O
indices	O
in	O
patients	O
with	O
chronic	INDICATIONS
stable	INDICATIONS
angina	INDICATIONS
.	O
To	O
investigate	O
the	O
effect	O
of	O
nipradilol	O
(	O
6	O
mg	O
daily	O
)	O
on	O
silent	O
myocardial	O
ischemic	O
episodes	O
and	O
HRV	O
indices	O
,	O
and	O
to	O
study	O
its	O
effect	O
on	O
the	O
relationship	O
between	O
them	O
,	O
24	O
patients	O
with	O
chronic	INDICATIONS
stable	INDICATIONS
angina	INDICATIONS
underwent	O
exercise	O
treadmill	O
testing	O
and	O
a	O
24-hour	O
ambulatory	O
electrocardiogram	O
(	O
ECG	O
)	O
.	O
The	O
study	O
protocol	O
utilized	O
a	O
single	O
blind	O
,	O
4-week	O
placebo-controlled	O
design	O
.	O
The	O
HRV	O
indices	O
from	O
ambulatory	O
ECG	O
included	O
mean	O
RR	INDICATIONS
(	INDICATIONS
ms	INDICATIONS
)	O
,	O
SDNN	O
(	O
ms	O
)	O
,	O
SDANN	O
(	O
ms	O
)	O
,	O
SD	O
(	O
ms	O
)	O
,	O
rMSSD	O
(	O
ms	O
)	O
,	O
pNN50	O
(	O
%	O
)	O
;	O
frequency	O
analysis	O
of	O
HRV	O
consisted	O
of	O
total	O
(	O
ms	O
,	O
0.01-1.00	O
Hz	O
)	O
,	O
low	O
(	O
ms	O
,	O
0.04-0.15	O
Hz	O
)	O
and	O
high	O
(	O
ms	O
,	O
0.15-0.40	O
Hz	O
)	O
components	O
.	O
Nipradilol	O
significantly	O
decreased	O
the	O
mean	O
heart	O
rate	O
at	O
submaximal	O
and	O
maximal	O
exercise	O
and	O
the	O
mean	O
pressure	O
rate	O
product	O
at	O
submaximal	O
and	O
maximal	O
exercise	O
.	O
It	O
significantly	O
improved	O
exercise-induced	O
maximal	O
ST	O
segment	O
depression	O
from	O
-1.7	O
+/-	O
0.6	O
mm	O
to	O
-1.1	O
+/-	O
0.7	O
mm	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Silent	O
myocardial	O
ischemic	O
episodes	O
recorded	O
during	O
the	O
24-hour	O
ambulatory	O
ECG	O
significantly	O
decreased	O
after	O
nipradilol	O
administration	O
.	O
Nipradilol	O
also	O
significantly	O
influenced	O
several	O
HRV	O
indices	O
as	O
well	O
as	O
the	O
relationship	O
between	O
silent	O
myocardial	O
ischemic	O
episodes	O
and	O
the	O
HRV	O
indices	O
.	O
Nipradilol	O
significantly	O
increased	O
SD	O
,	O
rMSSD	O
,	O
pNN50	O
,	O
total	O
spectra	O
,	O
low	O
frequency	O
spectra	O
and	O
high	O
frequency	O
spectra	O
.	O
In	O
addition	O
,	O
nipradilol	O
significantly	O
decreased	O
the	O
LF/HF	O
ratio	O
from	O
1.7	O
(	O
1.5-2.0	O
)	O
to	O
1.5	O
(	O
1.3-1.8	O
)	O
.	O
These	O
effects	O
of	O
nipradilol	O
on	O
HRV	O
indices	O
concomitantly	O
occurred	O
with	O
the	O
reduction	O
in	O
silent	O
myocardial	O
ischemic	O
episodes	O
.	O
Nipradilol	O
was	O
found	O
to	O
effectively	O
improve	O
the	O
episodes	O
of	O
silent	INDICATIONS
myocardial	INDICATIONS
ischemia	INDICATIONS
as	O
well	O
as	O
exercise-induced	O
ischemia	INDICATIONS
probably	O
due	O
to	O
its	O
beta-blocking	O
properties	O
and	O
not	O
nitrate-like	O
actions	O
.	O
In	O
addition	O
,	O
nipradilol	O
also	O
had	O
a	O
favorable	O
effect	O
on	O
the	O
HRV	O
indices	O
.	O

Primary	O
CNS	INDICATIONS
lymphomas	INDICATIONS
prognosis	O
.	O

Socialization	O
and	O
behavioral	O
problems	O
of	O
elementary	O
school	O
pupils	O
with	O
developmental	INDICATIONS
coordination	INDICATIONS
disorder	INDICATIONS
.	O
The	O
present	O
study	O
examined	O
the	O
role	O
of	O
the	O
developmental	INDICATIONS
coordination	INDICATIONS
disorder	INDICATIONS
in	O
154	O
children	O
's	O
socialization	O
and	O
the	O
expression	O
of	O
deviant	O
behaviors	O
in	O
the	O
context	O
of	O
Greek	O
primary	O
education	O
.	O
For	O
assessment	O
of	O
their	O
motor	O
coordination	O
,	O
the	O
Movement	O
Assessment	O
Battery	O
for	O
Children	O
of	O
Henderson	O
and	O
Sugden	O
was	O
used	O
.	O
The	O
peer	O
nomination	O
method	O
(	O
sociogram	O
)	O
was	O
used	O
for	O
the	O
estimation	O
of	O
children	O
's	O
social	O
status	O
,	O
and	O
the	O
expression	O
of	O
deviant	O
behaviors	O
was	O
assessed	O
via	O
Conners	O
'	O
Teacher	O
Questionnaire	O
.	O
Analyses	O
showed	O
that	O
developmental	INDICATIONS
coordination	INDICATIONS
disorder	INDICATIONS
was	O
associated	O
with	O
poor	O
socialization	O
and	O
the	O
expression	O
of	O
deviant	O
behaviors	O
.	O
These	O
findings	O
support	O
the	O
development	O
of	O
educational	O
programs	O
to	O
include	O
children	O
with	O
poor	O
motor	O
coordination	O
.	O

Ten-year	O
trends	O
in	O
vitamin	O
intake	O
in	O
free-living	O
healthy	O
elderly	O
people	O
:	O
the	O
risk	O
of	O
subclinical	O
malnutrition	O
.	O
To	O
explore	O
the	O
trends	O
of	O
vitamin	O
intake	O
over	O
a	O
10-year	O
follow-up	O
in	O
a	O
group	O
of	O
successfully	O
aging	O
elderly	O
people	O
.	O
Longitudinal	O
study	O
.	O
City	O
of	O
Padua	O
,	O
Italy	O
.	O
78	O
(	O
34M/44F	O
)	O
free-living	O
and	O
still	O
well-functioning	O
survivors	O
among	O
the	O
Italian	O
participants	O
in	O
the	O
SENECA	O
multicenter	O
project	O
,	O
aged	O
70-75	O
y	O
at	O
the	O
baseline	O
.	O
data	O
were	O
collected	O
by	O
means	O
of	O
a	O
modified	O
validated	O
dietary	O
history	O
,	O
both	O
at	O
baseline	O
and	O
then	O
10	O
y	O
later	O
.	O
The	O
dietary	O
intake	O
of	O
vitamins	O
B1	O
,	O
B2	O
,	O
A	O
and	O
C	O
were	O
considered	O
,	O
calculating	O
the	O
percentages	O
of	O
individuals	O
with	O
an	O
intake	O
below	O
the	O
lowest	O
European	O
Recommended	O
Dietary	O
Intake	O
(	O
RDI	O
)	O
.	O
mean	O
energy	O
and	O
macronutrient	O
intake	O
were	O
consistent	O
with	O
dietary	O
guidelines	O
at	O
both	O
time	O
points	O
.	O
There	O
was	O
no	O
decline	O
in	O
total	O
energy	O
intake	O
after	O
a	O
decade	O
.	O
At	O
baseline	O
,	O
the	O
intake	O
of	O
all	O
vitamins	O
exceeded	O
the	O
Lowest	O
European	O
RDI	O
,	O
with	O
the	O
exception	O
of	O
vitamin	O
B1	O
,	O
for	O
which	O
44	O
%	O
of	O
the	O
men	O
and	O
60	O
%	O
of	O
the	O
women	O
were	O
already	O
deficient	O
.	O
After	O
a	O
decade	O
,	O
the	O
prevalence	O
of	O
vitamin	O
B2	O
and	O
vitamin	INDICATIONS
A	INDICATIONS
deficiencies	INDICATIONS
rose	O
to	O
50	O
%	O
of	O
the	O
sample	O
.	O
Vitamin	INDICATIONS
C	INDICATIONS
deficiencies	INDICATIONS
rose	O
in	O
a	O
decade	O
from	O
3	O
%	O
to	O
6	O
%	O
in	O
men	O
and	O
from	O
2.3	O
%	O
to	O
4.5	O
%	O
in	O
women	O
and	O
it	O
was	O
the	O
least	O
prevalent	O
.	O
despite	O
an	O
adequate	O
nutritional/functional	O
status	O
and	O
a	O
total	O
energy	O
intake	O
that	O
could	O
be	O
expected	O
to	O
cover	O
the	O
recommendations	O
for	O
micronutrients	O
too	O
,	O
a	O
considerable	O
proportion	O
of	O
our	O
successfully	O
aging	O
elderly	O
were	O
already	O
deficient	O
in	O
,	O
or	O
at	O
high	O
risk	O
of	O
becoming	O
deficient	O
in	O
several	O
essential	O
vitamins	O
.	O
Multivitamin	O
supplementation	O
may	O
be	O
necessary	O
,	O
even	O
in	O
healthy	O
individuals	O
,	O
to	O
ensure	O
an	O
adequate	O
micronutrient	O
intake	O
in	O
the	O
elderly	O
.	O

A	O
multi-faceted	INDICATIONS
program	O
for	O
continuing	O
education	O
in	O
nursing	O
.	O
The	O
three-year	O
project	O
,	O
a	O
Multi-Faceted	INDICATIONS
Program	O
for	O
Continuing	O
Education	O
in	O
Nursing	O
,	O
provided	O
for	O
development	O
of	O
multiple	O
new	O
and	O
innovative	O
approaches	O
to	O
providing	O
continuing	O
education	O
for	O
nurses	O
.	O
The	O
major	O
accomplishments	O
of	O
the	O
project	O
were	O
:	O
1	O
.	O
The	O
development	O
and	O
testing	O
of	O
a	O
nursing	O
self-assessment	O
inventory	O
.	O
2	O
.	O
The	O
establishment	O
of	O
learning	O
laboratories	O
for	O
nursing	O
continuing	O
education	O
in	O
rural	O
communities	O
with	O
emphasis	O
on	O
use	O
of	O
self-instructional	O
materials	O
.	O
3	O
.	O
Participation	O
in	O
the	O
implementation	O
of	O
a	O
regional	O
plan	O
for	O
continuing	O
education	O
in	O
nursing	O
.	O
4	O
.	O
The	O
preparation	O
of	O
nurses	O
in	O
rural	O
areas	O
in	O
the	O
skills	O
of	O
planning	O
and	O
implementation	O
of	O
local	O
nursing	O
continuing	O
education	O
programs	O
.	O
5	O
.	O
The	O
development	O
and	O
implementation	O
of	O
strategies	INDICATIONS
for	O
exposing	O
the	O
public	O
to	O
new	O
roles	O
of	O
nurses	O
through	O
the	O
use	O
of	O
mass	O
media	O
.	O

Detection	O
of	O
cytomegalovirus	INDICATIONS
DNA	O
in	O
sera	O
of	O
liver	O
transplant	O
recipients	O
.	O
We	O
prospectively	O
studied	O
the	O
utility	O
of	O
the	O
amplification	O
of	O
cytomegalovirus	INDICATIONS
(	O
CMV	O
)	O
DNA	O
in	O
the	O
sera	O
of	O
liver	O
transplant	O
recipients	O
in	O
order	O
to	O
predict	O
symptomatic	O
CMV	INDICATIONS
infection	INDICATIONS
,	O
thus	O
enabling	O
preemptive	O
therapy	O
with	O
antiviral	O
agents	O
.	O
Serum	O
samples	O
obtained	O
at	O
biweekly	O
intervals	O
from	O
20	O
sequential	O
liver	O
transplant	O
recipients	O
for	O
at	O
least	O
8	O
weeks	O
following	O
transplantation	O
were	O
tested	O
by	O
the	O
PCR	O
amplification	O
procedure	O
.	O
Results	O
were	O
correlated	O
with	O
blood	O
and	O
urine	O
cultures	O
,	O
histopathological	O
findings	O
from	O
infected	O
organs	O
,	O
and	O
clinical	O
manifestations	O
.	O
Six	O
patients	O
(	O
30	O
%	O
)	O
developed	O
symptomatic	O
CMV	INDICATIONS
infection	INDICATIONS
;	O
in	O
five	O
(	O
83	O
%	O
)	O
of	O
these	O
patients	O
,	O
CMV	O
DNA	O
was	O
detected	O
prior	O
to	O
symptomatic	O
CMV	INDICATIONS
infection	INDICATIONS
,	O
and	O
in	O
one	O
(	O
17	O
%	O
)	O
of	O
these	O
patients	O
,	O
CMV	O
DNA	O
was	O
detected	O
at	O
the	O
time	O
of	O
symptomatic	O
CMV	INDICATIONS
infection	INDICATIONS
.	O
CMV	O
DNA	O
was	O
detected	O
a	O
mean	O
of	O
13	O
days	O
(	O
range	O
,	O
0	O
to	O
23	O
days	O
)	O
prior	O
to	O
the	O
onset	O
of	O
symptomatic	O
CMV	INDICATIONS
infection	INDICATIONS
.	O
In	O
addition	O
,	O
CMV	O
DNA	O
was	O
detected	O
in	O
the	O
sera	O
of	O
four	O
of	O
five	O
patients	O
with	O
asymptomatic	O
viremia	INDICATIONS
and	O
two	O
patients	O
with	O
asymptomatic	O
viruria	O
.	O
Lastly	O
,	O
the	O
PCR	O
was	O
negative	O
for	O
sera	O
from	O
seven	O
patients	O
with	O
no	O
evidence	O
of	O
CMV	INDICATIONS
infection	INDICATIONS
.	O
We	O
found	O
that	O
PCR	O
was	O
able	O
to	O
detect	O
the	O
presence	O
of	O
CMV	O
DNA	O
in	O
the	O
sera	O
of	O
liver	O
transplant	O
recipients	O
at	O
a	O
sensitivity	O
of	O
92	O
%	O
and	O
a	O
specificity	O
of	O
100	O
%	O
for	O
CMV	INDICATIONS
infection	INDICATIONS
,	O
while	O
the	O
sensitivity	O
and	O
specificity	O
for	O
symptomatic	O
infection	O
were	O
100	O
and	O
57	O
%	O
,	O
respectively	O
.	O

Adaptive	O
cytoprotection	O
induced	O
by	O
pretreatment	O
with	O
ethanol	O
protects	O
against	O
gastric	O
cell	O
damage	O
by	O
NSAIDs	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
adaptive	O
cytoprotection	O
against	O
NSAIDs	O
in	O
human	O
gastric	INDICATIONS
carcinoma	INDICATIONS
cells	O
in	O
culture	O
.	O
Pretreatment	O
of	O
cells	O
with	O
low	O
(	O
nontoxic	O
)	O
concentrations	O
of	O
ethanol	O
protected	O
cells	O
from	O
cell	O
death	O
induced	O
by	O
subsequent	O
exposure	O
to	O
NSAIDs	O
.	O
The	O
adaptive	O
cytoprotection	O
against	O
NSAIDs	O
induced	O
by	O
ethanol	O
was	O
not	O
attenuated	O
by	O
pretreatment	O
of	O
cells	O
with	O
inhibitors	O
of	O
protein	O
synthesis	O
or	O
prostaglandin	O
synthesis	O
,	O
thus	O
inferring	O
that	O
neither	O
newly	O
synthesized	O
proteins	O
nor	O
prostaglandins	O
are	O
involved	O
in	O
this	O
process	O
.	O
Furthermore	O
,	O
treatment	O
of	O
cells	O
with	O
the	O
low	O
concentration	O
of	O
ethanol	O
did	O
not	O
affect	O
the	O
synthesis	O
and	O
secretion	O
of	O
mucin	O
.	O
In	O
in	O
vivo	O
experiments	O
on	O
rats	O
,	O
oral	O
preadministration	O
of	O
a	O
low	O
dose	O
of	O
ethanol	O
protected	O
the	O
gastric	O
mucosa	O
from	O
gastric	O
lesions	O
induced	O
by	O
subsequent	O
oral	O
administration	O
of	O
NSAIDs	O
.	O
One	O
possible	O
explanation	O
for	O
this	O
in	O
vivo	O
phenomenon	O
is	O
that	O
the	O
adaptive	O
cytoprotection	O
induced	O
by	O
ethanol	O
protects	O
the	O
gastric	O
mucosa	O
from	O
the	O
direct	O
cytotoxic	O
effect	O
of	O
NSAIDs	O
.	O

A	O
coordinate	O
descent	O
algorithm	O
for	O
computing	O
penalized	O
smooth	O
quantile	O
regression	O
The	O
computation	O
of	O
penalized	O
quantile	O
regression	O
estimates	O
is	O
often	O
computationally	O
intensive	O
in	O
high	O
dimensions	O
.	O
In	O
this	O
paper	O
we	O
propose	O
a	O
coordinate	O
descent	O
algorithm	O
for	O
computing	O
the	O
penalized	O
smooth	O
quantile	O
regression	O
(	O
cdaSQR	O
)	O
with	O
convex	O
and	O
nonconvex	O
penalties	O
.	O
The	O
cdaSQR	O
approach	O
is	O
based	O
on	O
the	O
approximation	O
of	O
the	O
objective	O
check	O
function	O
,	O
which	O
is	O
not	O
differentiable	O
at	O
zero	O
,	O
by	O
a	O
modified	O
check	O
function	O
which	O
is	O
differentiable	O
at	O
zero	O
.	O
Then	O
,	O
using	O
the	O
maximization-minimization	O
trick	O
of	O
the	O
gcdnet	O
algorithm	O
(	O
Yang	O
and	O
Zou	O
in	O
,	O
J	O
Comput	O
Graph	O
Stat	O
22	O
(	O
2	O
)	O
:396–415	O
,	O
2013	O
)	O
,	O
we	O
update	O
each	O
coefficient	O
simply	O
and	O
efficiently	O
.	O
In	O
our	O
implementation	O
,	O
we	O
consider	O
the	O
convex	O
penalties	O
$	O
$	O
\ell	O
_1+\ell	O
_2	O
$	O
$	O
ℓ1+ℓ2	O
and	O
the	O
nonconvex	O
penalties	O
SCAD	O
(	O
or	O
MCP	O
)	O
$	O
$	O
+	O
\ell	O
_2	O
$	O
$	O
+ℓ2	O
.	O
We	O
establishe	O
the	O
convergence	O
property	O
of	O
the	O
csdSQR	O
with	O
$	O
$	O
\ell	O
_1+\ell	O
_2	O
$	O
$	O
ℓ1+ℓ2	O
penalty	O
.	O
The	O
numerical	O
results	O
show	O
that	O
our	O
implementation	O
is	O
an	O
order	O
of	O
magnitude	O
faster	O
than	O
its	O
competitors	O
.	O
Using	O
simulations	O
we	O
compare	O
the	O
speed	O
of	O
our	O
algorithm	O
to	O
its	O
competitors	O
.	O
Finally	O
,	O
the	O
performance	O
of	O
our	O
algorithm	O
is	O
illustrated	O
on	O
three	O
real	O
data	O
sets	O
from	O
diabetes	O
,	O
leukemia	INDICATIONS
and	O
Bardet–Bidel	O
syndrome	O
gene	O
expression	O
studies	O
.	O

Influence	O
of	O
bushenhuoxue	O
on	O
primary	O
visual	O
cortex	O
'	O
BDNF	O
damage	O
in	O
rat	O
model	O
of	O
chronic	O
elevated	O
intraocular	O
pressure	O
AIM	O
:	O
To	O
observe	O
the	O
effect	O
of	O
traditional	O
Chinese	O
medicine	O
(	O
TCM	O
)	O
of	O
bushenhuoxue	O
on	O
primary	O
visual	O
cortex	O
(	O
PVC	O
)	O
brain-derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
in	O
rat	O
model	O
of	O
chronic	O
elevated	O
intraocular	O
pressure	O
(	O
EIOP	O
)	O
,	O
and	O
explore	O
the	O
mechanism	O
of	O
it	O
initially	O
.	O
METHODS	O
:	O
The	O
rat	O
model	O
of	O
chronic	O
EIOP	O
was	O
established	O
by	O
unilaterally	O
cauterizing	O
3	O
episcleral	O
veins	O
,	O
then	O
30	O
rats	O
were	O
divided	O
into	O
3	O
groups	O
randomly	O
:	O
control	O
group	O
,	O
model	O
group	O
,	O
and	O
treatment	O
group	O
.	O
After	O
given	O
drugs	O
or	O
normal	O
saline	O
for	O
8	O
weeks	O
,	O
the	O
rats	O
were	O
put	O
to	O
death	O
.	O
The	O
effect	O
of	O
intraocular	INDICATIONS
pressure	INDICATIONS
(	O
IOP	O
)	O
,	O
expression	O
of	O
BDNF	O
and	O
ultrastructure	O
of	O
neuron	O
cell	O
in	O
the	O
PVC	O
was	O
observed	O
.	O
RESULTS	O
:	O
Unilaterally	O
cauterizing	O
episcleral	O
veins	O
increased	O
IOP	O
of	O
the	O
rat	O
model	O
obviously	O
,	O
there	O
was	O
significant	O
difference	O
compared	O
with	O
pre-operation	O
(	O
P	O
<	O
0.01	O
)	O
.	O
Semi-quantitative	O
pathological	O
analysis	O
on	O
PVC	O
showed	O
that	O
BDNF	O
of	O
total	O
area	O
in	O
the	O
model	O
group	O
was	O
(	O
82438±2597.39	O
)	O
S/μm2	O
,	O
mean	O
optical	O
density	O
was	O
(	O
1155.9±123.14	O
)	O
,	O
integrated	O
optical	O
density	O
was	O
(	O
12915±673.28	O
)	O
,	O
compared	O
with	O
the	O
control	O
group	O
{	O
total	O
area	O
was	O
(	O
132370±7588.47	O
)	O
S/μm2	O
,	O
mean	O
optical	O
density	O
was	O
(	O
5365±379.65	O
)	O
,	O
integrated	O
optical	O
density	O
was	O
(	O
35102±2648.5	O
)	O
}	O
,	O
there	O
were	O
statistical	O
differences	O
(	O
all	O
P	O
<	O
0.05	O
)	O
,	O
there	O
was	O
statistical	O
difference	O
in	O
BDNF	O
of	O
total	O
area	O
between	O
model	O
group	O
and	O
treatment	O
group	O
{	O
(	O
108980±9126.77	O
)	O
S/μm2	O
,	O
P	O
<	O
0.05	O
}	O
,	O
significant	O
difference	O
in	O
mean	O
optical	O
density	O
between	O
the	O
model	O
group	O
and	O
treatment	O
group	O
(	O
3220.4±413.67	O
,	O
P	O
<	O
0.05	O
)	O
,	O
statistical	O
difference	O
in	O
integrated	O
optical	O
density	O
between	O
the	O
model	O
group	O
and	O
treatment	O
group	O
(	O
23821±3431.68	O
,	O
P	O
<	O
0.05	O
)	O
.	O
CONCLUSION	O
:	O
TCM	O
of	O
bushenhuoxue	O
can	O
repair	O
the	O
PVC	O
damage	O
in	O
the	O
rat	O
model	O
of	O
chronic	O
EIOP	O
by	O
enhancing	O
expression	O
of	O
BDNF	O
,	O
improving	O
ultrastructure	O
of	O
neuron	O
cell	O
.	O

Condensed	O
Tannins	O
from	O
Longan	O
Bark	O
as	O
Inhibitor	O
of	O
Tyrosinase	O
:	O
Structure	O
,	O
Activity	O
,	O
and	O
Mechanism	O
.	O
In	O
this	O
study	O
,	O
the	O
content	O
,	O
structure	O
,	O
antityrosinase	O
activity	O
,	O
and	O
mechanism	O
of	O
longan	O
bark	O
condensed	O
tannins	O
were	O
evaluated	O
.	O
The	O
findings	O
obtained	O
from	O
mass	O
spectrometry	O
demonstrated	O
that	O
longan	O
bark	O
condensed	O
tannins	O
were	O
mixtures	O
of	O
procyanidins	O
,	O
propelargonidins	O
,	O
prodelphinidins	O
,	O
and	O
their	O
acyl	O
derivatives	O
(	O
galloyl	O
and	O
p-hydroxybenzoate	O
)	O
.	O
The	O
enzyme	O
analysis	O
indicated	O
that	O
these	O
mixtures	O
were	O
efficient	O
,	O
reversible	O
,	O
and	O
mixed	O
(	O
competitive	O
is	O
dominant	O
)	O
inhibitor	O
of	O
tyrosinase	O
.	O
What	O
's	O
more	O
,	O
the	O
mixtures	O
showed	O
good	O
inhibitions	O
on	O
proliferation	O
,	O
intracellular	O
enzyme	O
activity	O
and	O
melanogenesis	O
of	O
mouse	INDICATIONS
melanoma	INDICATIONS
cells	O
(	O
B	O
)	O
.	O
From	O
molecular	O
docking	O
,	O
the	O
results	O
showed	O
the	O
interactions	O
between	O
inhibitors	O
and	O
tyrosinase	O
were	O
driven	O
by	O
hydrogen	O
bond	O
,	O
electrostatic	O
,	O
and	O
hydrophobic	O
interactions	O
.	O
In	O
addition	O
,	O
high	O
levels	O
of	O
total	O
phenolic	O
and	O
extractable	O
condensed	O
tannins	O
suggested	O
that	O
longan	O
bark	O
might	O
be	O
a	O
good	O
source	O
of	O
tyrosinase	O
inhibitor	O
.	O
This	O
study	O
would	O
offer	O
theoretical	O
basis	O
for	O
the	O
development	O
of	O
longan	O
bark	O
condensed	O
tannins	O
as	O
novel	O
food	O
preservatives	O
and	O
medicines	O
of	O
skin	INDICATIONS
diseases	INDICATIONS
.	O

Evaluation	O
of	O
the	O
human	O
melanoma	O
targeting	O
properties	O
of	O
radiolabeled	O
alpha-melanocyte	O
stimulating	O
hormone	O
peptide	O
analogues	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
human	O
MC1	O
receptor-mediated	O
melanoma	O
targeting	O
properties	O
of	O
two	O
metal	O
cyclized	O
alpha-MSH	O
peptide	O
analogues	O
,	O
(	O
188	O
)	O
Re-	O
(	O
Arg	O
(	O
11	O
)	O
)	O
CCMSH	O
and	O
(	O
188	O
)	O
Re-CCMSH	O
.	O
Initially	O
,	O
the	O
presence	O
and	O
density	O
of	O
the	O
MC1	O
receptor	O
were	O
determined	O
on	O
a	O
bank	O
of	O
human	O
melanoma	O
cell	O
lines	O
.	O
All	O
eight	O
human	O
melanoma	O
cell	O
lines	O
tested	O
in	O
this	O
study	O
displayed	O
the	O
MC1	O
receptor	O
at	O
a	O
density	O
of	O
900	O
to	O
5700	O
receptors	O
per	O
cell	O
.	O
Receptor	O
affinity	O
and	O
biodistribution	O
properties	O
of	O
(	O
188	O
)	O
Re-	O
(	O
Arg	O
(	O
11	O
)	O
)	O
CCMSH	O
and	O
(	O
188	O
)	O
Re-CCMSH	O
were	O
evaluated	O
in	O
a	O
cultured	O
TXM13	O
human	O
melanoma-xenografted	O
Scid	INDICATIONS
mouse	O
model	O
.	O
Biodistribution	O
results	O
demonstrated	O
that	O
3.06	O
+/-	O
0.68	O
%	O
ID/g	O
of	O
(	O
188	O
)	O
Re-	O
(	O
Arg	O
(	O
11	O
)	O
)	O
CCMSH	O
accumulated	O
in	O
the	O
tumors	O
1	O
h	O
postinjection	O
and	O
greater	O
than	O
65	O
%	O
of	O
the	O
activity	O
at	O
1	O
h	O
postinjection	O
remained	O
in	O
the	O
tumors	O
at	O
4	O
h	O
after	O
dose	O
administration	O
.	O
Whole	O
body	O
clearance	O
of	O
(	O
188	O
)	O
Re-	O
(	O
Arg	O
(	O
11	O
)	O
)	O
CCMSH	O
was	O
very	O
rapid	O
,	O
with	O
approximately	O
82	O
%	O
of	O
injected	O
dose	O
cleared	O
through	O
urinary	O
system	O
at	O
4	O
h	O
postinjection	O
.	O
There	O
was	O
very	O
little	O
activity	O
in	O
blood	O
and	O
major	O
organs	O
such	O
as	O
liver	O
,	O
lung	O
,	O
and	O
muscle	O
except	O
for	O
the	O
kidney	O
.	O
(	O
188	O
)	O
Re-CCMSH	O
exhibited	O
similar	O
tumor	O
uptake	O
and	O
retention	O
in	O
TXM13	O
human	O
melanoma-xenografted	O
Scid	O
mice	O
as	O
(	O
188	O
)	O
Re-	O
(	O
Arg	O
(	O
11	O
)	O
)	O
CCMSH	O
.	O
However	O
,	O
the	O
kidney	O
uptake	O
value	O
of	O
(	O
188	O
)	O
Re-CCMSH	O
was	O
two	O
times	O
higher	O
than	O
that	O
of	O
(	O
188	O
)	O
Re-	O
(	O
Arg	O
(	O
11	O
)	O
)	O
CCMSH	O
.	O
The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
the	O
MC1	O
receptor	O
is	O
present	O
on	O
the	O
surface	O
of	O
a	O
large	O
number	O
of	O
human	O
melanoma	O
cells	O
,	O
which	O
makes	O
the	O
MC1	O
receptor	O
a	O
good	O
imaging	O
or	O
therapeutic	O
target	O
.	O
Moreover	O
,	O
the	O
biodistribution	O
properties	O
of	O
(	O
188	O
)	O
Re-	O
(	O
Arg	O
(	O
11	O
)	O
)	O
CCMSH	O
and	O
(	O
188	O
)	O
Re-CCMSH	O
highlight	O
their	O
potential	O
as	O
therapeutic	O
agents	O
for	O
human	O
melanoma	O
.	O

Soft	O
palatal	O
webbing	O
flap	O
palatopharyngoplasty	O
for	O
both	O
soft	O
palatal	O
and	O
oropharyngeal	INDICATIONS
lateral	O
wall	O
collapse	O
in	O
the	O
treatment	O
of	O
snoring	O
and	O
obstructive	INDICATIONS
sleep	INDICATIONS
apnea	INDICATIONS
:	O
a	O
new	O
innovative	O
technique	O
without	O
tonsillectomy	O
.	O
The	O
soft	O
palate	O
and	O
the	O
lateral	O
pharyngeal	O
walls	O
have	O
been	O
known	O
to	O
contribute	O
to	O
the	O
collapse	O
of	O
the	O
upper	O
airway	O
in	O
many	O
patients	O
with	O
snoring	O
and	O
obstructive	INDICATIONS
sleep	INDICATIONS
apnea	INDICATIONS
(	O
OSA	O
)	O
.	O
To	O
our	O
knowledge	O
,	O
there	O
are	O
few	O
surgeries	O
that	O
specifically	O
reshape	O
the	O
soft	O
palate	O
and	O
create	O
enough	O
tension	O
in	O
the	O
lateral	O
pharyngeal	O
wall	O
in	O
the	O
same	O
operation	O
.	O
In	O
this	O
study	O
,	O
we	O
assessed	O
the	O
efficacy	O
of	O
a	O
new	O
technique	O
in	O
the	O
treatment	O
of	O
snoring	O
and	O
OSA	O
.	O
Twenty	O
eight	O
adults	O
with	O
a	O
body	O
mass	O
index	O
of	O
less	O
than	O
30	O
kg/m	O
(	O
2	O
)	O
with	O
Friedman	O
type	O
2	O
upper	O
airway	O
with	O
significant	O
soft	O
palatal	O
webbing	O
and	O
lateral	O
pharyngeal	O
wall	O
collapse	O
were	O
selected	O
for	O
the	O
study	O
with	O
a	O
minimum	O
follow-up	O
period	O
of	O
6	O
months	O
.	O
The	O
preoperative	O
to	O
postoperative	O
apnea-hypopnea	O
index	O
(	O
AHI	O
)	O
and	O
lowest	O
O2	O
saturation	O
were	O
statistically	O
improved	O
in	O
all	O
patients	O
.	O
Postoperative	O
endoscopic	O
findings	O
showed	O
significant	O
improvement	O
in	O
soft	O
palatal	O
and	O
lateral	O
pharyngeal	O
wall	O
collapse	O
.	O
Soft	O
palatal	O
webbing	O
flap	O
palatopharyngoplasty	O
provided	O
objective	O
clinical	O
improvement	O
of	O
OSA	O
in	O
adults	O
with	O
soft	O
palatal	O
and	O
lateral	O
pharyngeal	O
wall	O
collapse	O
and	O
has	O
the	O
potential	O
to	O
serve	O
as	O
an	O
effective	O
alternative	O
for	O
these	O
cases	O
.	O

Assessment	O
of	O
diabetic	INDICATIONS
retinopathy	INDICATIONS
in	O
newly	O
diagnosed	O
black	O
Kenyan	O
type	O
2	O
diabetics	O
.	O
To	O
determine	O
the	O
prevalence	O
and	O
pattern	O
of	O
diabetic	INDICATIONS
retinopathy	INDICATIONS
in	O
newly	O
diagnosed	O
black	O
African	O
patients	O
with	O
type	INDICATIONS
2	INDICATIONS
diabetes	INDICATIONS
mellitus	INDICATIONS
and	O
the	O
associated	O
risk	O
factors	O
.	O
Cross-sectional	O
hospital-based	O
study	O
.	O
Eye	O
clinic	O
of	O
Kenyatta	O
National	O
Hospital	O
,	O
Nairobi	INDICATIONS
,	O
Kenya	O
.	O
Africans	O
aged	O
20	O
years	O
and	O
above	O
with	O
newly	O
diagnosed	O
type	INDICATIONS
2	INDICATIONS
diabetes	INDICATIONS
mellitus	INDICATIONS
of	O
up	O
to	O
12	O
months	O
duration	O
.	O
One	O
hundred	O
and	O
forty	O
one	O
eyes	O
of	O
71	O
patients	O
were	O
included	O
in	O
this	O
study	O
,	O
while	O
slides	O
of	O
92	O
eyes	O
of	O
65	O
patients	O
were	O
of	O
good	O
enough	O
quality	O
for	O
evaluation	O
.	O
The	O
mean	O
duration	O
of	O
diabetes	O
was	O
11.7	O
weeks	O
(	O
SD	O
16.6	O
)	O
and	O
11.3	O
(	O
SD	O
10.1	O
)	O
in	O
men	O
and	O
women	O
respectively	O
.	O
Overall	O
,	O
the	O
prevalence	O
of	O
diabetic	INDICATIONS
retinopathy	INDICATIONS
and	O
clinically	O
significant	O
macula	O
oedema	INDICATIONS
was	O
30.4	O
%	O
and	O
8.7	O
%	O
respectively	O
.	O
There	O
was	O
a	O
positive	O
association	O
between	O
diabetic	INDICATIONS
retinopathy	INDICATIONS
and	O
systolic	O
blood	O
pressure	O
.	O
The	O
prevalence	O
of	O
diabetic	INDICATIONS
retinopathy	INDICATIONS
in	O
newly	O
diagnosed	O
Africans	O
with	O
type	INDICATIONS
2	INDICATIONS
diabetes	INDICATIONS
in	O
Kenya	O
is	O
very	O
high	O
.	O
This	O
suggests	O
longstanding	O
undiagnosed	O
diabetes	O
.	O

Comparison	O
between	O
NAEP	O
and	O
State	O
Mathematics	O
Assessment	O
Results	O
:	O
2003	O
.	O
Volume	O
1	O
.	O
Research	O
and	O
Development	O
Report	O
.	O
NCES	O
2008-475	O
In	O
late	O
January	O
through	O
early	O
March	O
of	O
2003	O
,	O
the	O
National	O
Assessment	O
of	O
Educational	O
Progress	O
(	O
NAEP	O
)	O
grade	O
4	O
and	O
8	O
reading	O
and	O
mathematics	O
assessments	O
were	O
administered	O
to	O
representative	O
samples	O
of	O
students	O
in	O
approximately	O
100	O
public	O
schools	O
in	O
each	O
state	O
.	O
The	O
results	O
of	O
these	O
assessments	O
were	O
announced	O
in	O
November	O
2003	O
.	O
Each	O
state	O
also	O
carried	O
out	O
its	O
own	O
reading	O
and	O
mathematics	O
assessments	O
in	O
the	O
2002-2003	O
school	O
year	O
,	O
most	O
including	O
grades	O
4	O
and	O
8	O
.	O
This	O
report	O
addresses	O
the	O
question	O
of	O
whether	O
the	O
results	O
published	O
by	O
NAEP	O
are	O
comparable	O
to	O
the	O
results	O
published	O
by	O
individual	O
state	O
testing	O
programs	O
.	O
Comparisons	O
to	O
address	O
the	O
following	O
four	O
questions	O
are	O
based	O
purely	O
on	O
results	O
of	O
testing	O
and	O
do	O
not	O
compare	O
the	O
content	O
of	O
NAEP	O
and	O
state	O
assessments	O
.	O
How	O
do	O
states	O
'	O
achievement	O
standards	O
compare	O
with	O
each	O
other	O
and	O
with	O
NAEP	O
?	O
Are	O
NAEP	O
and	O
state	O
assessment	O
results	O
correlated	O
across	O
schools	O
?	O
Do	O
NAEP	O
and	O
state	O
assessments	O
agree	O
on	O
achievement	O
trends	O
over	O
time	O
?	O
Do	O
NAEP	O
and	O
state	O
assessments	O
agree	O
on	O
achievement	O
gaps	O
between	O
subgroups	O
?	O
Although	O
this	O
report	O
does	O
not	O
focus	O
on	O
Adequate	O
Yearly	O
Progress	O
(	O
AYP	O
)	O
measurement	O
specifically	O
,	O
it	O
does	O
focus	O
on	O
the	O
measurement	O
of	O
mathematics	INDICATIONS
achievement	INDICATIONS
,	O
and	O
specifically	O
on	O
comparisons	O
of	O
the	O
messages	O
conveyed	O
by	O
NAEP	O
mathematics	O
assessment	O
results	O
and	O
state	O
mathematics	O
assessment	O
results	O
.	O
These	O
comparisons	O
center	O
on	O
four	O
facets	O
of	O
NAEP	O
and	O
state	O
assessment	O
results	O
:	O
(	O
1	O
)	O
achievement	O
standards	O
;	O
(	O
2	O
)	O
school-level	O
achievement	O
percentages	O
;	O
(	O
3	O
)	O
achievement	O
trends	O
;	O
and	O
(	O
4	O
)	O
achievement	O
gaps	O
.	O
These	O
facets	O
of	O
comparisons	O
are	O
summarized	O
in	O
this	O
volume	O
.	O
The	O
following	O
are	O
appended	O
:	O
(	O
1	O
)	O
Methodological	O
Notes	O
;	O
(	O
2	O
)	O
Tables	O
of	O
State	O
Mathematics	O
Standards	O
and	O
Tables	O
of	O
Standard	O
Errors	O
;	O
and	O
(	O
3	O
)	O
Standard	O
NAEP	O
Estimates	O
.	O
(	O
Contains	O
47	O
tables	O
,	O
29	O
figures	O
,	O
and	O
6	O
footnotes	O
.	O
)	O

Continuous	O
long-term	O
entecavir	O
therapy	O
in	O
naïve	O
chronic	INDICATIONS
hepatitis	INDICATIONS
B	O
patients	O
showing	O
partial	O
virologic	O
response	O
.	O
We	O
investigated	O
the	O
efficacy	O
of	O
continuous	O
long-term	O
entecavir	O
0.5	O
mg	O
treatment	O
in	O
naïve	O
chronic	INDICATIONS
hepatitis	INDICATIONS
B	O
patients	O
showing	O
a	O
partial	O
virologic	O
response	O
(	O
PVR	O
)	O
.	O
A	O
total	O
of	O
227	O
patients	O
were	O
included	O
.	O
PVR	O
was	O
defined	O
as	O
a	O
more	O
than	O
1	O
log10	O
IU/mL	O
decline	O
in	O
detectable	O
serum	INDICATIONS
hepatitis	INDICATIONS
B	O
virus	O
(	O
HBV	O
)	O
DNA	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
;	O
≥20	O
IU/mL	O
)	O
at	O
week	O
48	O
.	O
A	O
complete	O
virologic	O
response	O
(	O
CVR	O
)	O
was	O
defined	O
as	O
undetectable	O
serum	O
HBV	O
DNA	O
by	O
PCR	O
(	O
<	O
20	O
IU/mL	O
)	O
at	O
week	O
48	O
.	O
At	O
week	O
48	O
,	O
the	O
rate	O
of	O
the	O
PVR	O
was	O
64/227	O
(	O
28.2	O
%	O
)	O
.	O
Among	O
patients	O
with	O
PVR	O
,	O
the	O
cumulative	O
rates	O
of	O
virologic	O
response	O
(	O
serum	O
HBV	O
DNA	O
<	O
20	O
IU/mL	O
)	O
at	O
weeks	O
96	O
and	O
144	O
were	O
45.2	O
%	O
and	O
73.8	O
%	O
,	O
respectively	O
.	O
The	O
cumulative	O
rates	O
of	O
genotypic	O
resistance	O
were	O
not	O
significantly	O
different	O
between	O
patients	O
with	O
a	O
PVR	O
and	O
patients	O
with	O
a	O
CVR	O
(	O
p=0.057	O
)	O
.	O
However	O
,	O
the	O
cumulative	O
rates	O
of	O
virologic	O
breakthrough	O
were	O
higher	O
in	O
patients	O
with	O
PVR	O
than	O
in	O
patients	O
with	O
CVR	O
(	O
4	O
%	O
vs	O
0	O
%	O
and	O
11.2	O
%	O
vs	O
0	O
%	O
at	O
weeks	O
96	O
and	O
144	O
,	O
respectively	O
;	O
p	O
<	O
0.001	O
)	O
.	O
Long-term	O
continuous	O
entecavir	O
0.5	O
mg	O
treatment	O
in	O
patients	O
with	O
a	O
PVR	O
resulted	O
in	O
an	O
additional	O
virologic	O
response	O
without	O
a	O
significant	O
increase	O
in	O
genotypic	O
resistance	O
.	O
However	O
,	O
the	O
rate	O
of	O
virologic	O
breakthrough	O
was	O
higher	O
in	O
the	O
partial	O
responders	O
.	O

